



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Annals of the ICRP

ICRP PUBLICATION XXX

Patient and Staff Radiological Protection in Cardiology

Full Members:

Claire Cousins (Chair)
Donald Miller (Co-Chair)
Guglielmo Bernardi
Madan Rehani
Peter Schofield
Eliseo Vano

Corresponding Members:

Bernhard Geiger
Philip Heintz
Renato Padovani
Kui-Hian Sim
Andrew J. Einstein

32	Contents
33	
34	Abstract
35	
36	Preface
37	
38	Executive Summary
39	
40	Recommendations
41	
42	Glossary
43	
44	1. Introduction
45	
46	2. The Biological Effects of Radiation
47	
48	3. Clinical Examples of Deterministic Injury after
49	Fluoroscopically Guided Cardiac Procedures
50	
51	4. Principles of Radiological protection for Patients and Staff
52	
53	5. Managing Patient Dose in Fluoroscopically Guided
54	Interventions
55	
56	6. Radiation Doses and Protection of Staff during Interventional
57	Fluoroscopy
58	
59	7. Radiological Protection for Nuclear Cardiology
60	
61	8. Radiological Protection for Cardiac CT
62	
63	9. Radiological protection Training for Interventional
64	Fluoroscopy
65	
66	10. Quality Assurance Programmes
67	

68

69

Patient and Staff Radiological Protection in Cardiology

70

71

72

ICRP PUBLICATION XXX

73

74

Approved by the Commission in XXXXXXXX 20XX

75

76

77

78

79

80

81

82

83

84

Abstract- Cardiac nuclear medicine, cardiac CT, percutaneous coronary interventions and electrophysiology procedures are increasing in number and account for an important share of patient radiation exposure in medicine. Complex percutaneous coronary interventions and cardiac electrophysiology procedures are associated with high radiation doses. These procedures can result in patient skin doses high enough to cause radiation injury and, in children, an increased risk of cancer. Treatment of congenital heart disease in children is of particular concern. Additionally, staff in cardiac catheterization laboratories may receive high radiation doses if radiological protection tools are not used properly.

85

86

87

88

89

90

91

92

93

The Commission has provided recommendations for radiological protection during fluoroscopically guided interventions in *ICRP Publication 85*, for radiological protection in CT in *ICRP Publications 87 and 102*, and for training in radiological protection in *ICRP Publication 113* (ICRP 2000a,b, 2007, 2009). This report is focused specifically on cardiology, and brings together information relevant to cardiology from the Commission's published documents. There is emphasis on those imaging procedures and interventions specific to cardiology. The material and recommendations in the current document have been updated to reflect the most recent recommendations of the Commission.

94

95

96

97

98

99

100

This report provides guidance to assist the cardiologist with justification and optimization of cardiac CT studies, cardiac nuclear medicine studies and fluoroscopically guided cardiac interventions. It includes discussions of the biological effects of radiation, principles of radiological protection, protection of staff during fluoroscopically guided interventions, radiological protection training and establishment of a quality assurance programme for cardiac imaging and intervention.

101

102

103

104

105

106

107

Because tissue injury, principally skin injury, is a risk for fluoroscopically guided interventions, particular attention is devoted to clinical examples of radiation-related skin injuries from cardiac interventions, methods to reduce patient radiation dose, training recommendations, and quality assurance programs for interventional fluoroscopy.

© 2011 ICRP Published by Elsevier Ltd. All rights reserved.

108

109

110

111

Keywords: Cardiology, Computed Tomography, Nuclear Medicine, Cardiac Catheterization, Radiological Protection

112

PREFACE

113

114 Over the years, The International Commission on Radiological Protection (ICRP)
115 referred to below as ‘the Commission’, has issued a number of reports that provide
116 advice on radiological protection and safety in medicine. ICRP *Publication 105* is a
117 general overview of this area (ICRP, 2007a). These reports summarize the general
118 principles of radiological protection and provide advice on the application of these
119 principles to the various uses of ionising radiation in medicine.

120

121 Some previous reports have dealt in part with issues relevant to cardiology and
122 have appeared in print as *Publications 85, 87, 102 and 113* (ICRP, 2000a,b, 2007b,
123 2009) and *Supporting Guidance 2* (ICRP, 2001). The present report continues this
124 series of concise and focused documents.

124

125 In cardiology, patient radiation exposure is due to nuclear medicine, CT,
126 percutaneous coronary interventions and electrophysiology procedures. This rapidly
127 expanding field of medicine, both in numbers and complexity, requires guidance for
128 practitioners.

128

129 At their meeting in Beijing in 2004, the Commission decided that there would be
130 value in developing guidance on radiological protection for cardiologists. Due to a
131 variety of other priorities, work on the document was interrupted for a time and
132 resumed in earnest in 2010.

132

The membership of the Task Group was as follows:

133

C. Cousins (Chair)	D.L. Miller (Co-Chair)	G. Bernardi
M.M. Rehani	P. Schofield	(1) E. Vañó

134

135

Corresponding members were:

136

(2) B. Geiger	P. Heintz	R. Padovani
K.-H. Sim	A.J. Einstein	

137

138 In addition, Jacques Lochard and John Boice, Main Commission members, made
139 important contributions as critical reviewers.

140

The membership of Committee 3 during the period of final preparation of this

141

report was:

142

E. Vañó (Chair)	M. M. Rehani (Secretary)	M.R. Baeza
J.M. Cosset	L.T. Dauer	I. Gusev
J.W. Hopewell	P.-L. Khong	P. Ortiz López
S. Mattson	D.L. Miller	(3) K. Åhlström
		Riklund
H. Ringertz	M. Rosenstein	Y. Yonekura
B. Yue		

143

144

145

References

146

147 ICRP, 2000a. Avoidance of radiation injuries from medical interventional
148 procedures. ICRP Publication 85. Ann. ICRP 30 (2).



- 149 ICRP, 2000b. Managing patient dose in computed tomography. ICRP Publication
150 87. Ann. ICRP 30 (4).
- 151 ICRP, 2007a. Managing patient dose in multi-detector computed tomography. ICRP
152 Publication 102. Ann. ICRP 37 (1).
- 153 ICRP, 2007b. Radiological protection in medicine. ICRP Publication 105. Ann.
154 ICRP 37 (6).
- 155 ICRP, 2009. Recommendations of the International Commission on Radiological
156 Protection. ICRP Publication 113, Ann. ICRP 39 (5).
- 157 ICRP, 2001. Radiation and your patient – a guide for medical practitioners. ICRP
158 Supporting Guidance 2. Ann. ICRP 31 (4).
- 159
- 160
- 161

EXECUTIVE SUMMARY

In cardiology, patient radiation exposure is due to nuclear medicine, CT, percutaneous coronary interventions and electrophysiology procedures. Cardiac nuclear medicine, cardiac CT, percutaneous coronary interventions and electrophysiology procedures are increasing in number and account for an important share of patient radiation exposure in medicine. Complex percutaneous coronary interventions and cardiac electrophysiology procedures are associated with high radiation doses. These procedures can result in patient skin doses high enough to cause radiation injury and, in children, an increased risk of cancer. Treatment of congenital heart disease in children is of particular concern. Additionally, staff in cardiac catheterization laboratories may receive high radiation doses if radiological protection tools are not used properly.

1. The Biological Effects of Radiation

Stochastic effects are malignant disease and heritable effects for which the probability of an effect occurring, but not its severity, is regarded as a function of dose without threshold. The likelihood of inducing a stochastic effect increases with dose, but the exact relationship between dose and effect is not known. Children are approximately 2-3 times more sensitive to the stochastic effects of radiation than adults. They also have a longer potential lifespan than do adults, so they have more time to develop possible radiation related sequelae.

Deterministic effects (e.g., skin injury) are due to injury in populations of cells, characterised by a threshold dose and an increase in the incidence and severity of the reaction as the dose is increased further. Deterministic effects are also termed tissue reactions. Radiation-induced skin injuries may not become fully manifest until months after the radiation dose was administered. The diagnosis of a radiation-induced skin injury is often delayed. Deterministic injuries may extend into deeper tissues and can cause symptoms that persist for years. Deterministic injuries may be accompanied by an increase in stochastic risk.

The mechanisms of heart radiation damage include inflammatory processes, in particular after low doses, and after higher doses there is a progressive reduction in the number of patent capillaries eventually leading to ischemia, myocardial cell death and fibrosis, accelerated atherosclerosis in major blood vessels, decreased cardiac function, and fatal congestive heart failure. Cardiovascular radiation effects have been reported to occur at doses > 0.5 Gy. Organ doses may reach this level in some complex fluoroscopically guided cardiac procedures.

The lens of the eye is a radiosensitive tissue. Ionizing radiation typically causes posterior subcapsular cataract formation in the lens of the eye. Surveys of cardiologists and support staff working in catheterization laboratories have found a high percentage of lens opacities attributable to occupational radiation exposure when radiological protection tools have not been used properly.

2. Principles of Radiological Protection for Patients and Staff

The Commission recommends three principles of radiological protection: justification, optimization of protection, and application of dose limits (ICRP, 2007). The first two are source related and apply to all radiation exposure situations. The

211 third applies to staff, but does not apply to medical exposures of patients or to carers
212 and comforters.

213 Justification means that a medical procedure should only be performed when it
214 is appropriate for a particular patient— the anticipated clinical benefits should
215 exceed all anticipated procedural risks, including radiation risk. For CT and nuclear
216 medicine studies, justification is a responsibility shared between the referring
217 clinician and the cardiac imager. For fluoroscopically guided interventions, the
218 responsibility rests with the interventionalist.

219 Optimization means that the radiation dose to the patient is suitable for the
220 medical purpose, and radiation that is clinically unnecessary or unproductive is
221 avoided. Patient radiation dose is optimized when imaging is performed with the
222 least amount of radiation required to provide adequate image quality, diagnostic
223 information, and for fluoroscopy, adequate imaging guidance.

224
225
226

3. Managing patient dose in fluoroscopically guided interventions

227
228
229
230
231

The informed consent process should include information on radiation risk if the risk of radiation injury is thought to be significant. Important aspects of the patient's medical history that should be considered when estimating radiation risk are genetic factors, co-existing diseases, medication use, radiation history, and pregnancy.

232
233
234
235
236
237
238

Some of the factors that affect the patient's radiation dose depend on the x-ray system, but many others depend on how the operator uses the x-ray system. During the procedure, the cardiologist should be kept aware of the fluoroscopy time, the number of cine series and cine frames, and the total patient dose. As patient radiation dose increases, the operator should consider the radiation dose already delivered to the patient and the additional radiation necessary to complete the procedure.

239
240
241
242
243
244
245
246

Patient radiation dose reports should be produced at the end of the procedure, and archived. Radiation dose data should be recorded in the patient's medical record after the procedure. When the patient's radiation dose from the procedure is high, clinical follow-up is essential for early detection and management of skin injuries. Patients who have received a substantial radiation dose should have follow-up at 10-14 days and at one month after the procedure for potential radiation injuries.

247
248

4. Protection of staff during interventional fluoroscopy

249
250
251
252
253
254
255
256

The basic tools of occupational radiological protection are time, distance and shielding. The use of personal protective shielding is necessary in the cardiac catheterization laboratory. Occupational doses can be reduced to very low levels if ceiling suspended lead screens and protective lead curtains suspended from the side of the procedure table are used properly. In general, reducing patient dose will also reduce operator dose. With proper use of radiological protection tools and techniques, the effective dose (E) for an interventionalist is typically 2–4 mSv/year, and is well below the 20 mSv/year limit recommended by the Commission.

257
258

Radiation exposure to the operator is neither uniform nor symmetric. Radiological protection for the eyes is necessary for interventionalists. Proper use of

259 personal monitoring badges is necessary in cardiac catheterization laboratories in
260 order to monitor and audit occupational radiation dose.

261

262

263 **5. Radiological protection for nuclear cardiology**

264

265 Appropriate use criteria and guidelines that help to set standards for

266 justification of nuclear cardiology procedures have been developed through

267 consensus efforts of professional societies. Justification needs to be performed on

268 an individualized, patient-by-patient basis. Optimization of nuclear cardiology

269 procedures involves the judicious selection of radiopharmaceuticals and

270 administered activities to ensure diagnostic image quality while minimizing patient

271 dose. Administered activities should be within pre-specified ranges, as provided in

272 international and national guidelines, and should reflect patient habitus. If stress

273 imaging is normal, rest imaging can be omitted to minimize total dose. For SPECT

274 protocols, Tc-99m-based agents yield lower effective doses than Tl-201, and are

275 preferred on dosimetric grounds. Practitioners need good quality dosimetry data to

276 perform proper benefit-risk analyses for their patients.

277

278

279 **6. Radiological protection for cardiac CT**

280

281 Appropriate use criteria and guidelines for justification of cardiac CT have

282 been developed through consensus efforts of professional societies. Justification

283 needs to be performed on an individualized, patient-by-patient basis, weighing the

284 benefits and risks of each imaging test under consideration as well as of doing no

285 test. Assessment of radiation risk is one part of this process.

286 Dose from cardiac CT is strongly dependent on scanner mode, tube current,

287 and tube voltage. For patients with a heart rate less than 65-70 bpm and a regular

288 rhythm, diagnostic image quality can generally be maintained while using dose-

289 reduction methods such as ECG-controlled tube current modulation and axial

290 imaging. The maximum tube current should be appropriate for the patient's habitus.

291 Further research is needed to develop and validate methods, such as newer scan

292 modes and low-voltage scanning, to minimize radiation dose to patients and

293 practitioners.

294

295

296 **7. Radiological protection training for interventional fluoroscopy**

297

298 Legislation in most countries requires that individuals who take responsibility

299 for medical exposures must be properly trained in radiological protection (RP).

300 Interventional cardiologists worldwide typically have little or no training in RP. The

301 Commission recommends that, in addition to the training recommended for other

302 physicians who use X-rays, interventionalists, including interventional cardiologists,

303 should receive a second, higher level of RP training.

304 Training programmes should include both initial training for all incoming staff

305 and regular updating and retraining. Scientific congresses should include refresher

306 courses on RP, attendance at which could be a requirement for continuing

307 professional development.

308 Training activities in RP should be followed by an evaluation of the

309 knowledge acquired from the training programme (a formal examination system).

310 Physicians who have completed training should be able to demonstrate that they

308 possess the knowledge specified by the curriculum by passing an appropriate
309 certifying examination.

310 The Commission recommends that nurses and other healthcare professionals
311 who assist during fluoroscopic procedures should be familiar with radiation risks
312 and radiological protection principles, in order to minimise their own exposure and
313 that of others.

314

315

8. Quality assurance programmes

316

317 Two basic objectives of the radiological protection quality assurance
318 programme (QAP) are to evaluate patient radiation dose on a periodic basis and to
319 monitor occupational radiation dose for workers in cardiology facilities where
320 radiation is used. A cardiologist should be in charge of the QAP aspects of RP for
321 cardiology procedures, and should be assisted by a medical physicist. A senior
322 interventionalist and a medical physicist should be included in the planning for a
323 new interventional fluoroscopy laboratory, installation of a new x-ray or nuclear
324 medicine system and the upgrade of existing equipment.

325

326 Periodic evaluation of image quality and procedure protocols should be
327 included in the QAP. The QAP should establish a trigger level for individual clinical
328 follow-up when there is a risk of radiation-induced skin injuries. The QAP should
329 ensure the regular use of personal dosimeters and include a review of all abnormal
329 dose values.

330

331 Patient dose reports should be produced at the end of procedures, archived and
332 recorded in the patient's medical record. If dose reports are not available, dose
333 values should be recorded in the patient's medical record together with procedure
334 and patient identification. Patient dose audits (including comparison with Diagnostic
334 Reference Levels) and reporting are important components of the QAP.

335

336

9. Reference

337

338 ICRP, 2007. The 2007 Recommendations of the International Commission on
339 Radiological Protection. ICRP publication 103. Ann. ICRP 37, 1-332.

340

341 **Recommendations**

342

- 343 • **Individuals who request, perform or interpret cardiology imaging**
- 344 **procedures should be aware of the radiation risks of the procedure.**
- 345 • **Appropriate use criteria and guidelines for justification have been**
- 346 **developed and should be used in clinical practice.**
- 347 • **Nuclear cardiology examinations and cardiac CT examinations should be**
- 348 **optimized and dose reduction techniques used whenever applicable.**
- 349 • **The informed consent process should include information on radiation risk**
- 350 **if a risk of radiation injury is thought to exist.**
- 351 • **Radiation dose data should be recorded in the patient's medical record**
- 352 **after the procedure; patient dose reports should be archived for quality**
- 353 **assurance purposes.**
- 354 • **When the patient's radiation dose from an interventional procedure**
- 355 **exceeds the institution's trigger level, clinical follow-up should be**
- 356 **performed for early detection and management of skin injuries.**
- 357 • **Suggested values for the trigger level are a skin dose of 3 Gy, a kerma-area**
- 358 **product of 500 Gy·cm², or an air kerma at the patient entrance reference**
- 359 **point of 5 Gy.**
- 360 • **Individuals who perform cardiology procedures where there is a risk of**
- 361 **deterministic injury to patients should be able to recognize these skin**
- 362 **injuries.**
- 363 • **Individuals who perform interventional cardiology procedures should be**
- 364 **familiar with methods to reduce radiation dose to patients and staff.**
- 365 • **Nurses and other healthcare professionals who assist during fluoroscopic**
- 366 **procedures should be familiar with radiation risks and radiological**
- 367 **protection principles, in order to minimise their own exposure and that of**
- 368 **others.**
- 369 • **Whenever there is a possibility of occupational radiation exposure, staff**
- 370 **should use personal protective shielding.**
- 371 • **Training programmes in radiological protection should include both initial**
- 372 **training for all incoming staff and regular updating and retraining.**
- 373 • **In addition to the training recommended for other physicians who use X-**
- 374 **rays, interventionalists, including interventional cardiologists, should**
- 375 **receive a second, higher level of radiological protection training.**
- 376 • **A cardiologist should be in charge of the quality assurance programme**
- 377 **aspects of radiological protection for cardiology procedures, and should be**
- 378 **assisted by a medical physicist.**
- 379 • **Quality assurance programmes in cardiology should include patient dose**
- 380 **audits.**
- 381 • **Quality assurance programmes should ensure the regular use of personal**
- 382 **dosimeters and should include a review of all abnormal dose values.**

383

384

385
386
387
388
389
390
391
392
393
394

GLOSSARY

1. Definitions

Absorbed dose, D

The fundamental dose quantity given by

$$D = \frac{d\bar{\epsilon}}{dm}$$

395
396
397
398
399
400
401

Where $d\bar{\epsilon}$ is the mean energy imparted to matter of mass dm by ionising radiation. The SI unit for absorbed dose is joule per kilogram (J kg^{-1}). Its special name is gray (Gy) (ICRP, 2007). In layman's terms, absorbed dose is the measure of energy absorbed by tissue from ionizing radiation.

Acceptance test

402
403
404
405
406
407

A test carried out after new equipment has been installed or major modifications have been made to existing equipment, in order to verify compliance with the manufacturer's specifications, contractual specifications and applicable local regulations.

ALARA

408
409
410

An acronym for As Low As Reasonably Achievable. *See* Optimisation of protection.

Becquerel (Bq)

411
412
413

The special name for the SI unit of activity. $1 \text{ Bq} = 1 \text{ s}^{-1}$ ($\approx 2.7 \cdot 10^{-11} \text{ Ci}$).

Brachytherapy

414
415
416

Radiation treatment of a patient using sealed or unsealed sources of radiation placed within the patient's body.

Bradycardia

417
418
419
420

An abnormally slow heart rhythm. Depending on the heart rate and the underlying abnormality, bradycardias may or may not require treatment.

Cardiomyopathy

421
422
423
424

Any condition that results in weakening of the pumping strength of the cardiac ventricles, or that causes areas of scar tissue to develop in the ventricles.

Cardioverter-defibrillator

425
426
427
428
429
430
431

Devices, usually implanted in the same way as pacemakers, that continuously monitor the heart rhythm, automatically function as pacemakers

432 for bradycardia, and deliver life-saving shocks if a dangerous tachycardia is
433 detected.

434

435 Carers and comforters

436 Individuals, other than staff, who care for and comfort patients. These
437 individuals include parents and others, normally family or close friends, who
438 hold children during diagnostic procedures or may come close to patients
439 following the administration of radiopharmaceuticals or during
440 brachytherapy (ICRP, 2007).

441

442 Commissioning

443 Testing carried out after new equipment has been installed, in order to verify
444 that the equipment is properly configured for its clinical application at the
445 centre (NCRP, 2010).

446

447 Constancy test

448 Each of a series of tests, carried out to ensure that the functional performance
449 of equipment meets established criteria, or to enable the early recognition of
450 changes in the properties of components of the equipment (IEC, 1993).

451

452 Deterministic effect

453 Injury in populations of cells, characterised by a threshold dose and an
454 increase in the severity of the reaction as the dose is increased further.
455 Deterministic effects are also termed tissue reactions. In some cases,
456 deterministic effects are modifiable by post-irradiation procedures including
457 biological response modifiers (ICRP, 2007).

458

459 Diagnostic reference level

460 Used in medical imaging with ionizing radiation to indicate whether, in
461 routine conditions, the patient dose or administered activity (amount of
462 radioactive material) from a specified procedure is unusually high or low for
463 that procedure (ICRP, 2007).

464

465 Diastasis

466 The midportion of diastole, when the blood enters the ventricle slowly or
467 ceases to enter. Diastasis duration is in inverse proportion to heart rate and is
468 absent at very high heart rates.

469

470 Dose coefficient

471 Used as a synonym for dose per unit intake of a radioactive substance, but
472 sometimes also used to describe other coefficients linking quantities or
473 concentrations of activity to doses or dose rates, such as the external dose
474 rate at a specified distance above a surface with a deposit of a specified
475 activity per unit area of a specified radionuclide (ICRP, 2007).

476

477 Dose limit

478 The value of the effective dose or the equivalent dose to individuals from
479 planned exposure situations that shall not be exceeded (ICRP, 2007).

480

481 Dysrhythmia

482 A disorder of heart rhythm, also called arrhythmia. Dysrhythmias may be
 483 due to electrical, circulatory or structural diseases or disorders. Some
 484 dysrhythmias are harmless, and some are life-threatening.

485
 486 Effective dose, E

487 The tissue-weighted sum of the equivalent doses in all specified tissues and
 488 organs of the body, given by the expression:

$$E = \sum_T w_T \sum_R w_R D_{T,R} \quad \text{or} \quad E = \sum_T w_T H_T$$

490
 491

492 where H_T or $w_R D_{T,R}$ is the equivalent dose in a tissue or organ, T, and w_T is
 493 the tissue weighting factor. The unit for the effective dose is the same as for
 494 absorbed dose, $J\ kg^{-1}$. Its special name is sievert (Sv) (ICRP, 2007).
 495 Effective dose was developed as a practical quantity for use in the general
 496 system of radiation protection, particularly with regard to applying the
 497 principles of optimization of radiation protection and dose limitation for
 498 stochastic effects.

499

500 Electrophysiology

501 Cardiac electrophysiology is directed at evaluation and treating abnormalities
 502 of the electrical conduction system of the heart. Cardiac electrophysiology
 503 procedures involve the recording of intracardiac electrical signals and
 504 programmed electrical stimulation of the heart. The procedure may be
 505 performed for diagnostic purposes only or may be part of a combined
 506 diagnostic and therapeutic (e.g., ablation) procedure. Catheters for pacing
 507 and recording are advanced through blood vessels into multiple cardiac
 508 chambers. The designs of the catheters and the sites appropriate for their
 509 placement are determined according to the nature of the arrhythmia under
 510 investigation.

511

512 Employer

513 An organisation, corporation, partnership, firm, association, trust, estate,
 514 public or private institution, group, political or administrative entity, or other
 515 persons designated in accordance with national legislation, with recognized
 516 responsibility, commitment, and duties towards a worker in her or his
 517 employment by virtue of a mutually agreed relationship. A self-employed
 518 person is regarded as being both an employer and a worker (ICRP, 2007).

519

520 Equivalent dose, H_T

521 The dose in a tissue or organ T given by:

522

$$H_T = \sum_R w_R D_{T,R}$$

523
 524

525 where $D_{T,R}$ is the mean absorbed dose from radiation R in a tissue or organ
 526 T, and w_R is the radiation weighting factor. Since w_R is dimensionless, the

527 unit for the equivalent dose is the same as for absorbed dose, J kg^{-1} . This
 528 unit's special name is sievert (Sv) (ICRP, 2007). For x-rays used in
 529 fluoroscopy, $w_R = 1$, so the equivalent dose is numerically equal to the mean
 530 absorbed dose in mGy.

531

532 Fluoroscopically guided interventions

533 Procedures comprising guided therapeutic and diagnostic interventions, by
 534 percutaneous or other access, usually performed under local anaesthesia
 535 and/or sedation, with fluoroscopic imaging used to localise the
 536 lesion/treatment site, monitor the procedure, and control and document the
 537 therapy (ICRP, 2000).

538

539 Gray (Gy)

540 The special name for the SI unit of absorbed dose: $1 \text{ Gy} = 1 \text{ J kg}^{-1}$.

541

542 Justification

543 The process of determining whether either (1) a planned activity involving
 544 radiation is, overall, beneficial, i.e. whether the benefits to individuals and to
 545 society from introducing or continuing the activity outweigh the harm
 546 (including radiation detriment) resulting from the activity; or (2) a proposed
 547 remedial action in an emergency or existing exposure situation is likely,
 548 overall, to be beneficial, i.e., whether the benefits to individuals and to
 549 society (including the reduction in radiation detriment) from introducing or
 550 continuing the remedial action outweigh its cost and any harm or damage it
 551 causes (ICRP, 2007).

552

553 Interventional Reference Point, *see* Patient Entrance Reference Point

554

555 KAP, *see* Kerma-area product

556

557 Kerma, K

558 The quotient of the sum of the kinetic energies, dE_{tr} , of all charged particles
 559 liberated by uncharged particles in a mass dm of material, and the mass dm
 560 of that material.

561

$$K = \frac{dE_{tr}}{dm}$$

562

563

564 Kerma is defined as a non-stochastic quantity and dE_{tr} is the expectation
 565 value of the sum of the kinetic energies. The unit for kerma is joule per
 566 kilogram (J kg^{-1}). This unit's special name is gray (Gy) (ICRP, 2007).
 567 "Kerma" is an acronym for Kinetic Energy Released in a Mass.

568

569 Kerma-area product, KAP

570 The integral of air kerma across the entire x-ray beam emitted from the x-ray
 571 tube. Kerma-area product is a surrogate measurement for the entire amount
 572 of energy delivered to the patient by the beam. Kerma-area product is
 573 measured in units of $\text{Gy}\cdot\text{cm}^2$. This quantity was previously called dose-area

574 product. Earlier publications used the abbreviation ‘DAP’ for this quantity
575 (Stecker et al, 2009).

576

577 Mean absorbed dose in a tissue or organ (T), D_T

578 The absorbed dose D_T , averaged over the tissue or organ T, which is given
579 by

580

$$D_T = \frac{\epsilon_T}{m_T}$$

581

582

583 where ϵ_T is the mean total energy imparted in a tissue or organ T, and m_T is
584 the mass of that tissue or organ (ICRP, 2007).

585

586 Medical exposure

587 Exposure incurred by patients as part of their own medical or dental
588 diagnosis or treatment; by persons, other than those occupationally exposed,
589 knowingly, while voluntarily helping in the support and comfort of patients;
590 and by volunteers in a programme of biomedical research involving their
591 exposure (ICRP, 2007).

592

593 Myocardial perfusion

594 Blood flow to the heart muscle.

595

596 Occupational exposure

597 This refers to all exposure incurred by workers in the course of their work,
598 with the exception of 1) excluded exposures and exposures from exempt
599 activities involving radiation or exempt sources; 2) any medical exposure;
600 and 3) the normal local natural background radiation (ICRP, 2007).

601

602 Optimisation of protection (and safety)

603 The process of determining what level of protection and safety makes
604 exposures, and the probability and magnitude of potential exposures, as low
605 as reasonably achievable, economic and societal factors being taken into
606 account (ICRP, 2007).

607

608 Patient Entrance Reference Point

609 For isocentric fluoroscopic systems such as C-arm fluoroscopes, the Patient
610 Entrance Reference Point is located along the central x-ray beam at a
611 distance of 15 cm from the isocenter in the direction of the focal spot (IEC,
612 2010). The earlier version of this standard refers to this point as the
613 Interventional Reference Point. (IEC, 2000). The Patient Entrance Reference
614 Point is close to the patient’s entrance skin surface when the heart is at the
615 isocenter of the gantry.

616

617 Peak Skin Dose, PSD

618 The maximum absorbed dose to the most heavily irradiated localized region
619 of skin (i.e., the localized region of skin that lies within the primary x-ray
620 beam for the longest period of time during an FGI procedure). Peak skin
621 dose is measured in units of Gy (NCRP, 168).

622

623 Percutaneous coronary intervention (PCI)

624 PCI encompasses a variety of procedures used to treat patients with diseased
625 coronary arteries. A catheter is advanced into the diseased artery, and a
626 balloon is inflated within the stenotic portion of the artery, often
627 accompanied by placement of a stent (a wire mesh tube) to act as a
628 permanent scaffold. The procedure is commonly known as coronary
629 angioplasty.

630

631 Principles of protection

632 A set of principles that apply equally to all controllable exposure situations:
633 the principle of justification, the principle of optimisation of protection, and
634 the principle of application of limits on maximum doses in planned situations
635 (ICRP, 2007).

636

637 PSD, *see* Peak Skin Dose

638

639 Radiation weighting factor, w_R

640 A dimensionless factor by which the organ or tissue absorbed dose is
641 multiplied to reflect the higher biological effectiveness of high-LET
642 radiations compared with low-LET radiations. It is used to derive the
643 equivalent dose from the absorbed dose averaged over a tissue or organ
644 (ICRP, 2007).

645

646 Radiofrequency ablation

647 In cardiology, a procedure where one or more catheters are guided via
648 fluoroscopy into the blood vessels and directed to the heart muscle. A burst
649 of radiofrequency energy destroys very small areas of tissue that give rise to
650 abnormal electrical signals.

651

652 Reference Air Kerma (RAK)

653 Air kerma of the primary X-ray beam measured under specific conditions
654 and expressed as the equivalent value at the Patient Entrance Reference Point
655 (IEC, 2004, IEC, 2010). It is the air kerma accumulated at a specific point in
656 space relative to the fluoroscopic gantry (see Patient Entrance Reference
657 Point, above) during a procedure. Reference air kerma does not include
658 backscatter and is measured in units of Gy. Reference air kerma is sometimes
659 referred to as reference dose or cumulative air kerma. Earlier publications
660 used the term 'cumulative dose' and the abbreviation 'CD' for this quantity
661 (Stecker, 2009).

662

663 Sievert (Sv)

664 The special name for the SI unit of equivalent dose, effective dose, and
665 operational dose quantities. The unit is joule per kilogram ($J\ kg^{-1}$).

- 666
667 SRDL, *see* Substantial Radiation Dose Level
668
669 Stochastic effects of radiation
670 Malignant disease and heritable effects for which the probability of an effect
671 occurring, but not its severity, is regarded as a function of dose without
672 threshold (ICRP, 2007).
673
674 Stenosis
675 Narrowing of a hollow structure. With respect to percutaneous coronary
676 interventions, narrowing of the inner diameter of a coronary artery.
677
678 Stress test
679 A standardized procedure for assessing the effect of stress on heart function
680 and myocardial perfusion. Stress may be induced by exercise or simulated by
681 administration of drugs. A normal stress test implies that blood flow through
682 the coronary arteries is normal.
683
684 Substantial Radiation Dose Level (SRDL)
685 An appropriately selected reference value used to trigger additional dose
686 management actions during a procedure and medical follow-up for a
687 radiation level that might produce a clinically relevant injury in an average
688 patient. There is no implication that radiation levels above the SRDL will
689 always cause an injury or that radiation levels below the SRDL will never
690 cause an injury (NCRP 168, 2010).
691
692 Tachycardia
693 An abnormally fast heart rhythm. Depending on the heart rate and the
694 underlying abnormality, tachycardias may or may not require treatment.
695
696 Threshold dose for tissue reactions
697 Dose estimated to result in only 1% incidence of tissue reactions (ICRP,
698 2007).
699
700 Tissue reaction
701 See ‘Deterministic effect’.
702
703 Tissue weighting factor, w_T
704 The factor by which the equivalent dose in a tissue or organ T is weighted to
705 represent the relative contribution of that tissue or organ to the total health
706 detriment resulting from uniform irradiation of the body (ICRP 1991). It is
707 weighted such that:
708
$$\sum_T w_T = 1$$

709
710
711 (ICRP, 2007).
712
713 Valvular heart disease

714 Heart disease due to one or more abnormal heart valves. Abnormally
715 narrowed or leaky heart valves can interfere with the heart's ability to push
716 blood forward from chamber to chamber, and then out to the lungs and body.

717

718 Worker

719 Any person who is employed, whether full time, part time or temporarily, by
720 an employer, and who has recognised rights and duties in relation to
721 occupational radiological protection (ICRP, 2007).

722

723

2. References

724

725 IEC, 1993. Medical electrical equipment - Part 1-61223: Evaluation and routine
726 testing in medical imaging departments. 1st ed. Geneva, Switzerland:
727 International Electrotechnical Commission.

728 IEC, 2000. Medical electrical equipment. Part 2-43: Particular requirements for the
729 safety of X-ray equipment for interventional procedures. IEC 60601-2-43.
730 Geneva, Switzerland: International Electrotechnical Commission.

731 IEC, 2004. Medical electrical equipment - Technical Report 60788: Glossary of
732 defined terms. IEC TR 60788. 2nd edition. Geneva, Switzerland: International
733 Electrotechnical Commission.

734 IEC, 2010. Medical electrical equipment. Part 2-43: Particular requirements for the
735 safety of X-ray equipment for interventional procedures. IEC 60601-2-43. 2nd
736 edition. Geneva, Switzerland: International Electrotechnical Commission.

737 ICRP, 1991. The 1990 Recommendations of the International Commission on
738 Radiological Protection. ICRP Publication 60. Ann ICRP 21(1-3):1-201.

739 ICRP, 2000. Avoidance of radiation injuries from medical interventional
740 procedures. ICRP Publication 85. Ann ICRP 30:7-67.

741 ICRP, 2007. The 2007 Recommendations of the International Commission on
742 Radiological Protection. ICRP Publication 103. Ann ICRP 37(2-4):1-332.

743 NCRP, 2010. Radiation dose management for fluoroscopically guided
744 interventional medical procedures. NCRP Report No. 168. Bethesda, MD:
745 National Council on Radiation Protection and Measurements.

746 Stecker MS, Balter S, Towbin RB, Miller DL, Vañó E, Bartal G, Angle JF, Chao
747 CP, Cohen AM, Dixon RG, Gross K, Hartnell GG, Schueler B, Statler JD, de
748 Baère T, and Cardella JF. Guidelines for patient radiation dose management. J
749 Vasc Interv Radiol 2009; 20: S263-S273.

750

751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799

1. INTRODUCTION

Main Points

- In cardiology, patient radiation exposure is due to nuclear medicine, CT, percutaneous coronary interventions, electrophysiology procedures, procedures for the correction of congenital heart disease or acquired valvular disease, and other vascular interventional procedures.
- Cardiac nuclear medicine, CT, percutaneous coronary interventions and electrophysiology procedures are increasing in number and account for a disproportionate share of patient radiation exposure.
- Interventional cardiology procedures can result in patient skin doses high enough to cause radiation injury and an increased risk of cancer in children.
- Complex percutaneous coronary interventions and cardiac electrophysiology procedures are associated with higher radiation doses
- Treatment of congenital heart disease in children is of particular concern, due to their greater sensitivity to radiation.
- Staff in cardiac catheterization laboratories may receive high radiation doses if radiological protection tools are not used properly.

1.0 Introduction

(1) In cardiology, patients are exposed to ionizing radiation from three different modalities: fluoroscopy (including cineangiography), computed tomography (CT) and nuclear medicine. These three modalities differ considerably in the frequency with which they are performed, in patient radiation doses, in the way radiation is administered to the patient, and in radiation dose to operators and staff.

1.1 Fluoroscopically guided procedures

(2) Cardiologists perform a variety of fluoroscopically guided procedures. These include procedures to diagnose and treat abnormal coronary arteries, procedures to diagnose and treat cardiac dysrhythmias, procedures to diagnose and treat congenital and valvular heart disease and other vascular interventions. These procedures may be performed on patients of all ages, from newborns to the elderly. The Commission has addressed avoidance of radiation injury from fluoroscopically guided procedures in the past (ICRP 2000), but advances in technology and in our understanding of radiation effects have occurred in the past decade.


1.1.1 Percutaneous coronary interventions (PCI)

(3) Despite the continuing development of non-invasive cardiac imaging techniques over the past decade, including echocardiography, cardiac CT scanning and cardiac MRI, an increasing number of patients undergo fluoroscopically guided

800 invasive cardiac diagnostic and therapeutic procedures. In Europe there was a 3-fold
 801 increase in coronary angiography (CA) and a 5-fold increase in percutaneous
 802 coronary interventions (PCI) between 1992 and 2001, primarily due to the
 803 introduction of coronary stents (Togni, et al, 2004, fig. 1.1) Between 1990 and 2003,
 804 the average annual rate of increase in coronary angioplasty procedures in Europe
 805 ranged from 3.78% in the Netherlands to 11.82% in Finland, with a mean of 6.73%
 806 (Faulkner and Werduch, 2008a). An estimated 3,043,000 coronary arteriograms and
 807 910,000 percutaneous coronary interventions, with 690,000 coronary stent
 808 placements, were performed in Europe in 2007 (Faulkner and Werduch, 2008b).

809 (4) Similar growth rates were observed in North America (Laskey et al, 2000,
 810 Anderson et al, 2002) for the time period 1990-2000. Between 2006 and 2008,
 811 however, the number of invasive coronary procedures in the U.S. declined by
 812 approximately 2% (NCRP Report 168, 2010), and appears to be declining in some
 813 European countries as well (Meier, 2010). This is presumed due to the increase in
 814 cardiac CT.

815 (5) In the United States, interventional fluoroscopy procedures were the third
 816 largest source of medical exposure of patients in 2006, accounting for 14% of
 817 medical exposure (NCRP report 160, 2009). Cardiac procedures were 28% of the
 818 total interventional fluoroscopy procedures, but accounted for 53% of the
 819 interventional fluoroscopy exposure.
 820



821

822

823 **Figure 1.1:** Coronary angiograms, coronary angioplasty (PTCA) and
 824 coronary stenting in Europe from 1992—2001, in thousands of procedures
 825 (from Togni, EHJ reproduced with permission [to be requested from Elsevier
 826 Ltd.]

827

828 (6) This growth has involved mainly the Western world, but a similar trend is
829 seen in other countries: in China the annual increment rate for PCI is around 40%
830 (Cheng et al, 2004). This number is relatively small and may reflect the lower
831 prevalence of coronary artery disease in the Chinese population (3-7%, about one
832 quarter of that of Western Caucasians), but is expected to grow as a consequence of
833 changing dietary habits, life-style and cigarette smoking (Cheng et al, 2004, Moran
834 2010).

835 (7) A survey of developing countries conducted by the IAEA revealed that
836 about 30% of the 20 participating countries demonstrated a 100% increase in
837 workload in the 3-year period from 2004 to 2007 (Tsapaki, 2009). The same study
838 indicated that the numbers of paediatric interventional procedures can reach the
839 levels of adult interventional procedures, even in developing countries.

840

841 1.1.2 Skin injuries

842 (8) Both PCI and interventional electrophysiology procedures can result in
843 patient skin doses high enough to cause deterministic skin injuries (see Chapters 2
844 and 3) (Miller 2008). At one centre, the frequency of skin injuries was estimated at
845 3×10^{-4} (Padovani 2005). Although the number of radiation injuries due to cardiac
846 procedures remains small, these injuries have a major impact on the patients who are
847 affected. Therefore, it is important to inform and continue to remind practicing
848 clinicians of the potential risks involved with these procedures.

849 (9) The number of patients undergoing multiple procedures continues to
850 increase (Laskey et al, 2001). Complex cases may be treated in more than one
851 session (staged procedures). Restenosis and disease progression may also prompt
852 repeated interventions. In a recent series of 3332 patients (Padovani et al, 2005)
853 almost one third underwent at least two procedures. Vano et al. (Vano 2001)
854 observed a much greater rate of skin effects in patients who had undergone multiple
855 fluoroscopically guided coronary procedures. Repeated procedures, especially when
856 performed within a short period of time, increase the risk of skin injury (Balter,
857 2010). Multiple cardiac fluoroscopic procedures should be a cause of concern with
858 regard to radiological protection. The risk of skin injuries should not be
859 underestimated.

860 (10) Patient radiation dose is related to procedure complexity (Bernardi et al,
861 2000, Peterzol et al, 2002, Balter et al, 2009, IAEA 2009). Multi-vessel PCI is
862 considered a complexity factor, but this may not be always the case (Bernardi et al,
863 2000). Other factors that appear to affect complexity for PCI include the type of
864 lesion, the chronicity of the occlusion, the degree of vessel tortuosity and the
865 involvement of vessel bifurcations (Balter et al, 2009, IAEA 2009).

866

867 1.1.3 Cardiac electrophysiology procedures

868 (11) A second field where there has been an increase in both the number and
869 complexity of procedures is interventional electrophysiology. Permanent pacemaker
870 implantation for bradycardia is carried out in large numbers of patients. From 1997
871 to 2001, the number of new pacemaker implants increased about 50% worldwide
872 (Mond et al, 2004). More recently, bi-ventricular pacemakers (cardiac
873 resynchronisation therapy) have been introduced for the treatment of patients with
874 cardiac failure and cardiomyopathies (Salukhe et al, 2004). The use of cardioverter-
875 defibrillators has also increased, as a result of studies (Moss et al, 2002, Salukhe et

876 al, 2004) that demonstrated their life-saving role in patients at risk of sudden cardiac
877 death. An estimated 554,000 pacemaker implantations were performed in Europe in
878 2007 (Faulkner and Werduch, 2008b) and an estimated 189,000 electrophysiology
879 procedures and 361,000 cardiac device implantations were performed in the U.S. in
880 2008 (NCRP Report No. 168, 2010).

881 (12) Cardiac electrophysiology procedures also include treatment of patients
882 with re-entrant tachycardias. These patients are often much younger than patients
883 with coronary heart disease, and require both diagnostic procedures and treatment by
884 radiofrequency ablation. Due to the long fluoroscopy times required for these
885 procedures, these patients can be exposed to very high radiation doses and a
886 substantial risk of deterministic effects if technique is not optimized (Rosenthal,
887 1998, McFadden, 2002).

888

889 **1.1.4 Congenital and valvular heart disease**

890 (13) Two other groups of cardiac disease where catheter techniques are used
891 and are likely to expand in the near future are congenital and valvular heart disease.
892 These groups represent a small percentage of patients undergoing percutaneous
893 interventions, but these diseases are seen in both children and adults. Children are at
894 greater risk for the development of stochastic radiation effects, principally cancer,
895 due to their longer expected life span and their increased sensitivity to radiation as
896 compared to adults (Hall, 2009). It has been estimated that approximately 7% of all
897 cardiac angiography procedures are carried out in children aged 0 to 15 years
898 (UNSCEAR 2000). The most widely performed procedures are balloon
899 valvuloplasty, device closure of atrial septal defect, patent foramen ovale or ductus
900 arteriosus, stenting of pulmonary artery stenosis or coarctation of the aorta and
901 electrophysiology studies. These procedures may involve long fluoroscopy times. In
902 addition to these well-established procedures, new procedures have been introduced,
903 including percutaneous pulmonary and aortic valve replacement, ventricular septal
904 defect closure, implantation of banding devices to limit pulmonary blood flow, and
905 radiofrequency perforation to create continuity between cardiac chambers and
906 vessels (Levi et al, 2003). (Percutaneous aortic valve replacement is performed
907 primarily in elderly patients unfit for surgery). A percutaneous or combined
908 percutaneous/surgical approach has been proposed to treat complex diseases such as
909 hypoplastic left heart syndrome. Fetal interventions are also possible.

910 (14) These techniques to treat congenital and valvular heart disease are largely
911 justified as they may replace very high-risk surgical procedures. Although
912 transesophageal and intracardiac ultrasound may partially replace fluoroscopy (Rice
913 et al, 2002, Zanchetta et al, 2004), radiation risk still remains a problem and is often
914 underestimated. Fluoroscopy times as high as 129 minutes may be required to
915 implant a pulmonary valve (Bonhoeffer et al, 2002). There is little literature
916 concerning the safety issues of these new devices to be used in infants and children
917 (Levi et al, 2003).

918

919 **1.1.5 Paediatric patients**

920 (15) A survey of patient doses in 137 children, aged from < 1 year to 16 years,
921 undergoing cardiac procedures performed using a biplane flat panel detector X-ray
922 system, demonstrated mean values of 1.9 to 8.6 Gy·cm² for diagnostic procedures.
923 Mean dose values for therapeutic procedures, in both extremes of the paediatric age

924 group, ranged from 2.4 to 17.8 Gy·cm² (Martinez et al, 2007). In a series of 205
925 children (mean age 4.1 y) who underwent diagnostic cardiac catheterization, the
926 mean dose was 17 Gy·cm² (Chida et al, 2010). In comparison to proposed diagnostic
927 reference levels for fluoroscopically guided cardiac interventions in adults of 50
928 Gy·cm² for diagnostic procedures and 125 Gy·cm² for therapeutic procedures
929 (Balter et al, 2008), paediatric patients have typically received less than 20% of the
930 dose received by adult patients. Nonetheless, radiation doses from paediatric cardiac
931 catheterization procedures are of concern (Andreassi, 2006, Andreassi, 2009).
932

933 1.2 Cardiac CT

934

935 (16) Cardiac CT technology has evolved rapidly in recent years, and these
936 advancements have enabled a variety of types of cardiac CT studies to be performed
937 that go well beyond detection of the coronary arteries. Today, cardiac CT
938 encompasses several distinct procedures, including coronary artery calcium (CAC)
939 scoring, CT coronary angiography (CTCA), pulmonary vein CT angiography, and
940 CT attenuation correction of nuclear cardiology image data. Recent technological
941 advances have been associated with an increase in the number of procedures
942 performed, although reliable statistics on worldwide numbers are not presently
943 available. In the United States, CT was the largest source of medical exposures to
944 patients in 2006, accounting for 49% of the medical exposure of patients (NCRP
945 report 160, 2009). Cardiac CT (including CTCA and CAC) accounted for 4.7% of
946 CT examinations, but 12.1% of patient exposure from CT.
947

948 1.3 Nuclear cardiology

949

950 (17) An estimated 32.7 million diagnostic nuclear medicine procedures are
951 performed annually worldwide (UNSCEAR 2008). Of these, approximately 14
952 million are nuclear cardiology procedures, and this number has increased rapidly
953 (Davis, 2006). More than 90% of nuclear cardiology studies are myocardial
954 perfusion scintigraphy studies for the assessment of myocardial perfusion and/or
955 viability. The vast majority of nuclear cardiology procedures performed employ
956 single photon emission computed tomography (SPECT), although a small but
957 growing number of laboratories perform positron emission tomography (PET)
958 studies.

959 (18) In the U.S., nuclear medicine procedures accounted for 26% of the
960 medical exposure of patients in 2006, and cardiac studies accounted for 85% of the
961 nuclear medicine exposure (NCRP report 160, 2009). Nuclear medicine procedures
962 were the second largest source of medical exposures, after CT.

963 (19) More nuclear cardiology procedures are performed in the United States
964 than in the rest of the world combined. Reasons suggested for this disparity include
965 better access to testing, a more litigious medicolegal climate, and profit motives for
966 testing. However, multiple U.S. series have demonstrated that for those procedures
967 where sufficient data are available to permit a determination of appropriateness, only
968 ~15% are performed for inappropriate indications (Gibbons, 2008; Hendel, 2010).
969 Nonetheless, cardiologists should consider using alternative methodologies that do
970 not require ionizing radiation, such as stress echocardiography, whenever possible.
971

972

973

1.4 Occupational radiation risk

974 (20) Radiation risk is not limited to patients. Operators and staff receive
975 radiation exposure during fluoroscopically guided procedures. The increased
976 complexity of interventional cardiology procedures appears to have offset dose
977 reductions due to improvements in technology (Kim, 2008). There is considerable
978 variation in operator doses observed for the same type of procedure, indicating that
979 radiological protection practices can be improved (Kim, 2009). Recent studies have
980 shown that there is an increased incidence of radiation-related cataracts in
981 interventional cardiologists when radiological protection tools are not used properly
982 (Vano, 2010, Ciraj-Bjelac, 2010) Unfortunately, there is lack of proper monitoring
983 of radiation doses to staff and lack of reliable data on occupational doses (Padovani,
984 2011).

985

986

1.5 Summary

987 (21) In summary, fluoroscopically guided cardiology procedures are increasing
988 in number and complexity. The benefits for patients are clear, but radiation doses for
989 both patients and staff are important and must be managed appropriately. For young
990 patients, the increased risk of cancer should be considered in the optimisation of
991 these procedures. For older patients cancer risk is not as important, but avoidance of
992 deterministic effects (skin injuries) should be taken into account. Interventional
993 cardiologists are among the radiation workers with the highest occupational
994 radiation risk, and should know how to protect both patients and themselves. This
995 ICRP report is intended to help achieve this goal.

996

997

1.6 References

- 998 Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC, McKay CR,
999 Weintraub WS. A contemporary overview of percutaneous coronary
1000 interventions. The American College of Cardiology-National Cardiovascular
1001 Data Registry (ACC-NCDR). *J Am Coll Cardiol* 2002; 39:1096-103.
- 1002 Andreassi MG, Ait-Ali L, Botto N, Manfredi S, Mottola G, Picano E. Cardiac
1003 catheterization and long-term chromosomal damage in children with congenital
1004 heart disease. *Eur Heart J* 2006; 27:2703–2708.
- 1005 Andreassi MG. Radiation risk from pediatric cardiac catheterization: friendly fire
1006 on children with congenital heart disease. *Circulation* 2009;120(19):1847-1849.
- 1007 Balter S, Miller DL, Vano E, Ortiz Lopez P, Bernardi G, Cotelo E, Faulkner K,
1008 Nowotny R, Padovani R, Ramirez A. A pilot study exploring the possibility of
1009 establishing guidance levels in x-ray directed interventional procedures. *Med*
1010 *Phys* 2008;35:673-80.
- 1011 Balter S, Hopewell JW, Miller DL, Wagner LK, Zelefsky MJ. Fluoroscopically
1012 guided interventional procedures: A review of radiation effects on patients' skin
1013 and hair. *Radiology* 2010;254:326-341.
- 1014 Bernardi G, Padovani R, Morocutti G, Vano E, Malisan MR, Rinuncini M,
1015 Spedicato L, Fioretti PM. Clinical and technical determinants of the complexity
1016 of PTCA procedures. Analysis in relation to radiation exposure parameters.
1017 *Cathet Cardiovasc Interv* 2000;51:1-9.
- 1018 Bonhoeffer P, Boudjemline Y, Qureshi SA, Le Bidois J, Iserin L, Acar P, Merckx J,
1019 Kachaner J, Sidi D. Percutaneous insertion of the pulmonary valve. *J Am Coll*
1020 *Cardiol* 2002;39:1664-9.

- 1021
1022 Ciraj-Bjelac O, Rehani MM, Sim KH, Liew HB, Vano E, Kleiman NJ. Risk for
1023 radiation induced cataract for staff in interventional cardiology: Is there reason
1024 for concern? *Catheter Cardiovasc Interv* 2010;76(6):826-834.
- 1025 Cheng TO. The current state of cardiology in China. *Int J Cardiol.* 2004
1026 Sep;96(3):425-39.
- 1027 Chida K, Ohno T, Kakizaki S, Takegawa M, Yuuki H, Nakada M, Takahashi S,
1028 Zuguchi M. Radiation dose to the pediatric cardiac catheterization and
1029 intervention patient. *AJR American Journal of Roentgenology* 2010;
1030 195(5):1175-1179.
- 1031 Davis W. Mapping improvements in molecular imaging. *Medical Imaging.*
1032 2006;May 2006. Available at:
1033 http://www.imagingeconomics.com/issues/articles/MI_2006-05_01.asp
1034 Accessed December 31, 2010.
- 1035 Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR,
1036 Guermontprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin
1037 M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E,
1038 Wulfert E. Maintenance of long-term clinical benefit with sirolimus-eluting
1039 coronary stents: three-year results of the RAVEL trial. *Circulation*
1040 2005;111:1040-4.
- 1041 Faulkner K, Werduch A. An estimate of the collective dose to the European
1042 population from cardiac x-ray procedures. *Br J Radiol* 2008a; 81:955-962.
- 1043 Faulkner K, Werduch A. Analysis of the frequency of interventional cardiology in
1044 various European countries. *Rad Prot Dosim* 2008b; 129(1-3):74-76.
- 1045 Hall EJ. Radiation biology for pediatric radiologists. *Pediatr Radiol* 2009;39 Suppl
1046 1:S57-64.
- 1047 Gibbons RJ, Miller TD, Hodge D, et al. Application of appropriateness criteria to
1048 stress single-photon emission computed tomography sestamibi studies and
1049 stress echocardiograms in an academic medical center. *J Am Coll Cardiol.*
1050 2008;51(13):1283-1289. International Atomic Energy Agency. Establishing
1051 guidance levels in x ray guided medical interventional procedures: A pilot
1052 study. Safety Reports Series No. 59. Vienna: International Atomic Energy
1053 Agency; 2009.
- 1054 Hendel RC, Cerqueira M, Douglas PS, et al. A multicenter assessment of the use of
1055 single-photon emission computed tomography myocardial perfusion imaging
1056 with appropriateness criteria. *J Am Coll Cardiol.* 2010;55(2):156-162.
- 1057 International Commission on Radiological Protection. Avoidance of radiation
1058 injuries from medical interventional procedures. ICRP Publication 85. *Ann*
1059 *ICRP* 2000;30:7-67.
- 1060 Kim KP, Miller DL, Balter S, Kleinerman RA, Linet MS, Kwon D, Simon SL.
1061 Occupational radiation doses to operators performing cardiac catheterization
1062 procedures. *Health Phys* 2008;94:211-227.
- 1063 Kim KP, Miller DL. Minimising radiation exposure to physicians performing
1064 fluoroscopically guided cardiac catheterisation procedures: a review. *Radiat*
1065 *Prot Dosimetry* 2009;133:227-33.
- 1066 Laskey WK, Kimmel S, MD, Krone RJ. Contemporary Trends in Coronary
1067 Intervention: A Report From the Registry of the Society for Cardiac
1068 Angiography and Interventions *Cathet. Cardiovasc. Intervent.* 49:19–22, 2000.

- 1069 Laskey WK, Williams DO, Vlachos HA, MS, H, Holmes DR, King SB, Kelsey SF,
1070 Slater J, Faxon D, Al-Bassam M, Block E, Detre KM for the Dynamic Registry
1071 Investigators. Changes in the Practice of Percutaneous Coronary Intervention: A
1072 Comparison of Enrollment Waves in the National Heart, Lung, and Blood
1073 Institute (NHLBI) Dynamic Registry. *Am J Cardiol* 2001;87:964–969.
- 1074 Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoyer A,
1075 Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma
1076 SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of
1077 sirolimus-eluting stents compared with conventional bare stent implantation in
1078 the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam
1079 Cardiology Hospital (RESEARCH) registry. *Circulation* 2004;109:190-5.
- 1080 Levi DS, Alejos JC, Moore JW. Future of interventional cardiology in pediatrics.
1081 *Curr Opin Cardiol*. 2003;18:79-90.
- 1082 Martinez LC, Vano E, Gutierrez F, Rodriguez C, Gilarranz R, Manzananas MJ.
1083 Patient doses from fluoroscopically guided cardiac procedures in pediatrics.
1084 *Phys Med Biol*. 2007;52(16):4749-59.
- 1085 McFadden SL, Mooney RB, Shepherd PH. X-ray dose and associated risks from
1086 radiofrequency catheter ablation procedures. *Br J Radiol* 2002;75:253-65.
- 1087 Meier, B. Cardiac catheterization interventions: European statistics 2007/2008.
1088 Presented at Euro PCR, May, 2010. Available at:
1089 [http://www.escardio.org/communities/EAPCI/Documents/Cardiac-](http://www.escardio.org/communities/EAPCI/Documents/Cardiac-catheterization-Interventions-stats07-08-EAPCI-Assembly-may2010.pdf)
1090 [catheterization-Interventions-stats07-08-EAPCI-Assembly-may2010.pdf](http://www.escardio.org/communities/EAPCI/Documents/Cardiac-catheterization-Interventions-stats07-08-EAPCI-Assembly-may2010.pdf)
1091 Accessed February 22, 2011.
- 1092 Miller DL. Overview of contemporary interventional fluoroscopy procedures.
1093 *Health Phys* 2008;95:638-44.
- 1094 Mond HG, Irwin M, Morillo C, Ector H. The world survey of cardiac pacing and
1095 cardioverter defibrillators: calendar year 2001. *Pacing Clin Electrophysiol*
1096 2004;27:955-64
- 1097 Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, Liu J, Cheng J, Bibbins-
1098 Domingo K, Shen YM, He J, Goldman L. Future cardiovascular disease in
1099 china: markov model and risk factor scenario projections from the coronary
1100 heart disease policy model-china. *Circ Cardiovasc Qual Outcomes*.
1101 2010;3(3):243-52.
- 1102 Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo
1103 A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study
1104 Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-
1105 Expandable Stent in the Treatment of Patients with de Novo Native Coronary
1106 Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a
1107 standard stent for coronary revascularization. *N Engl J Med* 2002;346:1773-80.
- 1108 Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP,
1109 Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator
1110 Implantation Trial II Investigators. Prophylactic implantation of a defibrillator
1111 in patients with myocardial infarction and reduced ejection fraction. *N Engl J*
1112 *Med* 2002;346:877-83.
- 1113 National Council on Radiation Protection and Measurements. Ionizing radiation
1114 exposure of the population of the United States. NCRP Report No. 160.
1115 Bethesda, MD: National Council on Radiation Protection and Measurements;
1116 2009.

- 1117 National Council on Radiation Protection and Measurements. Radiation dose
1118 management for fluoroscopically guided interventional medical procedures.
1119 NCRP Report No. 168. Bethesda, MD: National Council on Radiation
1120 Protection and Measurements; 2010.
- 1121 Padovani R, Bernardi G, Quai E, Toh HS, Signor M, Morocutti G, Spedicato L.
1122 Retrospective evaluation of occurrence of skin injuries in interventional cardiac
1123 procedures. *Radiat Prot Dosimetry* 2005; 117 (1-3):247-250.
- 1124 Padovani, R., Le Heron, J., Cruz-Suarez, R., Duran, A., Lefaure, C., Miller, D.L.,
1125 Sim, H.K., Vano, E., Rehani, M., Czarwinski, R., 2010. International project on
1126 individual monitoring and radiation exposure levels in interventional
1127 cardiology. *Radiat Prot Dosimetry* 2011; in press.
- 1128 Peterzol A, Quai E, Padovani R, Bernardi G, Kotre J, Dowling A. Reference levels
1129 in PTCA as a function of procedure complexity. *Radiat Prot Dosimetry*
1130 2005;117 (1-3): 54-58.
- 1131 Prieto C, Vano E, Fernández JM, Galvan C, Sabate M, Gonzalez L, Martinez D. Six
1132 years experience in intracoronary brachytherapy procedures: patient doses from
1133 fluoroscopy. *Br J Radiol.* 2006 Sep; 79(945): 730-733.
- 1134 Rice MJ, McDonald RW, Li X, Shen I, Ungerleider RM, Sahn DJ. New
1135 Technology and Methodologies for Intraoperative, Perioperative, and
1136 Intraprocedural Monitoring of Surgical and Catheter Interventions for
1137 Congenital Heart Disease *Echocardiography* 2002; 19:725-734.
- 1138 Rosenthal LS, Mahesh M, Beck TJ, Saul JP, Miller JM, Kay N, Klein LS, Huang S,
1139 Gillette P, Prystowsky E, Carlson M, Berger RD, Lawrence JH, Yong P,
1140 Calkins H. Predictors of fluoroscopy time and estimated radiation exposure
1141 during radiofrequency catheter ablation procedures. *Am J Cardiol* 1998;82:451-
1142 458.
- 1143 Salukhe TV, Dimopoulos K, Francis D. Cardiac resynchronisation may reduce all-
1144 cause mortality: meta-analysis of preliminary COMPANION data with
1145 CONTAk-CD, InSync ICD, MIRACLE and MUSTIC. *Int J Cardiol*
1146 2004;93:101-3.
- 1147 The SoS Investigators. Coronary artery bypass surgery versus percutaneous
1148 coronary intervention with stent implantation in patients with multivessel
1149 coronary artery disease (the Stent or Surgery trial): a randomized controlled
1150 trial. *Lancet* 2002;360:965–70.
- 1151 Togni M, Balmer F, Pfiffner D, Maier W, Zeiher AM, Meier B, on behalf of the
1152 Working Group Interventional Cardiology and Coronary Pathophysiology of the
1153 European Society of Cardiology. Percutaneous coronary interventions in Europe
1154 1992–2001. *Eur Heart J* 2004;25:1208–1213.
- 1155 Tsapaki, V., Ahmed, N.A., AlSuwaidi, J.S., Beganovic, A., Benider, A.,
1156 BenOmrane, L., Borisova, R., Economides, S., El-Nachef, L., Faj, D.,
1157 Hovhannesian, A., Kharita, M.H., Khelassi-Toutaoui, N., Manatrakul, N.,
1158 Mirsaidov, I., Shaaban, M., Ursulean, I., Wambani, J.S., Zaman, A., Ziliukas, J.,
1159 Zontar, D., Rehani, M.M., 2009. Radiation exposure to patients during
1160 interventional procedures in 20 countries: initial IAEA project results. *AJR.*
1161 *Am. J. Roentgenol.* 193, 559-569.
- 1162 UNSCEAR. Sources and effects of ionizing radiation: volume I, sources: annex D,
1163 medical radiation exposure. Report to the General Assembly of the United
1164 Nations; 2000; New York, NY Available at:

- 1165 http://www.unscear.org/unscear/en/publications/2000_1.html Accessed
1166 December 31, 2010.
- 1167 UNSCEAR. Sources of ionizing radiation: volume I. Report to the General
1168 Assembly, with scientific annexes; 2010; New York, NY. Available at:
1169 http://www.unscear.org/unscear/en/publications/2008_1.html Accessed
1170 December 31, 2010.
- 1171 Vano E, Goicolea J, Galvan C, Gonzalez L, Meiggs L, Ten JJ, Macaya C. Skin
1172 radiation injuries in patients following repeated coronary angioplasty
1173 procedures. *Br J Radiol*. 2001 Nov;74(887):1023-31.
- 1174 Vano E, Kleiman NJ, Duran A, Rehani MM, Echeverri D, Cabrera M. Radiation
1175 cataract risk in interventional cardiology personnel. *Radiat Res*, 2010;
1176 174(4):490-495
- 1177 Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G,
1178 Thomas M, Calman F, Disco C, Serruys PW, Wijns W, Piessens M, Kurtz J,
1179 Simon R, Delafontaine P, Erbel R. Endoluminal Beta-Radiation Therapy for the
1180 Prevention of Coronary Restenosis after Balloon Angioplasty. *N Engl J Med*
1181 2001;344:243-249.
- 1182 Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, Mintz GS,
1183 Satler LF, Pichard AD, Leon MB, Kent KK. Intracoronary beta-radiation
1184 therapy inhibits recurrence of in-stent restenosis. *Circulation* 2000;101:1895-8.
- 1185 Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, Coady
1186 P, Cohen H, Cowley M, Dorros G, Faxon D, Holmes DR, Jacobs A, Kelsey SF,
1187 King SB, Myler R, Slater J, Stanek V, Vlachos HA, Detre KM. Percutaneous
1188 Coronary Intervention in the Current Era Compared With 1985–1986 The
1189 National Heart, Lung, and Blood Institute Registries. *Circulation*
1190 2000;102:2945-2951.
- 1191 Zanchetta M, Maiolino P. Intracardiac echocardiography. Do we need a new
1192 ultrasonographic window? *Ital Heart J* 2004;5:173-177.
1193

1194

1195

2. THE BIOLOGICAL EFFECTS OF RADIATION

1196

1197

Main Points

1198

1199

- **Deterministic effects are due to injury in populations of cells, characterised by a threshold dose and an increase in the incidence and severity of the reaction as the dose is increased further. Deterministic effects are also termed tissue reactions.**

1200

1201

1202

1203

- **Stochastic effects are malignant disease and heritable effects for which the probability of an effect occurring, but not its severity, is regarded as a function of dose without threshold.**

1204

1205

1206

- **Radiation-induced skin injuries may not become fully manifest until months after the radiation dose was administered.**

1207

1208

- **The diagnosis of a radiation induced skin injury is often delayed.**

1209

- **The lens of the eye is a radiosensitive tissue.**

1210

- **In the lens of the eye, ionizing radiation typically causes posterior subcapsular cataract formation.**

1211

1212

- **Surveys of cardiologists and support staff working in catheterization laboratories have found a high percentage of lens opacities attributable to occupational radiation exposure when radiological protection tools have not been used properly.**

1213

1214

1215

1216

1217

2.1 Types of radiation effects

1218

1219

(22) The effects of radiation can be classified into two groups: deterministic effects (harmful tissue reactions) and stochastic effects (cancer and heritable effects).

1220

1221

1222

(23) *Deterministic effects* (e.g. skin injury) are largely caused by the reproductive sterilisation of cells following high radiation doses. The induction of tissue reactions is generally characterised by a threshold dose. The reason for the presence of this threshold dose is that radiation-induced reproductive survival of a critical population of cells in a given tissue needs to be sustained before injury is expressed in a clinically relevant form. Above the threshold dose the incidence and severity of the injury, including impairment of the capacity for tissue recovery, increases with dose (ICRP 103). The threshold is variable, depending on the nature and condition of the exposed tissue (Balter, 2010).

1223

1224

1225

1226

1227

1228

1229

1230

1231

(24) The injury is not expressed clinically until the cells die as a result of an unsuccessfully attempt at cell division or differentiation and are lost as part of the normal process of tissue turnover (Balter, 2010). The incidence as well as the severity of the injury, including impairment of the capacity for tissue recovery, increases with dose. After a high radiation dose, the outcome for the affected individual can be devastating (Balter, 2010).

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

(25) Eighty percent of reported radiation-induced skin injuries in one large series were from cardiac procedures (Koenig et al 2001). Nonetheless, cardiologists often do not recognise that a radiation injury is related to a cardiac procedure, either because they are unaware of the magnitude of radiation dose delivered or they do not know that radiation can cause skin injuries.

1242 (26) The dose of radiation received by some patients is high and the number of
1243 radiation injury cases is increasing (NCI, 2005). However, most currently practising
1244 interventional cardiologists have no personal experience of a case of radiation
1245 injury. The number of radiation injuries is small compared with the number of
1246 fluoroscopically guided cardiology procedures performed worldwide.

1247 (27) *Stochastic effects* The accumulation of cellular and animal data relevant to
1248 radiation tumourigenesis has, since 1990, strengthened the view that DNA damage
1249 response processes in single cells are of critical importance to the development of
1250 cancer after radiation exposure. Epidemiological and experimental studies provide
1251 evidence of radiation risk, albeit with uncertainties at doses about 100 mSv or less
1252 (ICRP 103).

1253 (28) These effects are probabilistic—there is no identifiable threshold for
1254 producing the effect. The likelihood of inducing a stochastic effect increases with
1255 dose, but the exact relationship between dose and effect is not known. In the low
1256 dose range, below about 100 mSv, it is scientifically plausible to assume that the
1257 incidence of cancer or heritable effects will rise in direct proportion to an increase in
1258 the equivalent dose in the relevant organs and tissues (the “linear-non-threshold” or
1259 LNT model) (ICRP 103). Dose has no relationship to the severity of the effect.

1260 (29) Children are approximately 2-3 times more sensitive to the stochastic
1261 effects of radiation than adults (ICRP 1991). They also have a longer potential
1262 lifespan than do adults, so they have more time to develop possible radiation related
1263 sequelae. In children, the probability of a fatal cancer per fluoroscopically guided
1264 procedure is estimated at approximately 0.07-0.08%, but this risk may vary widely
1265 depending on patient age, underlying life expectancy and how the procedure is
1266 performed (Martinez et al, 2007, Bacher et al, 2005).

1267 (30) While there is compelling evidence that radiation causes heritable effects
1268 in experimental animals, there continues to be no direct evidence that exposure of
1269 humans to radiation leads to excess heritable disease in offspring (ICRP 103).

1270

1271

2.2 Background

1272

1273 (31) Some months after the discovery of x-rays in 1895, radiation-induced skin
1274 changes were observed (Daniel 1896, Codman 1896). Some early radiologists
1275 suffered severe dermatitis, radiation cancer and amputation of digits. There was a
1276 delay in recognising that x-rays were the cause because they are invisible and do not
1277 cause any sensation during exposure. As noted in ICRP Publication 103, the goal of
1278 preventing these radiation injuries was the impetus for the formation of what is now
1279 the Commission (ICRP 2007).

1280 (32) Following the dramatic rise in the number of percutaneous coronary
1281 interventional procedures, cases of patients with deep skin ulceration and necrosis
1282 were reported in the 1990s (Shope, 1996). In 1994 the U.S. Food and Drug
1283 Administration issued an advisory regarding skin injury from fluoroscopically
1284 guided procedures (FDA 1994). Radiation skin injury has also been reported
1285 following radiofrequency catheter ablations (Vano, 1998). This is of particular
1286 concern because many of these patients are young adults, and some are children.
1287 The Commission drew attention to prevention of skin injuries from interventional
1288 fluoroscopy procedures in Publication 85 (ICRP 2000), and reiterated the
1289 importance of preventing skin injuries in Publication 105 (ICRP 2007).

1290

2.3 Radiation Effects and the Skin

1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331

(33) The response of the skin to radiation is dose-related and occurs when this dose is concentrated on one area, usually the site where the x-rays enter the patient. The term “absorbed dose” is used to assess the amount of radiation to which a tissue is exposed (see the Glossary). The skin response follows a characteristic pattern, although the time course is variable (Balter et al, 2010). The threshold doses and time of appearance for various types of skin injury are summarised in **Table 2.1**.

(34) Defects in DNA repair genes may predispose individuals to radiogenic cancer or lower the threshold for the development of deterministic effects. Some patients with serious and unanticipated radiation injuries may be among the 1% of the population heterozygous for the ATM gene, an autosomal recessive gene responsible for ataxia telangiectasia, or may harbour some other ATM abnormality. (Hymes, 2006, Allan, 2008) Other disorders with a genetic component affecting DNA breakage or repair also increase radiation sensitivity, including Fanconi anaemia, Bloom syndrome and xeroderma pigmentosum. Familial polyposis, Gardner syndrome, hereditary malignant melanoma and dysplastic nevus syndrome also increase radiation sensitivity (Hymes, 2006). Certain familial cancer syndromes may increase susceptibility to radiogenic cancer, including neurofibromatosis, Li-Fraumeni syndrome and hereditary retinoblastoma (Allan, 2008).

(35) Autoimmune and connective tissue disorders predispose patients to the development of severe cutaneous radiation effects in an unpredictable fashion. These typically occur in association with the high radiation doses administered during radiation therapy. The aetiology is not known. These disorders include scleroderma, systemic lupus erythematosus and possibly rheumatoid arthritis. (Wagner et al, 1999, Hymes, 2006) Hyperthyroidism and diabetes mellitus are also associated with increased radiation sensitivity (Koenig Part 1, 2001) Diabetes is believed to predispose to radiation injury secondary to small vessel vascular disease and consequent decreased healing capacity (Herold, 1999). A number of drugs increase radiation sensitivity, including actinomycin D, doxorubicin, bleomycin, 5-fluorouracil and methotrexate (Koenig Part 1, 2001) Again, this effect is usually seen only with the high radiation doses delivered during radiation therapy.


(36) It is apparent from the foregoing and from **Table 2.1** that there are no rigid thresholds for dose or time of appearance of radiation-induced skin changes, because individuals vary in their radio-sensitivity and radio-responsiveness (Balter et al, 2010). These ranges are shown graphically in **Figure 2.1**. In the discussion below, threshold doses are given for an average person, but it should be understood that these will vary from individual to individual. For most patients, clinically important skin reactions occur only when the absorbed skin dose is greater than 5 Gy (Balter et al, 2010; **ICRP Tissue Reactions, 2011a**).

1332 **Table 2.1: Tissue reactions from a single-delivery radiation dose to the skin of the neck, torso, pelvis, buttocks or**
 1333 **arms.** (from Balter et al, 2010)

- This table is applicable to the normal range of patient radiosensitivities in the absence of mitigating or aggravating physical or clinical factors.
 - Skin dose refers to absorbed skin dose (including backscatter). This quantity is **not** the reference air kerma ($K_{a,r}$) described by the Food and Drug Administration (21 CFR § 1020.32 (2008)) or the International Electrotechnical Commission.(IEC, 2010)
 - This table does not apply to the skin of the scalp.
 - Abrasion or infection of the irradiated area is likely to exacerbate radiation effects.
 - **The dose and time bands are not rigid boundaries. Signs and symptoms are expected to appear earlier as the skin dose increases.**

Band	Single-site Acute Skin-Dose Range (Gy) ¹	NCI Skin Reaction Grade*	Approximate time of onset of effects			
			(4) Prompt < 2 weeks	(5) Early 2 – 8 weeks	Mid term 6 – 52 weeks	Long term > 40 weeks
A1	0-2	N/A	No observable effects expected			
A2	2-5	1	- Transient erythema	- Epilation	- Recovery from hair loss	(6) - None expected
B	5-10	1	- Transient erythema	- Erythema, epilation	- Recovery. - At higher doses; prolonged erythema, permanent partial epilation	(7) - Recovery. - At higher doses dermal atrophy/induration.
C	10-15	1-2	- Transient erythema	- Erythema, epilation. - Possible dry or moist desquamation (8) - Recovery from desquamation	(9) - Prolonged erythema. - Permanent epilation.	(10) - Telangiectasia ² - Dermal atrophy/induration. - Skin likely to be weak.
D	> 15	3-4	- Transient erythema - After very high doses, edema and acute ulceration; long-term surgical intervention likely to be required.	- Erythema, epilation. (11) - Moist desquamation	(12) - Dermal atrophy, - Secondary ulceration due to failure of moist desquamation to heal; surgical intervention likely to be required. - At higher doses, dermal necrosis; surgical intervention likely to be required..	(13) - Telangiectasia ² . - Dermal atrophy/induration, - Possible late skin breakdown. - Wound might be persistent and progress into a deeper lesion. - Surgical intervention likely to be required.
¹ Skin dosimetry is unlikely to be more accurate than ± 50% ² Refers to radiation-induced telangiectasia. Telangiectasia associated with an area of initial moist desquamation or the healing of ulceration may be present earlier. *NCI = U.S. National Cancer Institute						

1334
1335



1336
1337
1338
1339
1340
1341
1342

Figure 2.1: Graphical representation of data in Table 2.1 showing overlap in the skin effects with both dose and time.

(37) The lowest dose that may produce a noticeable skin change in individuals with average radiation sensitivity is conventionally considered to be 2 Gy. Histamine-like substances are activated and dilate capillaries, resulting in reddening (transient erythema). This usually occurs within hours of exposure and fades after 24 hours. This effect is likely to be under-reported due to its short duration.

(38) After a dose of 6 Gy, a second hyperaemic phase (main erythema) commences at approximately 10 days. This phase may be apparent earlier after doses > 6 Gy. It results from the destruction of proliferating basal cells in the epidermis. The patient may complain of burning, tenderness and itching, and the skin becomes warm and oedematous. The erythema usually peaks at 2 weeks and fades by 4 weeks (Koenig et al, 2001).

(39) If doses exceed 10 Gy, the erythema may be more prolonged, with hyperpigmentation. At skin doses > 14 Gy the inflammation can progress to dry desquamation—the erythematous skin is covered with scales and flakes of corneum, with an appearance resembling sunburn. Moist desquamation occurs at doses of about 18 Gy. The skin blisters and sloughs with weeping of serum from the deep cutaneous layers.

1359 This is associated with considerable pain and the skin becomes susceptible to infection.
1360 Topical antibiotics are often required (Shack et al, 1987). The proliferative cells in the
1361 basal layer of the epidermis are damaged and reduced in number. Desquamation usually
1362 appears 4 weeks after exposure and can last many weeks, particularly if secondary
1363 infection occurs.

1364 (40) A late phase of erythema can develop 8-10 weeks after radiation exposure of
1365 approximately 15 Gy. The skin has a mauve or dusky appearance. A skin dose of about
1366 18 Gy may result in vascular insufficiency of the dermis, leading to ischemic dermal
1367 necrosis 10-16 weeks following exposure. The damage is greater at higher doses (Koenig
1368 et al, 2001).

1369 (41) Dermal atrophy occurs after prolonged erythema, particularly when associated
1370 with moist desquamation. This is typically seen in two phases, initially at 3 months and
1371 then at 1 year. At doses above 10 Gy, telangiectasia may also develop because of dilation
1372 of the dermal capillaries. This is often a late phenomenon, occurring more than a year
1373 after exposure, but has been noted earlier and can increase over time (Tureson et al,
1374 1986). Trauma may precipitate late necrosis in skin that shows these late changes. The
1375 threshold for this is approximately 12 Gy, so it may be seen in the absence of earlier skin
1376 desquamation.

1377 (42) The diagnosis of a radiation-induced skin injury is often delayed because these
1378 lesions are relatively rare and the cause may not be recognized. Also, there is often a
1379 latent period of many months before the lesion is fully apparent (Balter et al, 2010).
1380 Patients often seek care from a dermatologist, rather than the physician who performed
1381 the interventional procedure. As a result, the history of fluoroscopy may be overlooked
1382 or considered irrelevant (Frazier et al 2007). Skin biopsy is frequently performed,
1383 although the results are not specific for radiation injury and can lead to a non-healing
1384 ulcer, as can other forms of trauma. Misdiagnoses are often made, including contact
1385 dermatitis from an electrode pad, allergy to adhesive tape or skin disinfectant, drug
1386 eruption, viral or bacterial infection and even insect bite. The deep pain associated with
1387 an injury may lead to extensive chest and abdominal evaluation (Vlietstra et al 2004).
1388 Severe injuries may extend into muscle (Monaco et al, 2003).

1389 (43) Skin cancer directly related to radiation from an interventional procedure has
1390 not been reported. Cases of basal cell carcinoma have been documented following x-ray
1391 treatment for scalp ringworm (Shore 2002) with a relative risk of 3.6 after a scalp dose of
1392 4.8 Gy. The relative risk of skin cancer in Chinese medical x-ray workers has been
1393 estimated at 4.1 in a cohort studied from 1950 – 1995. (Wang 2002)

1394



1395

2.4 The Lens of the Eye and Radiation

1396

1397 (44) The prevalence of cataract is difficult to estimate, as it depends in part on the
1398 definition of cataract. The Framingham Eye Study (Kahn et al, 1977) found a 91%
1399 prevalence in 75-85 year olds, although this figure was reduced to 46% if ‘modest visual
1400 deficit’ is added to the definition. A more recent Spanish study gave a prevalence of
1401 cataract and decreased visual acuity of more than 60% of 75 year olds. (Acosta et al,
1402 2006)

1403 (45) The majority of lens opacities that are not due to radiation are associated with
1404 cortical changes in the superficial substance of the lens. The lens is a radiosensitive
1405 tissue. Ionizing radiation typically causes posterior subcapsular (PSC) cataract formation
1406 (Figure 2.2). Unlike an age-related cataract, which usually interferes initially with visual
1407 acuity, a PSC cataract reduces contrast sensitivity before reducing visual acuity.
1408
1409



1426

1427

1428 **Figure 2.2:** a) A radiation-induced posterior subcapsular (PSC) cataract is shown as a
1429 central black shadow at the posterior aspect of the lens. b) Retroillumination photograph
1430 of a PSC cataract at the posterior aspect of the lens. This causes glare and poor vision in
1431 bright light conditions as well as poor reading vision. (From RSNA News, June 2004
1432 (<http://www.rsna.org/Publications/rsnanews/upload/jun2004.pdf>)) [Permission to be
1433 requested from RSNA]

1434

1435 (46) The response of the lens to radiation has traditionally been considered a
1436 deterministic effect. The threshold dose for detectable human lens opacities has been
1437 considered to be 2 Sv for a single acute exposure and 5 Sv for protracted exposure. For
1438 cataract with visual impairment, the thresholds have been considered to be 5 Sv and 8 Sv
1439 respectively. (ICRP 1991, NCRP 1993). More recent data in populations exposed to
1440 lower doses of radiation suggest that dose related lens opacification occurs at exposures
1441 significantly lower than 2 Sv, and that there may be no dose threshold. (Worgul et al,
1442 2007, Kleiman 2007, NCRP 168, 2010, Shore 2010, ICRP XXX [Tissue Reactions],
1443 2011a)

1444 (47) There have been reports of radiation-induced cataracts in interventionalists
1445 who have performed procedures for a number of years, and of doses to the lens
1446 approaching the annual limit of 150 mSv during angiographic procedures (Figure 2.3)

1447 (Vano et al, 1998, Pages 2000, Hidajat 2006, Vano et al 2010). Recent studies have
1448 shown that with typical reported interventional workloads the radiation dose to the lens
1449 may exceed the current threshold for deterministic effects after several years of work, if
1450 radiological protection tools are not used (Vano et al, 2008, Kim et al, 2008) Several
1451 surveys of cardiologists and support staff working in catheterization laboratories,
1452 conducted with coordination provided by the International Atomic Energy Agency
1453 (IAEA) in Latin America and Asia, have found a high percentage of lens opacities
1454 attributable to occupational radiation exposure (Vano et al, 2010, Ciraj-Bjelac et al,
1455 2010).

1456 (48) These recent data and the mechanistic uncertainties regarding cataract
1457 development have highlighted the need for a detailed reappraisal of the radiosensitivity of
1458 the lens of the eye. This issue is addressed in ICRP Publication **XXX**, on Tissue
1459 Reactions and Other Non-Cancer Effects of Radiation and its Statement on Tissue
1460 Reactions (ICRP, 2011a, 2011b). The previous Commission recommendation (ICRP,
1461 1991) of a dose limit of 150 mSv per year for occupational exposure in a planned
1462 exposure situation (e.g., occupational exposure of interventionalists) has been changed.
1463 The Commission now recommends that the lens dose limit for chronic occupational
1464 exposure should be 20 mSv in a year, averaged over defined periods of 5 years, with no
1465 single year exceeding 50 mSv, i.e. the same as the annual whole body limit for workers
1466 (ICRP, 2011a, 2011b).

1467 (49) The Commission now considers the threshold in absorbed dose to the lens of
1468 the eye to be 0.5 Gy (ICRP, 2011b). The Commission judges, based on existing
1469 evidence, that an acute dose of up to around 100 mGy produces no functional impairment
1470 of tissues, including the lens of the eye with respect to cataract, although the use of a
1471 threshold model remains uncertain for this tissue (ICRP, 2011a).

1472
1473



1474
1475
1476
1477

Figure 2.3: PSC cataract in the eye of an interventionist using an old x-ray system and high scatter radiation from improper working conditions (E. Vano BJR 1998)

1478

1479

1480

2.5 Cardiovascular effects of radiation exposure

1481

1482 (50) The mechanisms of heart radiation damage include inflammatory processes, in
1483 particular after low doses, and after higher doses there is a progressive reduction in the
1484 number of patent capillaries eventually leading to ischemia, myocardial cell death and
1485 fibrosis, accelerated atherosclerosis in major blood vessels, decreased cardiac function,
1486 and fatal congestive heart failure. There are no known mitigators of radiation-induced
1487 cardiovascular disease (ICRP, 2011).

1488 (51) Analyses of the atomic bomb survivors have shown that radiation doses above
1489 0.5 Gy are associated with an elevated risk of both stroke and heart disease (Shimizu et
1490 al, 2010). These findings are consistent with other studies that demonstrated an increased
1491 risk of heart disease after radiation therapy to the chest (Bhatti et al, 2008). There is
1492 compelling evidence that ionizing radiation in the doses using for radiation therapy can
1493 increase the risk of heart disease (McGale and Darby, 2008).

1494 (52) Radiation induced heart disease can occur as a result of both microvascular
1495 damage to the myocardium, leading to focal myocardial degeneration and fibrosis, and
1496 accelerated atherosclerosis in major blood vessels. Cardiovascular radiation effects have
1497 been reported to occur at doses > 0.5 Gy (ICRP, 2011). Although uncertainty remains,
1498 medical practitioners should be aware that the absorbed dose threshold for circulatory
1499 disease may be as low as 0.5 Gy to the heart (ICRP, 2011b). In some complex
1500 fluoroscopically guided cardiac procedures, organ doses may be > 0.5 Gy. These
1501 radiation effects need to be considered during the optimization process.

1502 (53) At lower doses (below 0.5 Gy) the relationship between radiation dose and
1503 increased cardiovascular risk is unclear (Shimizu et al, 2010). McGeoghegan and
1504 colleagues (2008) observed an association between mortality from non-cancer causes of
1505 death, particularly circulatory system disease, and exposure to ionizing radiation in their
1506 analysis of 42,000 radiation workers with low-dose, long-term radiation exposure. Other
1507 studies have shown mixed results (McGale and Darby, 2008). Recent reviews of
1508 epidemiological studies of populations medically, occupationally or environmentally
1509 exposed to relatively low-dose radiation showed that there was substantial heterogeneity
1510 in the association between radiation exposure and circulatory disease, with respect to the
1511 risk per unit radiation dose, possibly resulting from confounding factors or bias (ICRP,
1512 2011). As there is no clear understanding of the underlying biological mechanisms, it is
1513 difficult to interpret these mixed results (Dauer et al, 2010).

1514

1515

2.6 Occupational radiation exposure and intracranial neoplasms

1516

1517 (54) Ionizing radiation is one of the few established causes of neural tumours
1518 (Yonehara et al., 2004). Preston and colleagues studied the incidence of nervous system
1519 tumours in atomic bomb survivors (Preston et al., 2007; Preston et al., 2002). They found
1520 a significant dose-related excess of nervous system tumours. They concluded that
1521 exposure to doses of radiation as low as < 1 Sv is associated with an elevated incidence

1522 of nervous system tumours (Preston et al., 2002). It is clear that in children, radiation
1523 exposure is associated with the development of brain cancer, but the relationship in
1524 individuals exposed as adults is much less clear. The association between benign
1525 intracranial tumours and radiation appears to be substantially stronger than for malignant
1526 tumours (UNSCEAR, 2000). However, the BEIR-VII report does not explicitly present
1527 Lifetime Attributable Risk (LAR) for brain cancer incidence or mortality (NRC, 2006).
1528 What is clear is that for operators and staff, the brain is one of the least protected organs
1529 during interventional fluoroscopy procedures.

1530 (55) Radiation dose to the brain in fluoroscopists has not been well studied. Wenzl
1531 noted that cardiologists may receive the highest radiation doses of any specialists who
1532 use fluoroscopy for interventional procedures (Wenzl, 2005). Renaud determined that
1533 the annual exposure to cardiologists' heads was approximately 20 – 30 mSv (Renaud,
1534 1992). However, Renaud's study was performed with data from 1984 through 1988,
1535 when both cardiac interventions and fluoroscopic equipment were less sophisticated than
1536 they are now.

1537 (56) Finkelstein suggested that the occurrence of brain tumours in two Toronto
1538 cardiologists in a one-year period might indicate that they were radiation-induced
1539 (Finkelstein, 1998). Epidemiologic evidence for radiation-induced brain cancer in
1540 fluoroscopists is suggestive, but by no means conclusive. In 1975, Matanoski and
1541 colleagues found that the death rate from brain cancer in American radiologists was
1542 almost 3 times that of other medical specialists who did not use radiation (Matanoski et
1543 al., 1975). In a Swedish case-control study of 233 patients with brain tumours, Hardell
1544 and colleagues reported that work as a physician using fluoroscopy increased the risk of
1545 developing a brain tumour, with an odds ratio of 6.0 (95% confidence interval, 0.62-
1546 57.7), but there were only 3 such individuals among the 233 cases (Hardell et al., 2001).
1547 No increased risk was found for other health care workers. In a case-control study of 476
1548 individuals diagnosed with gliomas between 1991 and 1994 in the San Francisco area,
1549 Carozza and colleagues observed an increased risk in physicians and surgeons (odds ratio
1550 3.5, 95% confidence interval 0.7-17.6) (Carozza et al., 2000). There were only 6
1551 physicians in the group, and the authors suggested that the increased risk might be due to
1552 occupational exposure to numerous biologic agents and chemicals as well as to radiation.
1553 On the other hand, Blettner and colleagues conducted a case-control study in Germany of
1554 844 patients with brain tumours and 1737 control subjects, using self-reported medical
1555 and occupational data (Blettner et al., 2007). More than 2/3 of the 91 participants
1556 occupationally exposed to radiation were in the medical field (physicians, nurses,
1557 radiographers). Blettner and colleagues found no significant risk of brain tumours as a
1558 result of exposure to medical ionizing radiation. Karipidis and colleagues conducted a
1559 case-control study in Australia of 416 patients with gliomas and 422 controls and found
1560 no evidence of an association between gliomas and ionizing radiation (Karipidis et al.
1561 2007).

1562
1563
1564

2.7 References

- 1565 Acosta R, Hoffmeister L, Roman R, Comas M, Castilla M, Castells X. Systematic
1566 review of population-based studies of the prevalence of cataracts. *Arch Soc Esp*
1567 *Oftalmol* 2006; 81: 509-516
- 1568 Allan JM. Genetic susceptibility to radiogenic cancer in humans. *Health Phys* 2008;
1569 95:677-686.
- 1570 Bacher K, Bogaert E, Lapere R, De Wolf D, Thierens H. Patient-specific dose and
1571 radiation risk estimation in pediatric cardiac catheterization. *Circulation*. 2005 Jan
1572 4;111(1):83-9.
- 1573 Balter S, Hopewell JW, Miller DL, Wagner LK, Zelefsky MJ. Fluoroscopically guided
1574 interventional procedures: A review of radiation effects on patients' skin and hair.
1575 *Radiology* 2010; 254:326-41.
- 1576 Bhatti P, Sigurdson AJ, Mabuchi K. Can low-dose radiation increase risk of
1577 cardiovascular disease? *Lancet* 2008; 372:697-699.
- 1578 Blettner M., Schlehofer B., Samkange-Zeeb F., Berg G., Schlaefer K., Schüz J. (2007)
1579 Medical exposure to ionising radiation and the risk of brain tumours: Interphone
1580 study group, Germany. *Eur J Cancer* 43:1990-8.
- 1581 Carozza S.E., Wrensch M., Miike R., Newman B., Olshan A.F., Savitz D.A., Yost M.,
1582 Lee M. (2000) Occupation and adult gliomas. *Am J Epidemiol* 152:838-46.
- 1583 Finkelstein M.M. (1998) Is brain cancer an occupational disease of cardiologists? *Can J*
1584 *Cardiol* 14:1385-8.
- 1585 Ciraj-Bjelac O, Rehani MM, Sim KH, Liew HB, Vano E, Kleiman NJ. Risk for radiation
1586 induced cataract for staff in interventional cardiology: Is there reason for concern?
1587 *Catheter Cardiovasc Interv* 2010;76(6):826-834.
- 1588 Codman EA. The cause of burns from x-rays. (letter) *Bos Med Surg J* 1896; 136:610-
1589 611
- 1590 Daniel J. The x-rays. (letter) *Science* 1896; 3:562
- 1591 Dauer LT, Brooks AL, Hoel DG, Morgan WF, Stram D, Tran P. Review and evaluation
1592 of updated research on the health effects associated with low-dose ionising radiation.
1593 *Radiat Prot Dosim* 2010; 140(2):103-136
- 1594 Frazier TH, Richardson JB, Fabre VC, Callen JP. Fluoroscopy-induced chronic
1595 radiation skin injury: a disease perhaps often overlooked. *Arch Dermatol* 2007;
1596 143(5): 637-640
- 1597 Hardell L., Hansson Mild K., Pålsson A., Hallquist A. (2001) Ionizing radiation, cellular
1598 telephones and the risk for brain tumours. *Eur J Cancer Prev* 10:523-9.
- 1599 Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor for late radiation
1600 morbidity. *Int J Radiat Oncol Biol Phys* 1999; 43: 475-479
- 1601 Hidajat N, Wust P, Felix R, Schroder RJ. Radiation exposure to patient and staff in
1602 hepatic chemoembolization: risk estimation of cancer and deterministic effects.
1603 *Cardiovasc Intervent Radiol* 2006; 29(5): 791-796
- 1604 Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation,
1605 pathophysiology, and treatment 2006. *J Am Acad Dermatol* 2006;54:28-46
- 1606 IEC. Report 60601 Medical electrical equipment - Part 2-43: Particular requirements for
1607 the safety of X-ray equipment for interventional procedures. 2nd ed. Geneva,
1608 Switzerland: International Electrotechnical Commission; 2010.

- 1609 ICRP, 1990. The 1990 Recommendations of the International Commission on
1610 Radiological Protection. ICRP Publication 60. Ann ICRP 1991; 21(1-3):1-201
1611 ICRP, 2000. Avoidance of radiation injuries from medical interventional procedures.
1612 ICRP Publication 85. Ann ICRP 30:7-67.
1613 ICRP, 2007a. The 2007 Recommendations of the International Commission on
1614 Radiological Protection. ICRP Publication 103. Ann ICRP 37(2-4):1-332
1615 ICRP, 2007b.. Radiological protection in medicine. ICRP Publication 105. Ann ICRP
1616 37:1-63
1617 ICRP Protection 2011a. Tissue Reactions and Other Non-Cancer Effects of Radiation.
1618 ICRP Publication XXX. Ann ICRP 2011; in press
1619 ICRP 2011b. Statement on Tissue reactions. Approved by the Commission on April
1620 21, 2011. Available at
1621 <http://www.icrp.org/docs/ICRP%20Statement%20on%20Tissue%20Reactions.pdf>
1622 Accessed May 9, 2011. (in press)
1623 Kahn, HA, Liebowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR.
1624 The Framingham Eye Study. I. Outline and major prevalence findings. Am J
1625 Epidemiol 1977; 106(1): 17-32
1626 Karipidis KK, Benke G, Sim MR, Kauppinen T, Giles G. (2007) Occupational exposure
1627 to ionizing and non-ionizing radiation and the risk of glioma. Occup Med (Lond)
1628 57:518-524.
1629 Kim KP, Miller DL, Balter S, Kleinerman RA, Linet MS, Kwon D, Simon SL.
1630 Occupational radiation doses to operators performing cardiac catheterization
1631 procedures. Health Phys 2008;94:211-227.
1632 Kleiman NJ. Radiation cataract. In: Working Party on Research Implications on Health
1633 and Safety Standards of the Article 31 Group of Experts, ed. Radiation Protection
1634 145 EU Scientific Seminar 2006 New insights in radiation risk and basic safety
1635 standards. Brussels: European Commission; 2007:81-95. Available at
1636 http://ec.europa.eu/energy/nuclear/radioprotection/publication/doc/145_en.pdf
1637 Accessed July 28, 2010
1638 Koenig TR, Wolff D, Mettler FA, Wagner LK. Skin injuries from fluoroscopically
1639 guided procedures: Part 1, Characteristics of radiation injury. AJR 2001; 177: 3-11
1640 Martinez LC, Vano E, Gutierrez F, Rodriguez C, Gilarranz R, Manzanas MJ. Patient
1641 doses from fluoroscopically guided cardiac procedures in pediatrics. Phys Med Biol
1642 2007; 52: 4749-4759.
1643 Matanoski G.M., Seltser R., Sartwell P.E., Diamond E.L., Elliott E.A. (1975) The
1644 current mortality rates of radiologists and other physician specialists: specific causes
1645 of death. Am J Epidemiol 101:199-210.
1646 McGale P, Darby SC. Commentary: A dose-response relationship for radiation-induced
1647 heart disease—current issues and future prospects. Int J Epidemiol 2008; 37:518-
1648 523
1649 McGeoghegan D, Binks K, Gillies M, Jones S, Whaley S. The non-cancer mortality
1650 experience of male workers at British Nuclear Fuels plc, 1946-2005. Int J Epidemiol
1651 2008; 37:506-518

- 1652 Monaco JL, Bowen K, Tadros PN, Witt PD. Iatrogenic deep musculocutaneous radiation
1653 injury following percutaneous coronary intervention. *J Invasive Cardiol*
1654 2003;15:451-3.
- 1655 National Cancer Institute, 2005. Interventional fluoroscopy: reducing radiation risks for
1656 patients and staff. NIH Publication No. 05-5286. National Cancer Institute,
1657 Bethesda, MD. Available at: [http://www.cancer.gov/images/Documents/45bae965-
1658 697a-4de8-9dae-b77222e0e79d/InterventionalFluor.pdf](http://www.cancer.gov/images/Documents/45bae965-697a-4de8-9dae-b77222e0e79d/InterventionalFluor.pdf) Accessed December 31,
1659 2010.
- 1660 National Council on Radiation Protection and Measurements. Limitation of exposure to
1661 ionizing radiation. NCRP Report 116. Bethesda, MD: National Council on Radiation
1662 Protection and Measurements; 1993.
- 1663 National Council on Radiation Protection and Measurements. Radiation dose
1664 management for fluoroscopically guided interventional medical procedures. NCRP
1665 Report No. 168. Bethesda, MD: National Council on Radiation Protection and
1666 Measurements; 2010.
- 1667 NRC. (2006) Health risks from exposure to low levels of ionizing radiation: BEIR-VII
1668 Phase 2 National Academy Press, Washington, DC.
- 1669 Pages J. Effective dose and dose to the crystalline lens during angiographic procedures.
1670 *JBR-BTR* 2000; 83:108-110
- 1671 Preston D.L., Ron E., Tokuoka S., Funamoto S., Nishi N., Soda M., Mabuchi K.,
1672 Kodama K. (2007) Solid cancer incidence in atomic bomb survivors: 1958-1998.
1673 *Radiat Res* 168:1-64.
- 1674 Preston D.L., Ron E., Yonehara S., Kobuke T., Fujii H., Kishikawa M., Tokunaga M.,
1675 Tokuoka S., Mabuchi K. (2002) Tumors of the nervous system and pituitary gland
1676 associated with atomic bomb radiation exposure. *J Natl Cancer Inst* 94:1555-63.
- 1677 Renaud L. (1992) A 5-y follow-up of the radiation exposure to in-room personnel during
1678 cardiac catheterization. *Health Phys* 62:10-15.
- 1679 Shack RB, Lynch JB. Radiation dermatitis. *Clin Plast Surg* 1987; 14: 391-401
- 1680 Shimizu Y, Kodama K, Nishi N, Kasagi F, Suyama A, Soda M, Grant EJ, Sugiyama H,
1681 Sakata R, Moriwaki H, Hayashi M, Konda M, Shore RE. Radiation exposure and
1682 circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-
1683 2003. *BMJ* 2010; 340:b5349
- 1684 Shope, T.B., 1996. Radiation-induced skin injuries from fluoroscopy. *Radiographics* 16,
1685 1195-1199.
- 1686 Shore RE, Moseson M, Xue X, Tse Y, Harley N, Pasternack BS. Skin cancer after x-ray
1687 treatment for scalp ringworm. *Radiat Res* 2002; 157 (4): 410-418
- 1688 Shore, R.E., Neriishi, K., Nakashima, E., 2010. Epidemiological studies of cataract risk
1689 at low to moderate radiation doses: (not) seeing is believing. *Radiat. Res.* 174, 889-
1690 894.
- 1691 Turreson I, Notter G. The predictive value of skin telangiectasia for late radiation effect
1692 in different normal tissues. *Int J Radiat Oncol Biol Phys* 1986; 12 603-609
- 1693 UNSCEAR. (2000) Sources and effects of ionizing radiation. United Nations, New
1694 York.



1695 United States Food and Drug Administration . Public Health Advisory. Avoidance of
1696 serious x-ray induced skin injuries to patients during fluoroscopically guided
1697 procedures. Rockville, MD: Center for Devices and Radiological Health, United
1698 States Food and Drug Administration, 1994 Available at
1699 <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotificati>
1700 [ons/ucm063084.htm](http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotificati) Accessed July 29, 2010.

1701 Vano E, Arranz L, Sastre JM, Moro C, Ledo A, Garate MT, Minguez I. Dosimetric and
1702 radiation protection considerations based on some cases of patient skin injuries in
1703 interventional cardiology. *Br J Radiol* 1998; 71: 510-516

1704 Vano E, Gonzalez L, Beneytez F, Moreno F. Lens injuries induced by occupational
1705 exposure to non-optimized interventional radiology laboratories. *Br J Radiol* 1998;
1706 71: 728-733

1707 Vano E, Gonzalez L, Fernandez M, Haskal ZJ. Eye lens exposure to radiation in
1708 interventional suites: caution is warranted. *Radiology* 2008; 248: 945-953

1709 Vano E, Kleiman NJ, Duran A, Rehani MM, Echeverri D, Cabrera. M. Radiation
1710 cataract risk in interventional cardiology personnel. *Radiat Res*, 2010; 174(4):490-
1711 495

1712 Vlietstra RE, Wagner LK, Koenig T, Mettler F. Radiation burns as a severe complication
1713 of fluoroscopically guided cardiological interventions. *J Int Cardiol* 2004; 17(3): 1-
1714 12

1715 Wagner LK, McNesse MD, Marx MV, Siegel EL. Severe skin reactions from
1716 interventional fluoroscopy: case report and review of literature. *Radiology* 1999;
1717 213: 773-776

1718 Wang JX, Zhang LA, Li BX, Zhao YC, Wang ZQ, Zhang JY, Aoyama T. Cancer
1719 incidence and risk estimation among medical x-ray workers in China, 1950-1955.
1720 *Health Phys* 2002; 82(4): 455-466

1721 Wenzl T.B. (2005) Increased brain cancer risk in physicians with high radiation
1722 exposure. *Radiology* 235:709-10; author reply 710-1.

1723 Worgul BV, Kundiyevev YI, Sergiyenko NM, Chumak VV, Vitte PM, Medvedovsky C,
1724 Bakhanova EV, Junk AK, Kryrychenko OY, Musijachenko NV, Shylo SA, Vitte OP,
1725 Xu S, Xue X, Shore RE. Cataracts among Chernobyl clean-up workers: implications
1726 regarding permissible eye exposures. *Radiat Res* 2007; 167(2): 233-243

1727 Yonehara S., Brenner A.V., Kishikawa M., Inskip P.D., Preston D.L., Ron E., Mabuchi
1728 K., Tokuoka S. (2004) Clinical and epidemiologic characteristics of first primary
1729 tumors of the central nervous system and related organs among atomic bomb
1730 survivors in Hiroshima and Nagasaki, 1958-1995. *Cancer* 101:1644-54.
1731
1732
1733

3. CLINICAL EXAMPLES OF DETERMINISTIC INJURY AFTER FLUOROSCOPICALLY GUIDED CARDIAC PROCEDURES

Main Points

- There is increasing concern about skin radiation dose levels in cardiology.
- The cases presented in this chapter provide a clinical context and illustrate skin changes due to radiation injury.
- Deterministic injuries may extend into deeper tissues and can cause symptoms that persist for years.
- Deterministic injuries may be accompanied by an increase in stochastic risk.

3.1 Introduction

(57) There is increasing concern about skin radiation dose levels in cardiology. This is because of the discovery of deterministic injuries in patients who have undergone long procedures using suboptimal equipment, performed by individuals inadequately trained in radiological protection (UNSCEAR, 2010). However, high skin doses can occur in obese patients, or patients undergoing complex interventions, even when the procedure is performed by an experienced, well-trained operator using modern, well-maintained equipment (Suzuki, 2008; Bryk, 2006).

(58) The information presented in Chapter 2 (section 2.3) on the radiobiology of the skin can be difficult to interpret without a clinical context. The cases presented in this chapter provide that clinical context and illustrate the skin changes discussed in Chapter 2. It should be apparent that these injuries can be severe and debilitating. Some patients will require life-long therapy and observation. Treatment often requires a multidisciplinary team working in a specialized centre. Pain management and psychological support are important components of treatment.

(59) Methods to optimize patient radiation dose and minimize skin dose are described in Chapter 5 and listed in Table 5.1, but are repeated here because of their importance. Limit fluoroscopy time and the number of cine frames to the least number possible for successful completion of the procedure. Monitor patient radiation dose during the procedure. Use fluoroscopy equipment with pulsed fluoroscopy and use the lowest pulse rate that provides adequate fluoroscopic guidance. Use the lowest fluoroscopic and cine dose rates necessary for each stage of the procedure. When possible, slightly rotate the gantry so that the entrance beam is periodically directed at a different entrance skin site. Keep the image receptor (image intensifier or flat panel detector) as close as possible to the patient, and keep the x-ray tube as far away as possible from the entrance skin site.

1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789

3.2 Case 1 (Vliestra et al, 2004)

(60) A 53-year-old man weighing 141 kg (310 lbs) had two previous percutaneous transluminal coronary angioplasties (PTCA) 3 years earlier and now presented with unstable angina. A repeat coronary angiogram was followed immediately by PTCA of the distal circumflex artery. The procedure included use of the left anterior oblique (LAO) projection, biplane cinefluorography runs, high dose fluoroscopy mode and a total fluoroscopy time of 51.4 minutes. The estimated skin dose was 22 Gy.

(61) The patient presented six weeks later with a painful, itchy rash on his lower back in a square pattern (Fig. 3.1). This area developed into a painful ulcer. Debridement and skin grafting were required six months after the PTCA. Local discomfort persists.

1790



1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819

Figure 3.1 Case 1. See text for details. Reprinted from Vliestra, 2004. (Permission needed)

3.3 Case 2 (Koenig et al, 2001)

(62) A 75 year old woman had two previous coronary angiograms, followed by PTCA for a 90% stenosis of the right coronary artery. Ten months after the procedure she developed a skin lesion (Fig. 3.2). Skin dose estimates are not available.

1820



1835 **Figure 3.2** Case 2. The right lateral chest demonstrates both hyper- and
1836 hypopigmentation, in addition to skin atrophy and telangiectasia. Reprinted from Koenig,
1837 2001. (Permission needed)
1838

1839
1840
1841

3.4 Case 3 (Koenig et al, 2001)

1842 (63) A 49-year-old woman presented with an 8-year history of supraventricular
1843 tachycardia. Radiofrequency catheter ablation was performed. During the procedure her
1844 right arm was in the x-ray beam near the port. The separator (spacer) had been removed
1845 from the tube housing. Fluoroscopy time was approximately 20 minutes. Skin dose data
1846 are not available. She presented 3 weeks later with a skin lesion on her right elbow (Fig.
1847 3.3). If the patient's arm had been positioned outside the x-ray beam the injury could
1848 have been prevented or its severity decreased.
1849



1864

1865

1866



1877

1878 **Figure 3.3** Case 3. See text for details. A) 3 weeks: Area of sharply demarcated
 1879 erythema. B) 5 months: Tissue necrosis. C) 6½ months: Deep ulceration with exposure of
 1880 the bone. D) Following surgical flap. Reprinted from Koenig, 2001. (Permission
 1881 needed)

1882

1883

3.5 Case 4 (Vliestra et al, 2004)

1884

1885 (64) A 38-year-old man weighing 114 kg (250 lbs) was diagnosed with Wolff-
 1886 Parkinson-White syndrome. An attempt at radiofrequency ablation using biplane
 1887 fluoroscopy was unsuccessful. A few weeks after the procedure, the patient developed
 1888 areas of brownish-red discolouration on his back, which resolved. A second unsuccessful
 1889 ablation procedure was performed 2½ months later, with reappearance of the skin
 1890 discolouration after 1 week. The physician thought the skin lesion was due to the
 1891 grounding pad used for radiofrequency ablation rather than to radiation. A third
 1892 unsuccessful ablation procedure was performed; skin lesions appeared 8 days later (Fig
 1893 3.4). Each of the three procedures used more than 100 min of fluoroscopy time. Skin
 1894 dose estimates are not available. The severe injury to the right arm was due to its
 1895 position. If the arm had been positioned away from the entrance x-ray beam, the injury
 1896 might have been avoided.

1897

1898



1908

1909

1910 **Figure 3.4** Case 4. The right-sided lesions show desquamation. The erythema on the
1911 back healed into discoloured scars. The right arm lesion, closer to the x-ray beam,
1912 developed necrosis and required a skin graft. Reprinted from Vliestra, 2004. (Permission
1913 needed)

1914

1915

3.6 Case 5 (Vaño et al, 1998)

1916

1917 (65) A 17-year-old female underwent an electrophysiology ablation procedure for
1918 posterior pathway pre-excitation that lasted 5 hours. Eleven months later she underwent
1919 a second procedure that also lasted 5 hours. Both procedures were performed with
1920 biplane fluoroscopy. Fluoroscopy time for the lateral plane was estimated at 90-120
1921 minutes. Skin dose estimates are not available. Twelve hours after the second procedure
1922 she developed an erythematous plaque in the right axilla. One month later she consulted
1923 a dermatologist for red macular and blister lesions on her right side. Twenty-six months
1924 after the second procedure an indurated, atrophic plaque with linear edges, 10 x 5 cm²,
1925 was observed (Fig. 3.5). The diagnosis was chronic radiodermatitis. The muscles in her
1926 right arm have also been affected, with resultant limitation in the range of motion.
1927 Because of the patient's age and the region irradiated, her risk of subsequent breast
1928 cancer is also increased.

1929

1930



1931

1932

1933 **Figure 3.5** Case 5. Indurated, atrophic plaque with linear edges, with areas of hyper- and
1934 hypopigmentation. Reprinted from Vaño, 1998. (Permission needed)

1935

1936

1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957

3.7 Case 6 (Courtesy of Dr. M. Portas, Buenos Aires, Argentina)

(66) An obese 57-year-old female, a heavy smoker, underwent PTCA. The procedure time was approximately 6 hours. No data on radiation dose are available. Early manifestations were blisters on the skin of the back in the lumbar region. This was diagnosed by a dermatologist as a herpes zoster infection. Two months later, a deep ulcer (Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer [RTOG/EORTC] cutaneous radiotoxicity grade 4) appeared at the same site. (No photographs of the injury at this stage are available.) It was extremely painful. The following year the patient underwent a plastic surgery procedure, with two rotation flaps to close the wound. The rotation flaps subsequently underwent necrosis, leaving an ulcer approximately 20 x 20 cm (Fig. 3.6). During the next several years, conservative treatment was performed at a specialized burn centre. Wound coverage was performed with porcine dermis, skin allografts and autografts, in conjunction with anti-inflammatory and antibacterial therapy and hyperbaric oxygen treatments. This treatment led to progressive wound closure. After 3 years of treatment (5 years after the PTCA), the dimensions of the ulcer were reduced to 3 x 1.5 cm (Fig 3.7). *In vitro* radiosensitivity testing demonstrated that the patient had normal radiosensitivity. The injury and prolonged recovery were attributed to radiation exposure, obesity and heavy smoking.



1958
1959
1960
1961
1962
1963

Figure 3.6 Case 6. Appearance of the patient’s back following the initial surgery and necrosis of the rotation flaps. The ulcer is approximately 20 x 20 cm.

1964



1965

1966

1967

1968

1969

1970

1971

1972

1973

1974

1975

1976

1977

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

Figure 3.7 Case 6. Appearance of the patient's back 5 years after the PTCA. After 3 years of treatment, the ulcer is reduced in size to 3 x 1.5 cm. The patient's quality of life is much improved.

3.8 References

- Bryk, S.G., Censullo, M.L., Wagner, L.K., Rossman, L.L., Cohen, A.M., 2006. Endovascular and interventional procedures in obese patients: a review of procedural technique modifications and radiation management. *J. Vasc. Interv. Radiol.* 17, 27-33.
- Koenig, T.R., Wolff, D., Mettler, F.A., Wagner, L.K., 2001. Skin injuries from fluoroscopically guided procedures: Part 1, Characteristics of radiation injury. *AJR. Am. J. Roentgenol.* 177, 3-11.
- Suzuki, S., Furui, S., Isshiki, T., Kozuma, K., Koyama, Y., Yamamoto, H., Ochiai, M., Asakura, Y., Ikari, Y., 2008. Patients' skin dose during percutaneous coronary intervention for chronic total occlusion. *Catheter. Cardiovasc. Interv.* 71, 160-164.
- UNSCEAR. Sources of ionizing radiation: volume I. Report to the General Assembly, with scientific annexes; 2010; New York, NY. Available at: http://www.unscear.org/unscear/en/publications/2008_1.html Accessed December 31, 2010.



DRAFT REPORT FOR CONSULTATION

- 1988 Vañó, E., Arranz, L., Sastre, J.M., Moro, C., Ledo, A., Gárate, M.T., Minguez, I., 1998.
1989 Dosimetric and radiation protection considerations based on some cases of patient
1990 skin injuries in interventional cardiology. Br. J. Radiol. 71, 510-516.
1991 Vlietstra, R.E., Wagner, L.K., Koenig, T., Mettler, F., 2004. Radiation burns as a severe
1992 complication of fluoroscopically guided cardiological interventions. J Interv Cardiol
1993 17, 1-12.
1994
1995
1996

1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019

4. PRINCIPLES OF RADIOLOGICAL PROTECTION FOR PATIENTS AND STAFF

Main Points

- **Justification means that a medical procedure should only be performed when it is appropriate for a particular patient— the anticipated clinical benefits should exceed all anticipated procedural risks, including radiation risk.**
- **For CT and nuclear medicine studies, justification is a responsibility shared between the referring clinician and the cardiac imager. For fluoroscopically guided interventions, the responsibility rests with the interventionalist.**
- **Optimization means that the radiation dose to the patient is suitable for the medical purpose, and radiation that is clinically unnecessary or unproductive is avoided.**
- **Patient radiation dose is optimized when imaging is performed with the least amount of radiation required to provide adequate image quality, diagnostic information, and for fluoroscopy, adequate imaging guidance.**
- **Dose limits apply to occupational exposure of cardiologists and staff.**
- **Dose limits do not apply to medical exposures of patients or to carers and comforters.**

4.1 Introduction

(67) The Commission recommends three fundamental principles of radiological protection: justification, optimization of protection, and application of dose limits (ICRP 103, ICRP 105). The first two are source related and apply to all radiation exposure situations. The third applies to staff, but does not apply to medical exposures of patients or to carers and comforters.

4.2 Justification

(68) The principle of justification is that, in general, “any decision that alters the radiation exposure situation should do more good than harm. This means that by introducing a new radiation source, by reducing existing exposure, or by reducing the risk of potential exposure, one should achieve sufficient individual or societal benefit to offset the detriment it causes.” (ICRP 103, ICRP 105). The principal aim of medical exposures is to do more good than harm to the patient, subsidiary account being taken of the radiation detriment from the exposure of the radio- logical staff and of other individuals (ICRP 103).

(69) A medical procedure should only be performed when it is appropriate for a particular patient. The RAND Corporation has developed a definition of “appropriate” that is widely used: the expected health benefit (i.e., increased life expectancy, relief of pain, reduction in anxiety, improved functional capacity) exceeds the expected negative consequences (i.e., mortality, morbidity, anxiety of anticipating the procedure, pain produced by the procedure, misleading or false diagnoses, time lost from work) by a

2040 sufficiently wide margin that the procedure is worth doing (Sistrom, 2008, NHS, 1993).
2041 In other words, the anticipated clinical benefits should exceed all anticipated procedural
2042 risks, including radiation risk.

2043 (70) In the United States, appropriateness criteria have been developed for many
2044 clinical scenarios (Brindis et al, 2005, Douglas, 2008, Patel, 2009, Hendel 2009, ACR,
2045 2010, Taylor 2010). Similar guidelines have been developed in the United Kingdom,
2046 though they are less readily available (RCR, 2007). European guidelines are also
2047 available (Hesse, 2005, Schroeder 2008). These recommendations are typically based on
2048 a standardized literature review and compilation of evidence tables, followed by rating of
2049 each indication by an expert panel with varied composition (Patel et al, 2005).
2050 Appropriateness may vary based on national and local norms and practice patterns, as
2051 well as well as patient and family values and preferences (Wolk et al, 2004).

2052 (71) The responsibility for the justification of the use of a particular procedure falls
2053 on the relevant medical practitioners (ICRP 103). For CT and nuclear medicine studies,
2054 justification is a responsibility shared between the referring clinician and the cardiac
2055 imager. For the referring clinician, this entails weighing the benefits of a test against its
2056 risks, including radiation exposure, and considering such an analysis for all possible
2057 alternatives including performing no test. For the cardiac imager, justification entails
2058 ensuring that the test has a reasonable indication, given the available information, and
2059 discussing the indication with the referring clinician if there is concern in this respect.
2060 For fluoroscopically guided interventions, the responsibility rests with the
2061 interventionalist.

2062
2063

4.3 Optimization

2064 (72) The principle of optimization of protection is that “the likelihood of incurring
2065 exposures, the number of people exposed, and the magnitude of their individual doses
2066 should all be kept as low as reasonably achievable, taking into account economic and
2067 societal factors. This means that the level of protection should be the best under the
2068 prevailing circumstances, maximizing the margin of benefit over harm” (ICRP 103, ICRP
2069 105, NCRP 1993). This is often summarized using the acronym ALARA, which stands
2070 for As Low As Reasonably Achievable.

2071 (73) For cardiology procedures, this principle is applied in the design of cardiac
2072 facilities that use ionizing radiation, appropriate selection and use of equipment, and in
2073 day-to-day working procedures. Optimization is best described as a radiation dose to the
2074 patient that is suitable for the medical purpose, and avoidance of radiation that is
2075 clinically unnecessary or unproductive.

2076 (74) Dose optimization means delivering a radiation dose to the organs and tissues
2077 of clinical interest no greater than that required for adequate imaging and minimizing
2078 dose to other structures (e.g., the skin). Patient radiation dose is considered to be
2079 optimized when imaging is performed with the least amount of radiation required to
2080 provide adequate image quality and, for fluoroscopy, adequate imaging guidance (NCI,
2081 2005). The goal of every imaging procedure is to provide images adequate for the
2082 clinical purpose. Imaging requirements depend on the specific patient and the specific
2083 procedure. Reducing patient radiation dose to the point where images are inadequate is

2084 counterproductive; it results in radiation dose to the patient without answering the clinical
2085 question. Improving image quality beyond what is clinically needed subjects the patient
2086 to additional radiation dose without additional clinical benefit. The goal of radiation
2087 management is to keep patient radiation dose as low as possible consistent with the use of
2088 appropriate equipment and the imaging requirements for a specific patient and a specific
2089 procedure.

2090

4.4 Dose limits

2091 (75) The principle of application of dose limits states that “the total dose to any
2092 individual from regulated sources in planned exposure situations other than medical
2093 exposure of patients should not exceed the appropriate limits recommended by the
2094 Commission” (ICRP 103, ICRP 105). This principle does not apply to medical exposure
2095 of patients. As noted in ICRP Publication 105, “Provided that the medical exposures of
2096 patients have been properly justified and that the associated doses are commensurate with
2097 the medical purpose, it is not appropriate to apply dose limits or dose constraints to the
2098 medical exposure of patients, because such limits or constraints would often do more
2099 harm than good.”(ICRP 105) For interventional procedures, the medical condition being
2100 treated and the non-radiation risks of the procedure typically present substantially greater
2101 morbidity and mortality than do the radiation risks (Miller, 2008, NCRP 168, 2010).

2102

2103

2104

4.5 References

2105 What do we mean by appropriate health care? Report of a working group prepared for
2106 the Director of Research and Development of the NHS Management Executive. Qual
2107 Health Care 1993;2:117-23.

2108 American College of Radiology. ACR Appropriateness Criteria®. Available at:
2109 http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria.aspx
2110 Accessed August 3, 2010.

2111 Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM, Patel MR,
2112 Raskin IE, Bateman TM, Cerqueira MD, Gibbons RJ, Gillam LD, Gillespie JA,
2113 Iskandrian AE, Jerome SD, Krumholz HM, Messer JV, Spertus JA, Stowers SA.
2114 ACCF/ASNC appropriateness criteria for single-photon emission computed
2115 tomography myocardial perfusion imaging (SPECT MPI): a report of the American
2116 College of Cardiology Foundation Quality Strategic Directions Committee
2117 Appropriateness Criteria Working Group and the American Society of Nuclear
2118 Cardiology endorsed by the American Heart Association. J Am Coll Cardiol
2119 2005;46:1587-1605.

2120 Douglas, P.S., Khandheria, B., Stainback, R.F., Weissman, N.J., Peterson, E.D., Hendel,
2121 R.C., Blaivas, M., Des Prez, R.D., Gillam, L.D., Golash, T., Hiratzka, L.F.,
2122 Kussmaul, W.G., Labovitz, A.J., Lindenfeld, J., Masoudi, F.A., Mayo, P.H.,
2123 Porembka, D., Spertus, J.A., Wann, L.S., Wiegers, S.E., Brindis, R.G., Patel, M.R.,
2124 Wolk, M.J., Allen, J.M., 2008. ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR
2125 2008 appropriateness criteria for stress echocardiography: a report of the American
2126 College of Cardiology Foundation Appropriateness Criteria Task Force, American
2127 Society of Echocardiography, American College of Emergency Physicians,

- 2128 American Heart Association, American Society of Nuclear Cardiology, Society for
2129 Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed
2130 Tomography, and Society for Cardiovascular Magnetic Resonance endorsed by the
2131 Heart Rhythm Society and the Society of Critical Care Medicine. J. Am. Coll.
2132 Cardiol. 51, 1127-1147. Available at:
2133 <http://content.onlinejacc.org/cgi/content/full/51/11/1127> Accessed January 1, 2011.
- 2134 Hendel RC, Berman DS, Di Carli MF, et al.
2135 ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for
2136 cardiac radionuclide imaging: a report of the American College of Cardiology
2137 Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear
2138 Cardiology, the American College of Radiology, the American Heart Association,
2139 the American Society of Echocardiography, the Society of Cardiovascular Computed
2140 Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of
2141 Nuclear Medicine. Circulation. 2009;119(22):e561-587.
- 2142 Hesse, B., Tagil, K., Cuocolo, A., Anagnostopoulos, C., Bardies, M., Bax, J., Bengel, F.,
2143 Busemann Sokole, E., Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A.,
2144 Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P.Y., McKiddie, F.,
2145 O'Connor, M., Prvulovich, E., Underwood, R., van Eck-Smit, B., 2005. EANM/ESC
2146 procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J
2147 Nucl Med Mol Imaging 32, 855-897. Available at:
2148 http://www.eanm.org/scientific_info/guidelines/gl_cardio_myocard_perf.pdf
2149 Accessed January 1, 2011.
- 2150 International Commission on Radiological Protection. The 2007 Recommendations of
2151 the International Commission on Radiological Protection. ICRP Publication 103.
2152 Ann ICRP 2007; 37(2-4):1-332
- 2153 International Commission on Radiological Protection. Radiological protection in
2154 medicine. ICRP Publication 105. Ann ICRP 2007;37:1-63.
- 2155 Miller DL. Overview of contemporary interventional fluoroscopy procedures. Health
2156 Phys 2008; 95:638-644.
- 2157 NCI. Interventional fluoroscopy: reducing radiation risks for patients and staff. NIH
2158 Publication No. 05-5286. Bethesda:National Cancer Institute, 2005. Available at:
2159 [http://www.cancer.gov/images/Documents/45bae965-697a-4de8-9dae-
2160 b77222e0e79d/InterventionalFluor.pdf](http://www.cancer.gov/images/Documents/45bae965-697a-4de8-9dae-b77222e0e79d/InterventionalFluor.pdf) Accessed January 1, 2011.
- 2161 NCRP. Limitation of exposure to ionizing radiation. NCRP Report No. 116. Bethesda,
2162 MD: National Council on Radiation Protection and Measurements; 1993.
- 2163 NCRP. Radiation dose management for fluoroscopically guided interventional medical
2164 procedures. NCRP Report No. 168. Bethesda, MD: National Council on Radiation
2165 Protection and Measurements; 2010.
- 2166 Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, Wolk MJ,
2167 Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of
2168 cardiovascular imaging. J Am Coll Cardiol 2005;46:1606-1613.
- 2169 Patel, M.R., Dehmer, G.J., Hirshfeld, J.W., Smith, P.K., Spertus, J.A., 2009.
2170 ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary
2171 Revascularization: a report by the American College of Cardiology Foundation

- 2172 Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and
2173 Interventions, Society of Thoracic Surgeons, American Association for Thoracic
2174 Surgery, American Heart Association, and the American Society of Nuclear
2175 Cardiology Endorsed by the American Society of Echocardiography, the Heart
2176 Failure Society of America, and the Society of Cardiovascular Computed
2177 Tomography. J. Am. Coll. Cardiol. 53, 530-553. Available at:
2178 <http://content.onlinejacc.org/cgi/content/full/53/6/530> Accessed January 1, 2011.
- 2179 The Royal College of Radiologists. Making the best use of clinical radiology services:
2180 referral guidelines. 6th ed. London: The Royal College of Radiologists, 2007.
- 2181 Schroeder S, Achenbach S, Bengel F, et al. Cardiac computed tomography: indications,
2182 applications, limitations, and training requirements: report of a Writing Group
2183 deployed by the Working Group Nuclear Cardiology and Cardiac CT of the
2184 European Society of Cardiology and the European Council of Nuclear Cardiology.
2185 Eur Heart J 2008;29(4):531-556.
- 2186 Sistrom CL. In support of the ACR Appropriateness Criteria®. J Am Coll Radiol
2187 2008;5:630-635.
- 2188 Taylor, A.J., Cerqueira, M., Hodgson, J.M., Mark, D., Min, J., O'Gara, P., Rubin, G.D.,
2189 Kramer, C.M., Berman, D., Brown, A., Chaudhry, F.A., Cury, R.C., Desai, M.Y.,
2190 Einstein, A.J., Gomes, A.S., Harrington, R., Hoffmann, U., Khare, R., Lesser, J.,
2191 McGann, C., Rosenberg, A., Schwartz, R., Shelton, M., Smetana, G.W., Smith, S.C.,
2192 Jr., 2010. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010
2193 appropriate use criteria for cardiac computed tomography: a report of the American
2194 College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society
2195 of Cardiovascular Computed Tomography, the American College of Radiology, the
2196 American Heart Association, the American Society of Echocardiography, the
2197 American Society of Nuclear Cardiology, the North American Society for
2198 Cardiovascular Imaging, the Society for Cardiovascular Angiography and
2199 Interventions, and the Society for Cardiovascular Magnetic Resonance. J. Am. Coll.
2200 Cardiol. 56, 1864-1894. Available at:
2201 <http://content.onlinejacc.org/cgi/content/full/56/22/1864> Accessed January 1, 2011.in
2202 press.
- 2203 Wolk MJ, Peterson E, Brindis R, Eagle K. President's page: the appropriate cardiologist:
2204 responsible stewardship in a golden era of cardiology. J Am Coll Cardiol
2205 2004;44:933-935.
- 2206

2207 **5. MANAGING PATIENT DOSE IN FLUOROSCOPICALLY**
2208 **GUIDED INTERVENTIONS**

2209
2210 **Main Points**

- 2211
- 2212 • **The informed consent process should include information on radiation risk if**
2213 **the risk of radiation injury is thought to be significant.**
- 2214 • **Important aspects of the patient’s medical history that should be considered**
2215 **when estimating radiation risk are genetic factors, co-existing diseases,**
2216 **medication use, radiation history, and pregnancy.**
- 2217 • **Some of the factors that affect the patient’s radiation dose depend on the x-ray**
2218 **system, but many others depend on how the operator uses the x-ray system.**
- 2219 • **During the procedure, the cardiologist should be kept aware of the fluoroscopy**
2220 **time, the number of cine series and cine frames, and the total patient dose.**
- 2221 • **As patient radiation dose increases, the operator should consider the radiation**
2222 **dose already delivered to the patient and the additional radiation necessary to**
2223 **complete the procedure.**
- 2224 • **Patient radiation dose reports should be produced at the end of the procedure,**
2225 **and archived.**
- 2226 • **Radiation dose data should be recorded in the patient’s medical record after the**
2227 **procedure.**
- 2228 • **When the patient’s radiation dose from the procedure is high, clinical follow-up**
2229 **is essential for early detection and management of skin injuries.**
- 2230 • **Patients who have received a substantial radiation dose should have follow-up**
2231 **at 10-14 days and at one month after the procedure for possible deterministic**
2232 **effects.**
- 2233

2234 **5.1 Introduction**
2235

2236 (76) Fluoroscopically guided interventions (FGI) comprise guided therapeutic and
2237 diagnostic interventions, by percutaneous or other access, usually performed under local
2238 anaesthesia and/or sedation, with fluoroscopic imaging used to localise the
2239 lesion/treatment site, monitor the procedure, and control and document the therapy
2240 (ICRP, 2000). This chapter deals with clinical radiation management before, during and
2241 after FGI.

2242 (77) The doses received by patients during fluoroscopically guided cardiac
2243 procedures can be high, and some patients may have several procedures carried out in a
2244 relatively short period of time. Hence, it is essential that the cardiologist optimises
2245 patient radiation dose (Chambers, 2011). If a certain dose threshold is exceeded (see
2246 Chapter 2), the procedure could result in deterministic effects (harmful tissue reactions).
2247 High radiation doses also increase stochastic risk (cancer and heritable effects).
2248

2249 It is important for medical practitioners to be aware that although uncertainty remains, the
2250 absorbed dose threshold for circulatory disease may be as low as 0.5 Gy to the heart and
2251 brain (ICRP, 2011a). In some complex fluoroscopically guided cardiac procedures,
2252 organ doses may be > 0.5 Gy. Cardiovascular radiation effects have been reported to
2253 occur at these doses, including focal myocardial degeneration and fibrosis, and
2254 accelerated atherosclerosis in major blood vessels. (ICRP XXX Tissue Reactions,
2255 2011b).

2256 (78) The mean age of patients undergoing cardiac procedures is relatively high.
2257 Stochastic risk is not a great concern for older patients because of the latency period for
2258 the development of cancer and these patients' relatively shorter life expectancies.
2259 Stochastic risk is of greater concern when fluoroscopically guided procedures are
2260 performed on children. Children have longer life expectancies and are also more
2261 sensitive to the effects of radiation.

2262 (79) Initial and continuous training in dose management and radiological protection
2263 has a definitive influence on patient doses, and is essential for interventionalists
2264 (Hirshfeld, 2005, Rehani, 2007, ICRP 2009). Several recent publications have
2265 demonstrated that this training helps to optimise patient dose and reduce operator dose
2266 (Whitby, 2005, Vano, 2006, Bor, 2008, Bernardi, 2008, Kim, 2010, IAEA TECDOC
2267 1641, 2010). Training is discussed further in Chapter 9.

2268

2269

5.2 Before the Procedure

2270

2271 (80) A discussion of radiation risk is an appropriate part of the informed consent
2272 process if radiation risk factors are present or a substantial radiation dose is anticipated.
2273 ICRP recommends that patients should be counselled before the procedure if the risk of
2274 radiation injury is thought to be significant (ICRP Publication 85). Important aspects of
2275 the patient's medical history that should be considered when estimating radiation risk are
2276 genetic factors, co-existing diseases, medication use, radiation history, and pregnancy
2277 (Miller et al, 2010).

2278 (81) Obese patients are at a higher risk of radiation-induced skin injury because of
2279 poor radiation penetration and the accompanying closer proximity of the x-ray source to
2280 the patient (Bryk, 2006). Absorbed dose at the entrance skin site in obese patients can be
2281 as much as 10 times higher than in non-obese patients (Wagner, JVIR 2000). Many of the
2282 documented injuries associated with fluoroscopic procedures have been seen in larger
2283 patients (Koenig Part 2, 2001).

2284 (82) For some complex procedures, and especially when procedures are repeated in
2285 large or obese patients, a medical physicist can provide useful advice to help optimise the
2286 procedure. If a previous procedure has resulted in a high peak skin dose, the strategy for
2287 further possible procedures in the same patient should include modifying subsequent
2288 procedures to reduce skin dose, if possible. Other procedure modifications are often
2289 necessary in obese patients (Bryk, 2006).

2290 (83) Except for time-critical emergency procedures, pregnancy status should be
2291 determined prior to a fluoroscopically guided intervention (ICRP 105). If possible,
2292 elective procedures on pregnant patients should be deferred until the patient is no longer

2293 pregnant. When medically indicated FGI procedures must be performed on pregnant
2294 patients, and except for time-critical emergency procedures, the Commission
2295 recommends that procedure planning include feasible modifications to minimize
2296 conceptus dose, estimation of expected radiation dose to the conceptus, evaluation of the
2297 radiogenic risk to the conceptus, and inclusion in the informed consent process of the
2298 expected benefits and potential risks of the procedure to both the patient and the
2299 conceptus (ICRP 84). Whenever possible, and if time permits, the pre-procedure
2300 planning process should involve a qualified physicist.

2301 (84) The Commission has stated that in general, termination of pregnancy at foetal
2302 doses of less than 100 mGy is not justified based upon radiation risk (ICRP Publication
2303 84). For comparison, a typical fetal dose from CTA of the coronary arteries is
2304 approximately 0.1 mGy (McCcollough, 2007).

2305

2306

5.3 During the Procedure

2307

2308 (85) When optimizing patient radiation dose, the first priority must be to obtain a
2309 sufficient number of images of a high enough quality to permit diagnosis and guide
2310 interventions. This will require a certain minimum amount of fluoroscopy time and
2311 number and length of cine series. Optimal management of patient dose requires
2312 knowledge and control of the typical fluoroscopic dose rates and values of dose per cine
2313 frame for the most common operational modes.

2314 (86) Typical values of skin dose rate (surface entrance air kerma rate) during
2315 cardiology procedures for a medium size patient are 15-45 mGy/min for “medium”
2316 fluoroscopy mode and 50-150 mGy/min for “high” fluoroscopy mode. Skin dose per cine
2317 frame is typically between 0.1 and 1.0 mGy. Skin doses in cardiac procedures can reach
2318 several Gy, especially for complex procedures and when several projections with similar
2319 C-arm angulations are required (Miller, 2008). Organ doses may reach 100 Gy and
2320 effective doses may reach 50 mSv. Variation in patient doses between centres may be
2321 substantial. Some of this variation is likely to be due to the settings of the x-ray systems.
2322 A study carried out by the IAEA comparing x-ray systems from different countries
2323 demonstrated 10-fold differences for dose values when phantoms of the same thickness
2324 were imaged (Ortiz at al, 2004).

2325 (87) Several operational factors can substantially modify the radiation dose received
2326 by the patients and affect the kerma-area product (KAP) and the patient’s skin dose
2327 (Publication 85). These are also discussed and illustrated in an ICRP publication devoted
2328 to radiological protection outside the imaging department (reference ICRP TG 78). Some
2329 of these factors depend on the x-ray system (e.g. availability of pulsed fluoroscopy,
2330 virtual collimation, stored fluoroscopy loops, extra filtration, wedge filters, rotational and
2331 cone beam CT acquisition modes, etc.), but others depend on how the operator uses the x-
2332 ray system (e.g. collimation to the area of interest, use of low fluoroscopy modes when
2333 possible, acquiring cine series at 12.5-15 frames per second when possible, keeping the
2334 image detector as close as possible to the patient, avoiding steeply angulated projections,
2335 reducing the number of frames per cine series) (NCRP Report 168, 2010).
2336 Recommendations for dose optimization in the radiology literature apply equally to

2337 interventional cardiology procedures (Miller, 2002, Miller, 2010, Wagner, JVIR 2000,
2338 Wagner 2007). **Table 5.1** provides some practical advice.

2339 (88) During the procedure, the cardiologist should be aware of the fluoroscopy time,
2340 the number of cine series and cine frames, and the total patient dose, either as KAP or as
2341 Reference Air Kerma (RAK) the cumulative air kerma at the Interventional Reference
2342 Point (see Glossary). (The Interventional Reference Point is also known as the Patient
2343 Entrance Reference Point.) The need here is to monitor, in real time, whether the
2344 threshold doses for deterministic effects are being approached or exceeded (ICRP 105,
2345 ICRP **XXX** 2011b). Modern fluoroscopy systems that are compliant with the
2346 international standard for interventional fluoroscopy systems display radiation data to the
2347 operator during the procedure (IEC, 2010). The responsibility for monitoring radiation
2348 dose may be delegated to a technologist, nurse or other person depending on national or
2349 local regulations and the institution's policy and needs (NCRP 168, 2010). A specific
2350 individual should be tasked with this responsibility. The purpose of dose monitoring is to
2351 ensure that the operator is aware of how much radiation is being administered.

2352 (89) As patient radiation dose increases, the operator should consider the radiation
2353 dose already delivered to the patient and the additional radiation necessary to complete
2354 the procedure. It may be possible to reduce further radiation usage and control skin dose
2355 by limiting the number and length of cine series, decreasing the dose rate for cine or
2356 fluoroscopy, using collimation or changing the gantry angle slightly.

2357 (90) Knowledge of the patient's skin dose distribution could help to avoid the risk
2358 of skin injuries, but measurement of skin dose distribution is not an easy task in
2359 fluoroscopically guided procedures. This is especially true in cardiology, where very
2360 different C-arm angulations are used during the procedures and the regions of the
2361 irradiated skin can also be very different. However, using different C-arm angulations
2362 can help reduce peak skin dose, especially when collimation is also used (Miller, 2002).
2363 **Figure 5.1** shows an example of skin dose distribution measured with slow film (Vano et
2364 al. 1997) and how overlap of radiation fields can increase the dose to a certain area of the
2365 skin.

2366
2367
2368

5.4 After the procedure

2369 (91) Modern fluoroscopy systems that are compliant with the international standard
2370 for interventional fluoroscopy systems provide a dose report at the conclusion of the
2371 procedure (IEC, 2010). An example of a typical dose report is shown in **Fig 5.2**. Several
2372 companies offer dose reports for cardiology procedures that include information on skin
2373 dose distribution. Patient radiation dose reports should be produced at the end of the
2374 procedure, and archived. Radiation dose data should be recorded in the patient's medical
2375 record after the procedure (Chambers, 2011).

2376 (92) Patient doses for cardiac procedures are often reported as kerma-area product
2377 (KAP). Skin dose distribution, and especially RAK and peak skin dose (PSD) (defined in
2378 the glossary), are sometimes more important, particularly when repeated procedures are
2379 performed on the same patient (Miller, 2002). Fluoroscopy time does not include the
2380 effect of fluoroscopy dose rate and does not indicate the radiation dose from cine. It is

2381 not a useful descriptor of patient radiation dose (Chida, 2006, Fletcher, 2002).
2382 Fluoroscopy time should not be the only dose measurement recorded or audited
2383 (Chambers, 2011, NCRP Report 168, 2010).

2384 (93) The management and follow-up of patients who have received a high dose of
2385 radiation is also important. The operator should be notified promptly if the substantial
2386 radiation dose level (SRDL) was exceeded. (SRDL is defined in the Glossary and
2387 discussed further in Section 10.6.) The operator should write an appropriate note in the
2388 patient's medical record, stating that a substantial radiation dose has been administered,
2389 and indicating the reason (Hirshfeld, 2005). This information may be included in the
2390 post-procedure note.

2391 (94) When the SRDL has been exceeded, clinical follow-up is essential for early
2392 detection and management of skin injuries (NCRP Report 168, 2010, Chambers, 2011).
2393 The patient should be advised of the possibility of a deterministic skin injury, and should
2394 be told to examine the beam entrance site at 2 – 4 weeks after the procedure. The
2395 operator should be notified if any skin changes are seen. Patients should also be
2396 contacted by telephone at approximately 30 days after the procedure. If a skin injury is
2397 suspected, the interventionalist should see the patient at an office visit, and should
2398 arrange for appropriate follow-up care (NCRP Report 168, 2010, Chambers, 2011). The
2399 physician responsible for the patient's care should be informed of the possibility of
2400 radiation effects. Ideally, a system should be established to identify and monitor repeated
2401 procedures (ICRP 85, 2000).

2402
2403
2404

5.5 Paediatric Patients

2405 (95) Paediatric cardiology procedures require special consideration. These
2406 interventions are often challenging, time-consuming and may require multi-stage
2407 procedures, leading to high radiation exposure. Contributing factors include the higher
2408 heart rates, smaller cardiovascular structures, small body size and wider variety of
2409 unusual anatomic variants seen in children (Justino 2006).

2410 (96) Patient radiation dose from paediatric interventional cardiology procedures can
2411 be reduced by the use of dedicated radiographic protocols that include tighter collimation,
2412 pulsed fluoroscopy frame rates of 25-30 frames/sec and cine frame rates of 25-50
2413 frames/sec. As part of the Step Lightly initiative, the Alliance for Radiation Safety in
2414 Pediatric Imaging has published a checklist for use during paediatric interventional
2415 fluoroscopy to help reduce patient doses (Sidhu, 2009).

2416
2417
2418

5.6 References

2419 American College of Radiology. ACR practice guideline for imaging pregnant or
2420 potentially pregnant adolescents and women with ionizing radiation. Practice
2421 Guidelines and Technical Standards 2008. Reston, VA: American College of
2422 Radiology, 2008; p. 23-37. Available at:
2423 http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/Pregnancy.aspx
2424 Accessed August 11, 2010.

- 2425 Balter S. Interventional fluoroscopy. Physics, technology and safety. Wiley-Liss, New
2426 York, 2001.
- 2427 Bernardi G, Padovani R, Morocutti G, Vano E, Malisan MR, Rinuncini M, Spedicato L,
2428 Fioretti PM. Clinical and technical determinants of the complexity of percutaneous
2429 transluminal coronary angioplasty procedures: analysis in relation to radiation
2430 exposure parameters. *Catheter Cardiovasc Interv* 2000 Sep;51(1):1-9; discussion 10.
- 2431 Bernardi G, Padovani R, Trianni A, Morocutti G, Spedicato L, Zanuttini D, Werren M,
2432 Wagner LK. The effect of fellows' training in invasive cardiology on radiological
2433 exposure of patients. *Radiat Prot Dosimetry* 2008, 128(1):72-76.
- 2434 Bor D, Sancak T, Toklu T, Olgar T, Ener S. Effects of radiologists' skill and experience
2435 on patient doses in interventional examinations. *Radiat Prot Dosimetry* 2008;129:32-
2436 5.
- 2437 Bryk SG, Censullo ML, Wagner LK, Rossman LL, Cohen AM. Endovascular and
2438 interventional procedures in obese patients: a review of procedural technique
2439 modifications and radiation management. *J Vasc Interv Radiol* 2006;17:27-33.
- 2440 Chambers CE, Fetterly KA, Holzer R, Lin P-JP, Blankenship JC, Balter S, Laskey WK.
2441 Radiation safety program for the cardiac catheterization laboratory. *Catheter*
2442 *Cardiovasc Interv* 2011, in press.
- 2443 Chida K, Saito H, Otani H, Kohzuki M, Takahashi S, Yamada S, Shirato K, Zuguchi M.
2444 Relationship between fluoroscopic time, dose-area product, body weight, and
2445 maximum radiation skin dose in cardiac interventional procedures. *Am J Roentgenol*.
2446 2006;186:774-8.
- 2447 Den Boer A, de Feyter PJ, Hummel WA, Keane D, Roelandt JR. Reduction of radiation
2448 exposure while maintaining high-quality fluoroscopic images during interventional
2449 cardiology using novel x-ray tube technology with extra beam filtering. *Circulation*.
2450 1994 Jun;89(6):2710-4.
- 2451 Faulkner K, Vano E. Deterministic effects in interventional radiology. *Radiat Prot*
2452 *Dosimetry*. 2001;94(1-2):95-8.
- 2453 Fletcher DW, Miller DI, Balter S, Taylor MA. Comparison of four techniques to
2454 estimate radiation dose to skin during angiographic and interventional radiology
2455 procedures. *J Vasc Interv Radiol* 2002;13:391-97.
- 2456 Guibelalde E, Vano E, Gonzalez L, Prieto C, Fernandez JM, Ten JI. Practical aspects for
2457 the evaluation of skin doses in interventional cardiology using a new slow film. *Br J*
2458 *Radiol*. 2003 May;76(905):332-6.
- 2459 Hirshfeld JW Jr, Balter S, Brinker JA, Kern MJ, Klein LW, Lindsay BD, Tommaso CL,
2460 Tracy CM, Wagner LK, Creager MA, Elnicki M, Lorell BH, Rodgers GP, Weitz
2461 HH; American College of Cardiology Foundation; American Heart Association;
2462 HRS; SCAI; American College of Physicians Task Force on Clinical Competence
2463 and Training. ACCF/AHA/HRS/SCAI clinical competence statement on physician
2464 knowledge to optimize patient safety and image quality in fluoroscopically guided
2465 invasive cardiovascular procedures: a report of the American College of Cardiology
2466 Foundation/American Heart Association/American College of Physicians Task Force
2467 on Clinical Competence and Training. *Circulation*. 2005;111(4):511-32.

- 2468 IAEA, 2010. Patient dose optimization in fluoroscopically guided interventional
2469 procedures. IAEA-TECDOC-1641. Vienna: International Atomic Energy Agency,
2470 2010.
- 2471 International Commission on Radiological Protection. Radiological protection and safety
2472 in medicine. ICRP Publication 73. Ann ICRP 1996; 26(2):1-47
- 2473 International Commission on Radiological Protection. Pregnancy and medical radiation.
2474 ICRP Publication 84. Ann ICRP 2000; 30:1-43.
- 2475 International Commission on Radiological Protection. Avoidance of radiation injuries
2476 from medical interventional procedures. ICRP Publication 85. Ann ICRP 2000;
2477 30(2):1-67.
- 2478 International Commission on Radiological Protection. The 2007 Recommendations of
2479 the International Commission on Radiological Protection. ICRP publication 103.
2480 Ann ICRP 2007;37:1-332.
- 2481 International Commission on Radiological Protection. Radiological protection in
2482 medicine. ICRP Publication 105. Ann ICRP 2007; 37:1-63.
- 2483 ICRP, 2009. Recommendations of the International Commission on Radiological
2484 Protection. ICRP Publication 113, Ann. ICRP 39 (5).
- 2485 International Commission on Radiological Protection 2011a. Statement on Tissue
2486 reactions. Approved by the Commission on April 21, 2011. ICRP ref 4825-3093-
2487 1464. Available at
2488 <http://www.icrp.org/docs/ICRP%20Statement%20on%20Tissue%20Reactions.pdf>
2489 Accessed May 9, 2011.
- 2490 International Commission on Radiological Protection 2011b. Tissue Reactions and Other
2491 Non-Cancer Effects of Radiation. ICRP Publication XXX. Ann ICRP 2011; in press
- 2492 IEC. Medical electrical equipment. Part 2-43: Particular requirements for the safety of
2493 X-ray equipment for interventional procedures. IEC 60601-2-43. 2nd edition,
2494 Geneva, Switzerland: International Electrotechnical Commission; 2010.
- 2495 Justino H. The ALARA concept in pediatric cardiac catheterization: techniques and
2496 tactics for managing radiation dose. *Pediatr Radiol* 2006; 36:146-153
- 2497 Kim C, Vasaiwala S, Haque F, Pratap K, Vidovich MI. Radiation safety among
2498 cardiology fellows. *Am J Cardiol* 2010;106(1):125-128.
- 2499 Koenig TR, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided
2500 procedures: part 2, review of 73 cases and recommendations for minimizing dose
2501 delivered to patient. *AJR Am J Roentgenol*. 2001 Jul;177(1):13-20.
- 2502 McCollough CH, Schueler BA, Atwell TD, Braun NN, Regner DM, Brown DL, LeRoy
2503 AJ. Radiation exposure and pregnancy: when should we be concerned?
2504 *RadioGraphics* 2007; 27:9090-918.
- 2505 Miller DL, Balter S, Noonan PT, Georgia JD. Minimizing radiation-induced skin injury
2506 in interventional radiology procedures. *Radiology* 2002;225:329-36.
- 2507 Miller DL. Overview of contemporary interventional fluoroscopy procedures. *Health*
2508 *Phys* 2008, 95:638-644.
- 2509 Miller DL, Balter S, Schueler BA, Wagner LK, Strauss KJ, Vañó E. Clinical radiation
2510 management for fluoroscopically guided interventional procedures. *Radiology* 2010,
2511 in press.

- 2512 Neofotistou V, Vano E, Padovani R, Kotre J, Dowling A, Toivonen M, Kottou S,
2513 Tsapaki V, Willis S, Bernardi G, Faulkner K. Preliminary reference levels in
2514 interventional cardiology. *Eur Radiol*. 2003 Oct;13(10):2259-63.
- 2515 National Council on Radiation Protection and Measurements. Radiation dose
2516 management for fluoroscopically guided interventional medical procedures. NCRP
2517 Report No. 168. Bethesda, MD: National Council on Radiation Protection and
2518 Measurements; 2010.
- 2519 Neofotistou V. Review of patient dosimetry in cardiology. *Radiat Prot Dosimetry*.
2520 2001;94(1-2):177-82.
- 2521 Ortiz P, Vano E, Padovani R, Coteló E, Ramirez A, Mota H, Faulkner K, Balter S.
2522 Influence of the interventional equipment performance on patient dose and image
2523 quality. Results of a survey under the IAEA International Action Plan for the
2524 Radiological Protection of Patients. ECR 2004. Vienna. Austria.
- 2525 Rehani MM. Training of interventional cardiologists in radiation protection—the
2526 IAEA’s initiatives. *Int J Cardiol* 2007;114:256-260.
- 2527 Sidhu MK, Goske MJ, Coley BJ, Connolly B, Racadio J, Yoshizumi TT, Utley T,
2528 Strauss KJ. Image gently, step lightly: increasing radiation dose awareness in
2529 pediatric interventions through an international social marketing campaign. *J Vasc
2530 Interv Radiol* 2009; 20:1115-1119.
- 2531 Tsapaki V, Kottou S, Kollaros N, Dafnomili P, Kyriakidis Z, Neofotistou V. Dose
2532 performance evaluation of a charge coupled device and a flat-panel digital
2533 fluoroscopy system recently installed in an interventional cardiology laboratory.
2534 *Radiat Prot Dosimetry*. 2004;111(3):297-304.
- 2535 Tsapaki V, Kottou S, Vano E, Faulkner K, Giannouleas J, Padovani R, Kyrozi E,
2536 Koutelou M, Vardalaki E, Neofotistou V. Patient dose values in a dedicated Greek
2537 cardiac centre. *Br J Radiol*. 2003 Oct;76(910):726-30.
- 2538 Vano E, Arranz L, Sastre JM, Moro C, Ledo A, Garate MT, Minguez I. Dosimetric and
2539 radiation protection considerations based on some cases of patient skin injuries in
2540 interventional cardiology. *Br J Radiol*. 1998 May;71(845):510-6.
- 2541 Vano E, Goicolea J, Galvan C, Gonzalez L, Meiggs L, Ten JJ, Macaya C. Skin radiation
2542 injuries in patients following repeated coronary angioplasty procedures. *Br J Radiol*.
2543 2001 Nov;74(887):1023-31.
- 2544 Vano E, Gonzalez L, Ten JJ, Fernandez JM, Guibelalde E, Macaya C. Skin dose and
2545 dose-area product values for interventional cardiology procedures. *Br J Radiol*. 2001
2546 Jan;74(877):48-55.
- 2547 Vano E, Gonzalez L. Approaches to establishing reference levels in interventional
2548 radiology. *Radiat Prot Dosimetry*. 2001;94(1-2):109-12.
- 2549 Vano E, Guibelalde E, Fernandez JM, Gonzalez L, Ten JJ. Patient dosimetry in
2550 interventional radiology using slow films. *Br J Radiol*. 1997 Feb;70:195-200.
- 2551 Vano E, Prieto C, Fernandez JM, Gonzalez L, Sabate M, Galvan C. Skin dose and dose-
2552 area product values in patients undergoing intracoronary brachytherapy. *Br J Radiol*.
2553 2003 Jan;76(901):32-8.
- 2554 Vano E, Gonzalez L, Fernandez JM, Alfonso F, Macaya C. Occupational radiation doses
2555 in interventional cardiology: a 15-year follow-up. *Br J Radiol*. 2006;79(941):383-8.

- 2556 Vlietstra RE, Wagner LK, Koenig T, Mettler F. Radiation burns as a severe complication
2557 of fluoroscopically guided cardiological interventions. J Interv Cardiol. 2004
2558 Jun;17(3):131-42.
- 2559 Wagner LK and Archer BR. Minimising risks from fluoroscopic x rays. Third Edition.
2560 Partners in Radiation Management (R.M. Partnership). The Woodlands, TX 77381.
2561 USA 2000.
- 2562 Wagner LK, Archer BR, Cohen AM. Management of patient skin dose in
2563 fluoroscopically guided interventional procedures. J Vasc Interv Radiol 2000;11:23-
2564 33.
- 2565 Wagner LK. Radiation injury is a potentially serious complication to fluoroscopically-
2566 guided complex interventions. In: Biomedical Imaging and Intervention Journal.
2567 Lumpur, Malaysia: Dept. of Biomedical Imaging, University of Malaya; 2007:e22.
2568 Available at <http://www.bijj.org/2007/2/e22/> Accessed Aug 9, 2010
- 2569 Whitby M, Martin CJ. A study of the distribution of dose across the hands of
2570 interventional radiologists and cardiologists. Br J Radiol 2005;78:219-29.
2571
2572


2573 **Figure 5.1**
2574 Example of skin dose distribution in cardiology procedures (measured with slow film at
2575 the San Carlos University Hospital in Madrid). Skin dose distribution measured during a
2576 conventional PTCA. In this case the peak skin dose was 0.4 Gy.
2577

2578

2579

2580

2581



2582 **Figure 5.2**

2583 Example of a patient dose report produced by a Siemens Axiom Artis X ray system.
2584 Entries 1 to 5 indicate the series acquisition order. CARD is the name of the
2585 acquisition protocol. FIXED means a constant frame rate during the series run. Coro
2586 LD is the acquisition mode. Time in seconds is the duration of the series. Series frame
2587 rate, date, time of acquisition, kV, mA peak, pulse time, focus size, extra copper
2588 filter, KAP per series, RAK, X-ray beam angulation, and number of frames (for each
2589 series) are reported. Total fluoroscopy time, total KAP, and total RAK are also given
2590 at the end of the report. The original printing format of the X-ray system is
2591 maintained.
2592

2593

2594

```

Patient Position: HFS

1 CARD    FIXED  Coro LD           4s 15F/s 04-Apr-05 11:04:59
A 80kV 806mA 7.0ms 200CL large 0.0Cu 20cm 219.5µGym² 37.9mGy 1RAO 36CRA
61F

2 CARD    FIXED  Coro LD           2s 15F/s 04-Apr-05 11:16:39
A 75kV 799mA 7.0ms 400CL large 0.1Cu 20cm 56.8µGym² 7.7mGy 24LAO 5CAU 27F

3 CARD    FIXED  Coro LD           3s 15F/s 04-Apr-05 11:21:31
A 76kV 799mA 7.0ms 600CL large 0.1Cu 20cm 97.3µGym² 14.1mGy 30LAO 1CAU
47F

4 CARD    FIXED  Coro LD           4s 15F/s 04-Apr-05 11:28:03
A 76kV 799mA 7.0ms ***** large 0.1Cu 20cm 138.5µGym² 20.0mGy 30LAO 1CAU 67F

5 CARD    FIXED  Coro LD           5s 15F/s 04-Apr-05 11:28:36
A 90kV 819mA 7.0ms ***** large 0.0Cu 20cm 359.2µGym² 57.2mGy 0LAO 31CRA 71F

***Accumulated exposure data***
Phys: | Exposures: 0 Fluoro: 7.0min Total: 1705.4µGym² 246mGy
04-Apr-05 11:34:29
=====
```

2595

2596

2597

2598

2599

2600 **Table 5.1**

2601 Practical advice to reduce patient doses.

2602

2603

Techniques to reduce patient dose
Use a low-dose fluoroscopy mode when possible
Use the lowest-dose mode for image (cine) acquisition that is compatible with the required image quality
Minimize fluoroscopy time—use fluoroscopy only to guide devices and observe motion
Use the last-image-hold image for review when possible, instead of using fluoroscopy
When possible, store a fluoroscopy loop instead of performing a cine run
If it is available, use a stored fluoroscopy loop for review instead of using fluoroscopy
Minimize the number of cine series
Minimize the number of frames per cine series
Never use cine as a substitute for fluoroscopy
Collimate the radiation beam to the area of interest
Use virtual collimation if it is available
Use wedge filters when they are appropriate
Keep the image detector (image intensifier or flat detector) as close as possible to the patient.
Keep the patient as far as possible from the x-ray tube.
Try to avoid steeply angulated projections (especially LAO cranial)
Try to vary the C-arm angulation slightly, to avoid concentrating the radiation dose at a single site on the patient’s skin.
Use magnification only when necessary.
Remember that for large patients, and also for steeply angulated projections, the dose to the patient increases substantially.
Pay attention to the patient radiation dose display in the procedure room.
If the patient has had previous similar procedures, try to obtain information about the previous radiation doses to optimise subsequent procedures.

2604

2605

2606 **6. RADIATION DOSES AND PROTECTION OF STAFF DURING**
2607 **INTERVENTIONAL FLUOROSCOPY**

2608

2609 **Main Points**

2610

- 2611 • **In general, reducing patient dose will also reduce operator dose.**
- 2612 • **The basic tools of occupational radiological protection are time, distance and**
2613 **shielding.**
- 2614 • **The use of personal protective shielding is necessary in the cardiac**
2615 **catheterization laboratory.**
- 2616 • **Radiological protection for the eyes is necessary for interventionalists.**
- 2617 • **Occupational doses can be reduced to very low levels if ceiling suspended lead**
2618 **screens and protective lead curtains suspended from the side of the procedure**
2619 **table are used properly.**
- 2620 • **Radiation exposure to the operator is neither uniform nor symmetric.**
- 2621 • **Proper use of personal monitoring badges is necessary in cardiac**
2622 **catheterization laboratories in order to monitor and audit occupational**
2623 **radiation dose.**

2624

2625

6.1 Introduction

2626 (97) Despite regulatory limits on occupational dose, there have been reports of
2627 cataracts and of fairly high radiation doses to the hands and legs of staff and hair loss in
2628 the portions of the legs not shielded by a protective device (Balter, 2001a). The
2629 occurrence of radiation-induced cataracts in operators (Vano et al. 1998a, Vano et al,
2630 2010, ICRP 2000, Ciraj-Bjelac, 2010) and the debate regarding the incidence of brain
2631 cancer in interventional cardiologists (Finkelstein, 1998, Klein et al, 2009) highlight the
2632 importance of occupational radiological protection for interventionalists, especially for
2633 parts of the body not protected by the lead apron.

2634 (98) The operator is not normally exposed to the x-ray beam directly, but is exposed
2635 to a considerable amount of scatter radiation. There are a number of techniques,
2636 described in Chapter 5, and protective devices, discussed in this Chapter, that, if used
2637 appropriately, should result in the operator's annual effective dose being well within
2638 regulatory limits. With proper use of radiological protection tools and techniques, the
2639 effective dose (E) for an interventionalist is typically 2–4 mSv/year, and is well below the
2640 20 mSv/year limit recommended by the Commission (Dendy, 2008, Tsapaki, 2004,
2641 Miller, 2010, ICRP 2007). Proper use of personal monitoring badges is essential in
2642 cardiac catheterization laboratories in order to monitor and audit occupational radiation
2643 dose. Too often, personal monitoring badges are not worn, or are worn improperly
2644 (Padovani, 2011). Training in radiation management and radiological protection, as
2645 discussed in Chapter 9, is essential (ICRP 2000).

2646

6.2 Comparison of radiation exposure with that of other staff

2647 (99) The interventionalist encounters much more radiation than most other medical
2648 and paramedical staff in a hospital. The radiation intensity from radioisotopes used in
2649 nuclear medicine is smaller by a factor of a few tens or even hundred. Nuclear medicine
2650 staff are likely to be exposed to much less radiation, whether it emanates from the patient
2651 or from external sources (normally in shielded containers). Similarly, while the radiation
2652 sources used in radiotherapy are of very high strength (GBq or TBq of radioactivity),
2653 staff are exposed only to remnant radiation leaking through the shielding material and
2654 scattered through a large distance. Staff in the interventional laboratory who are
2655 positioned in the control room are protected by both shielding and distance from the x-ray
2656 beam. Typically, in a properly designed facility, the radiation intensity in the control
2657 room may be tens of thousands of times less than at the operator's position (Rehani and
2658 Ortiz-Lopez, 2005). Exposure factors for the interventionalist are a thousand times higher
2659 than for staff working in the control room.

2660 (100) The major protection in nuclear medicine accrues from the lower radiation
2661 intensity and in radiotherapy from shielding and distance. The situation in interventional
2662 fluoroscopy is very different. First, the operator's working position is quite close to the x-
2663 ray source and the source of scatter radiation (the patient). Second, the intensity of the x-
2664 ray beam lies in between the radiation intensities observed in nuclear medicine and
2665 radiotherapy. Also, beam intensity is 10-fold or 20-fold higher in cine mode than in
2666 fluoroscopy mode (NCRP Report 168, 2010). Shielding plays a major role in radiological
2667 protection in interventional fluoroscopy, due to variability in the operator's distance from
2668 the x-ray source, the relative position of the operator, patient, and x-ray source and the
2669 duration of the procedure.

2670

6.3 The essentials of occupational radiological protection

2671 (101) The essentials of occupational radiological protection are time, distance and
2672 shielding. Staff radiological protection cannot be handled independently from patient
2673 protection, since they correlate in many ways. Both patient and occupational radiological
2674 protection are also discussed in an ICRP publication devoted to radiological protection
2675 outside the imaging department (reference ICRP TG 78). In general, reducing patient
2676 dose will also reduce operator dose.

2677

2678 (102) *Time*, one essential component of radiological protection, is controlled by
2679 reducing the time the x-ray beam is on, both for fluoroscopy and for cine. Reducing
2680 fluoroscopy time and fluoroscopy dose rate reduces patient dose. Reduced patient dose
2681 results in reduced scatter, and therefore in reduced operator dose. Readers are advised to
2682 remember all of the factors discussed in Chapter 4.

2683 (103) *Distance* is a valuable tool for radiological protection. Radiation dose
2684 decreases as the square of the distance between the radiation source and the operator (the
2685 inverse square law). A person who moves away from the x-ray source to three times the
2686 original distance will receive only one-ninth of the original dose. During a procedure, the
2687 operator cannot normally move further away from the patient than arm's length. This can

2688 result in high operator radiation doses, especially if contrast medium is injected manually
2689 for angiographic runs. However, if a mechanical injector is used for contrast medium
2690 injection, the operator can move back away from the patient, and ideally behind a shield.

2691 (104) In general, scattered radiation is most intense on the entrance beam side of the
2692 patient (Balter, 2001b, Schueler et al, 2006, Stratakis et al, 2006). When using a C-arm
2693 in a lateral projection, the operator should be positioned on the image receptor side of the
2694 patient, if possible. When using a C-arm in a frontal projection, positioning the x-ray
2695 tube below the table will place the area of higher radiation scatter towards the floor, so
2696 that the operator's head and neck receive less radiation.

2697 (105) *Shielding* is of three types: architectural shielding, equipment mounted shields,
2698 and personal protective devices (Miller et al, 2010). Architectural shielding is built into
2699 the walls of the procedure room and is not discussed further here. Rolling and stationary
2700 shields that are constructed of transparent leaded plastic and rest on the floor are useful
2701 for providing additional shielding for both operators and staff. They are particularly well
2702 suited for use by nurses and anaesthesia personnel. The interventionalist is protected by
2703 equipment-mounted shields suspended from the ceiling and the procedure table, and by
2704 personal protective devices such as a lead apron, leaded glasses and a thyroid shield.

2705 (106) Simple measures, such as standing a little away from the table and patient,
2706 limiting the field size (collimation) and carrying out procedures quickly consistent with
2707 case complexity can be very effective in reducing occupational radiation dose. **Table 6.1**
2708 presents some practical advice to improve occupational protection in the catheterization
2709 laboratory and **Table 6.2** presents the relative change in scatter dose rates measured in a
2710 typical catheterization laboratory for different changes in technique. The values in **Table**
2711 **6.2** highlight the large changes in scatter dose associated with changes in technique and
2712 patient body size.

2713 6.4 Personal protective devices

2714
2715 (107) The use of personal protective shielding is essential in the cardiac
2716 catheterization laboratory. In the past, there has been a trend to use lead aprons of higher
2717 lead equivalence (0.5 mm rather than 0.25, 0.3 or 0.35 mm), even though physical
2718 measurements did not demonstrate a great difference in attenuation (Table 6.3). The
2719 inherently conservative safety factor has always influenced practice in radiation, both for
2720 interventionalists and for regulators.

2721 (108) When procedures are performed on thinner patients, and in particular on
2722 children, a lead apron of 0.25 mm lead equivalence will suffice for staff protection, but
2723 for procedures performed on thicker patients, and for procedures performed by physicians
2724 with heavy workload, a 0.5 mm lead apron may be more suitable. Lead is very effective
2725 for protecting against radiation, but is heavy. The weight can cause problems for staff
2726 who have to wear these aprons for long spans of time (Goldstein, 2004). There are reports
2727 of back injuries due to lead aprons among staff who wear these aprons for many years
2728 (NCRP, 2010). Some newer aprons are lighter weight while maintaining approximately
2729 the same lead equivalence. Newer apron designs distribute weight using a variety of
2730 different methods. Two-piece (skirt and vest) wraparound aprons distribute the apron's
2731 weight and also provide protection for the wearer's back.

2732 (109) Lead aprons should be properly placed on designated hangers and should not
2733 be folded, creased, or crumpled in any way. Sitting on them, folding them or improperly
2734 hanging them may result in damage that reduces their effectiveness. Lead aprons, gloves
2735 and other leaded protective clothing should be inspected before they are put into service
2736 and then periodically re-inspected to determine that they provide the shielding benefit for
2737 which they were designed. A combination of visual, physical and fluoroscopic inspection
2738 can be employed to ensure the integrity of the garments. Consideration should be given to
2739 minimizing the irradiation of inspectors by minimizing unnecessary fluoroscopy (NCRP
2740 168, 2010).

2741 (110) A lead apron does not protect the eyes, the hands, the lower legs or the back
2742 (unless the apron is the wrap-around type). Radiation exposure of these parts of the
2743 body has become a concern.

2744 (111) Radiological protection for the eyes is essential for interventionalists (Dauer et
2745 al, 2010). Preferably, this protection is provided by ceiling-suspended shields (section
2746 6.3), as these devices protect the entire head, and not just the eyes. However, there are
2747 many procedures where it is not practical to use ceiling-suspended shields, as they
2748 interfere with the operator's ability to perform the procedure (Miller et al., 2010). In
2749 these situations, leaded eyeglasses should be worn. Wearing these eyeglasses has been
2750 shown to significantly reduce radiation dose to the operator's eyes (Vano et al, 2008;
2751 Thornton et al, 2010).

2752 (112) While the dose reduction factor for 0.5 mm lead equivalent protective glasses
2753 is approximately 0.03 (i.e., 97% of the radiation is attenuated) the extent of radiation
2754 attenuation by the eyeglass lenses is not an adequate descriptor, by itself, of the
2755 effectiveness of the eyewear (NCRP report 168, 2010). For maximum effectiveness,
2756 radiation protective eyewear should intercept as much as possible of the scattered
2757 radiation that is directed at the interventionalist's eyes. During interventional procedures,
2758 interventionalists normally turn their heads away from the primary beam to view the
2759 fluoroscopy monitor. This results in exposure of the eyes to scattered radiation from the
2760 side. Protective eyewear should provide shielding for side exposure, using either side
2761 shields or a wrap-around design (NCRP report 168, 2010). Proper fit is necessary to
2762 ensure that the lenses and side shields adequately protect the eye and minimize exposure,
2763 and is also important to minimize discomfort from the weight of the eyewear (Schueler et
2764 al., 2009). Even properly designed and fitted leaded eyewear attenuates scattered
2765 radiation by only a factor of 2 or 3 (Moore et al., 1980; Thornton et al, 2010). The net
2766 effect of protective eyeglasses is dependent on the design of the glasses, the nature of the
2767 clinical procedure, and the wearer's work habits.

2768 (113) In younger individuals, the thyroid gland is relatively sensitive to radiation-
2769 induced cancer. However, the cancer incidence risk is strongly dependent on age at
2770 exposure, with very little risk after age 30 for males and age 40 for females (NRC, 2006).
2771 For younger workers, wearing a thyroid collar and a protective apron reduces effective
2772 dose to ~50 % of the effective dose achieved by wearing a protective apron alone
2773 (Martin, 2009; von Boetticher et al., 2009). Use of a thyroid collar (or a protective apron
2774 with thyroid coverage) is recommended for younger interventionalists and for all

2775 personnel whose personal monitor readings at the collar level (unshielded) exceed 4 mSv
2776 (E) in a month (Wagner, 2004).

2777 (114) Flexible, sterile, radiation-attenuating surgical gloves are available to reduce
2778 interventionalist hand exposure. A previous recommendation that protective gloves be
2779 worn in high exposure situations has been reconsidered (NCRP report 133, 2000, NCRP
2780 report 168, 2010). Attenuating surgical gloves may be used to provide a small degree of
2781 protection when hands are exposed only to scattered radiation, but the use of these gloves
2782 does not permit interventionalists to place their hands safely in the primary beam (NCRP
2783 168, 2010).

2784 (115) There are several factors that could lead to higher hand doses for
2785 interventionalists when these gloves are used (Miller et al, 2010). Just as with special
2786 tools that allow for increased distance between the hands of the interventionalist and the
2787 primary x-ray beam, the reduction in tactile feedback from radiation-attenuating surgical
2788 gloves may lead to an increase in fluoroscopy time or CT exposure time for delicate
2789 procedures. Because of the increased dose when any shielding is placed in the primary
2790 beam, and the false sense of security that these gloves provide, protective gloves can
2791 result in increased radiation dose to the hand when the gloved hand is in the primary
2792 beam (Wagner, 1996). With or without added protection, the hands should not be placed
2793 in the primary x-ray beam, except for those rare occasions when it is essential for the
2794 safety and care of the patient. This should be done for the shortest possible time. As a
2795 rule, if an operator's hands are visible on the monitor, then practices should be altered
2796 (Limacher et al. 1998).

2797

6.5 Equipment-mounted shields

2798 (116) The standard equipment-mounted shields used in catheterization laboratories at
2799 present are ceiling suspended lead screens and protective lead curtains suspended from
2800 the side of the procedure table. If these tools are used properly, occupational doses can be
2801 reduced to very low levels.

2802 (117) A leaded glass or plastic screen placed between the patient and the operator
2803 protects the operator's eyes, head and neck. Properly placed shields have been shown to
2804 dramatically reduce operator eye dose (Maeder et al., 2006, Thornton et al, 2010). These
2805 screens can effectively replace both leaded eyewear and a thyroid shield. The screens
2806 add no weight to the operator, eliminating the ergonomic consequences of the protective
2807 equipment they replace.

2808 (118) When a frontal (posteroanterior) projection is used and the x-ray tube is below
2809 the procedure table, scatter dose rates under the table are 3-4 times higher than the values
2810 over the table (Schueler et al, 2006). Leaded curtains suspended from the procedure table
2811 should be used to protect the interventionalist's lower legs. At present, these shields are
2812 available in almost all interventional suites.

2813 (119) Disposable, lightweight, sterile, lead-free radiological protection drape or pad
2814 shields can be positioned on the patient outside of the beam path to significantly reduce
2815 scattered radiation during cardiac interventional procedures (Sawdy et al, 2009, Germano
2816 et al, 2005). These contain metallic elements (typically bismuth or tungsten-antimony)
2817 and are placed on the patient after the operative site has been prepared and draped. They

2818 have been shown to reduce operator dose substantially, with reported reductions of 12-
2819 fold for the eyes, 26-fold for the thyroid and 29-fold for the hands (King et al, 2002,
2820 Dromi et al, 2006). While their use adds some cost to the procedure, disposable
2821 protective drapes should be considered for complex procedures and procedures where the
2822 operator's hands must be near the radiation field (e.g., pacemaker placement) (Miller et
2823 al., 2010). In some institutions they are used routinely (Kim et al, 2010). These drapes
2824 should not be visible in the fluoroscopic image. If they are, the result will be an increase
2825 in patient dose.

2826 **6.6 Overall impact of protective devices**

2827 (120) The effective dose (E) to the cardiologist per procedure has been reported to
2828 range from 0.2 to 18.8 μSv (Padovani and Rodella, 2001). A more recent review
2829 demonstrated a range of 0.02 to 38.0 μSv (Kim et al, 2008). The wide dose ranges are
2830 most likely due to both the wide variation in procedure complexity and the inconsistent
2831 use of shields and personal protective devices. Modest operator dose reductions over
2832 time were observed for both diagnostic catheterizations and ablation procedures, due to
2833 technological improvements, but doses were not reduced over time for percutaneous
2834 coronary interventions. This was believed to be due mainly to the increased complexity
2835 of interventions.

2836 (121) Even if one assumes a rather high workload of 1000 angiographic procedures
2837 per year, the annual threshold level of 20 mSv will rarely be exceeded. One study
2838 reported an estimate of E for the operator of only 0.04–0.05 mSv/year (Efsthapoulos et
2839 al. 2003), although other studies have reported 2–4 mSv/year (Dendy, 2008, Tsapaki,
2840 2004). The extensive studies by Kuon et al. establish that with proper choice of technique
2841 and shielding devices, the operator may be exposed to only 0.8% of typical radiation
2842 levels in advanced cardiac catheterization laboratories (Kuon et al. 2002).

2843 (122) When a lateral projection or steep gantry angulation is used, standing on the x-
2844 ray tube side of the C-arm increases operator dose. Kuon et al. have estimated the
2845 influence of angulation of the X-ray tube on the amount of scatter radiation to the
2846 operator (Kuon et al. 2004). Radiation levels have been found to be highest for the left
2847 anterior oblique (LAO) position, whereas in posteroanterior (PA) and right anterior
2848 oblique (RAO) angulations, levels are much lower (Kuon et al. 2002, 2003, 2004).
2849 Simultaneous craniocaudal angulation further increases the dose. The group has shown
2850 that the standard view for the left main stem coronary artery (LAO 60°/20°–) is
2851 associated with a 7.6-fold increase in dose to the operator and a 2.6-fold increase in dose
2852 for the patient as compared to an alternative less frequently used angulation (caudal
2853 PA0°/30°–).

2854 (123) Effective dose does not reflect the doses to susceptible, unprotected parts of the
2855 body—the hands and the eyes. Radiation exposure to the operator is neither uniform nor
2856 symmetric. A right-handed operator performing the procedure via the right femoral
2857 artery has his or her left side turned towards the patient. Therefore the left side of the
2858 body is exposed to the highest level of scatter radiation (Maeder et al. 2005). This is
2859 especially true for the hands, which are at the level where the X-ray beam enters the

2860 patient. During cardiac catheterization, the left hand has been reported to receive twice
2861 the dose as compared with the right hand (Vaño et al. 1998b). The left eye also receives
2862 higher doses than the right eye. Not surprisingly, a tall operator will receive a lower eye
2863 dose than a short operator, because of the greater distance from the tall operator's eyes to
2864 the patient.

2865 (124) Unless personal monitoring devices are always worn, and worn properly, it is
2866 not possible to estimate occupational dose accurately. Failure to wear personal
2867 monitoring devices may lead to the false belief that an individual's occupational dose is
2868 low when it is not.

2869 **6.7 Personal dosimetry**

2870 (125) The Commission recommends the use of two personal dosimeters for
2871 occupational dosimetry cardiac catheterization laboratories: one worn on the trunk of the
2872 body inside the apron and the other worn outside the apron at the level of the collar or the
2873 left shoulder (ICRP 2000). The dosimeter under the apron provides an estimate of the
2874 dose to the organs of the shielded region. The dosimeter worn outside the apron supplies
2875 an estimate of the dose to the organs of the head and neck, including the thyroid and lens
2876 of the eyes (if unshielded), but greatly overestimates the doses to organs of the trunk.
2877 Results obtained from both dosimeters can be used to estimate the occupational effective
2878 dose as recommended by the NCRP (NCRP, 1995) and ICRP (ICRP, 2000). A dosimeter
2879 for the hands may also be useful.

2880 (126) The effective dose, E , can be estimated from the dosimeter values for H_w
2881 (under the apron at the waist, although this position is not critical) and H_n (above the
2882 apron at the neck) from the equation:

$$2883 \quad E = 0.5 H_w + 0.025 H_n$$

2884
2885
2886 (127) NCRP report 122 (NCRP 1995) contains specific recommendations for
2887 calculating the effective dose when protective aprons are worn during diagnostic and
2888 interventional medical procedures involving fluoroscopy. In addition to the above
2889 formula, it states that the effective dose can be estimated as $H_n/21$ if only one dosimeter
2890 is worn on the neck outside the apron.

2891 (128) The European Commission DIMOND project addressed the issues regarding
2892 optimization of staff doses with an attempt to propose preliminary occupational dose
2893 constraints (Tsapaki et al. 2004). The proposed value for cardiologists' annual effective
2894 dose was 0.6 mSv. UNSCEAR (UNSCEAR 2000, paragraph 166) reported that
2895 cardiologists tend to be the most exposed staff in medicine; their average annual dose was
2896 0.4mSv, and an appreciable proportion received more than 1 mSv. A recent review of
2897 radiation exposures to operators from cardiac procedures over a 30 year period
2898 highlighted the difficulty in comparing reported dosimetry results because of significant
2899 differences in dosimetric methods in each study (Kim et al, Health Physics, 2008). Better
2900 standardization of dosimetric methods is recommended.

2901 (129) Many operators not only do not use protective equipment properly, but also do
2902 not regularly wear their dosimeters. Failure to wear dosimeters is a problem throughout

2903 the world (Vaño et al. 1998b, McCormick, 2002, Padovani, 2011). In addition to
2904 monitoring personal exposure, dosimeter use helps to increase awareness about
2905 radiological protection. In the absence of formal training in radiological protection for
2906 cardiologists in such countries, physicians in training adopt the practices of their seniors
2907 (Rehani and Ortiz-Lopez, 2005).

2908 (130) Compliance with the radiation badge policies is one of the main problems in
2909 many interventional cardiology services (Vano 2005). Reported occupational dose values
2910 are often surprisingly low, and the reason is likely not a high level of radiological
2911 protection, but rather failure to wear personal dosimeters. McCormick et al. (McCormick
2912 2002) reported that before a mandatory radiological protection training programme,
2913 compliance with the radiation badge policy for physicians and nurse clinicians was only
2914 36% in 1999, and afterwards reached a maximum of only 77%. A strict policy on the
2915 regular use of personal dosimeters should be part of any quality programme in cardiology
2916 laboratories.

2917

6.8 References

2918

2919 Balter, S, 2001a. *Interventional fluoroscopy – physics, technology, safety*. Wiley-Liss,
2920 New York.

2921 Balter S., 2001b. Stray radiation in the cardiac catheterization laboratory. *Radiat Prot*
2922 *Dosim* 94(1-2), 183-188.

2923 Ciraj-Bjelac O, Rehani MM, Sim KH, Liew HB, Vano E, Kleiman NJ. Risk for radiation
2924 induced cataract for staff in interventional cardiology: Is there reason for concern?
2925 *Catheter Cardiovasc Interv* 2010;76(6):826-834.

2926 Dauer, L.T., Thornton, R.H., Solomon, S.B., St Germain, J., 2010. Unprotected operator
2927 eye lens doses in oncologic interventional radiology are clinically significant:
2928 estimation from patient kerma-area-product data. *J. Vasc. Interv. Radiol.* 21, 1859-
2929 1861.

2930 Dendy PP. Radiation risks in interventional radiology. *Br J Radiol* 2008; 81:1-7.

2931 Dromi, S., Wood, B.J., Oberoi, J., Neeman, Z., 2006. Heavy metal pad shielding during
2932 fluoroscopic interventions. *J. Vasc. Interv. Radiol.* 17, 1201-1206.

2933 Efsthopoulos E, Makrygiannis SS, Kottou S, et al. Medical personnel and patient
2934 dosimetry during coronary angiography and intervention. *Phys Med Biol*
2935 2003;48:3059-68.

2936 Finkelstein MM. Is brain cancer an occupational disease of cardiologists? *Can J Cardiol*
2937 1998;14,1385-8.

2938 Germano, J.J., Day, G., Gregorius, D., Natarajan, V., Cohen, T., 2005.

2939 A novel radiation protection drape reduces radiation exposure during fluoroscopy guided
2940 electrophysiology procedures. *J. Invasive Cardiol.* 17, 469-72.

2941 Goldstein JA, Balter S, Cowley M, Hodgson J, Klein LW; Occupational hazards of
2942 interventional cardiologists: prevalence of orthopedic health problems in
2943 contemporary practice. *Catheter Cardiovasc Interv.* 2004 Dec;63(4):407-11.

2944 ICRP. Avoidance of radiation injuries from medical interventional procedures. ICRP
2945 Publication 85. *Ann ICRP* 2000;30(2).

- 2946 ICRP. The 2007 Recommendations of the International Commission on Radiological
2947 Protection. ICRP Publication 103. Ann ICRP 2007; 37(2-4):1-332
- 2948 Kim KP, Miller DL, Balter S, Kleinerman RA, Linet MS, Kwon D, Simon SL.
2949 Occupational radiation doses to operators performing cardiac catheterization
2950 procedures. Health Phys 94: 211-227, 2008.
- 2951 Kim, C., Vasaiwala, S., Haque, F., Pratap, K., Vidovich, M.I., 2010. Radiation safety
2952 among cardiology fellows. Am. J. Cardiol. 106, 125-128.
- 2953 King JN, Champlin AM, Kelsey CA, Tripp DA. Using a sterile disposable protective
2954 surgical drape for reduction of radiation exposure to interventionalists. Am J
2955 Roentgenol 2002; 178:153-157.
- 2956 Klein LW, Miller DL, Balter S, Laskey W, Haines D, Norbash A, Mauro MA, Goldstein
2957 JA. Occupational health hazards in the interventional laboratory: time for a safer
2958 environment. Heart Rhythm 2009, 6:439-444.
- 2959 Kuon E, Schmitt M, Dahm JB. Significant reduction of radiation exposure to operator
2960 and staff during cardiac interventions by analysis of radiation leakage and improved
2961 lead shielding. Am J Cardiol 2002; 89:44-9.
- 2962 Kuon E, Dahm J, Empen K, et al. Identification of less-irradiating tube angulations in
2963 invasive cardiology. J Am Coll Cardiol 2004;44:1420-8.
- 2964 Limacher MC, Douglas PS, Germano G, et al. ACC expert consensus document.
2965 Radiation safety in the practice of cardiology. J Am Coll Cardiol. 1998;31:892-913.
- 2966 Maeder M, Verdun FR, Stauffer JC et al. Radiation exposure and radiation protection in
2967 interventional cardiology. Kardiovaskuläre Medizin 2005;8:124-132.
- 2968 Maeder M, Brunner-La Rocca HP, Wolber T, Ammann P, Roelli H, Rohner F, Rickli H.
2969 Impact of a lead glass screen on scatter radiation to eyes and hands in interventional
2970 cardiologists. Catheter Cardiovasc Interv 2006; 67:18-23.
- 2971 Marshall NW, Faulkner K, Clarke P. An investigation into the effect of protective
2972 devices on the dose to radiosensitive organs in the head and neck. Br J Radiol. 1992
2973 Sep;65(777):799-802.
- 2974 Martin, CJ. A review of radiology staff doses and dose monitoring requirements. Radiat
2975 Prot Dosim 2009; 136(3), 140-157.
- 2976 McCormick VA, Schultz CC, Hollingsworth-Schuler V, Campbell JM, O'Neill WW,
2977 Ramos R. Reducing radiation dose in the cardiac catheterization laboratory by
2978 design alterations and staff education. Am J Cardiol 2002; 90:903-905.
- 2979 Miller DL, Vañó E, Bartal G, Balter S, Dixon R, Padovani R, Schueler B, Cardella JF,
2980 de Baère T. Occupational radiation protection in interventional radiology: A joint
2981 guideline of the Cardiovascular and Interventional Radiology Society of Europe and
2982 the Society of Interventional Radiology. Cardiovasc Interv Radiol 2010; 33:230-
2983 239.
- 2984 Moore WE, Ferguson G, Rohrmann C. Physical factors determining the utility of
2985 radiation safety glasses. Med Phys 1980; 7(1), 8-12.
- 2986 NRC. Health risks from exposure to low levels of ionizing radiation: Phase 2, BEIR VII.
2987 Washington, DC: The National Academies Press, 2006.
- 2988 NCRP. Use of personal monitors to estimate effective dose equivalent and effective dose
2989 to workers for external exposure to low-LET radiation. NCRP report No. 122.

- 2990 Bethesda, Maryland: National Council on Radiation Protection and Measurements;
2991 1995.
- 2992 NCRP. Radiation protection for procedures performed outside the radiology department.
2993 NCRP Report No. 133. Bethesda, Maryland: National Council on Radiation
2994 Protection and Measurements; 2000.
- 2995 NCRP. Radiation dose management for fluoroscopically guided interventional medical
2996 procedures. NCRP Report No. 168. Bethesda, MD: National Council on Radiation
2997 Protection and Measurements; 2010.
- 2998 Padovani R, Rodella CA. Staff dosimetry in interventional cardiology. *Radiat Prot*
2999 *Dosimetry* 2001;94:99-103.
- 3000 Padovani, R., Le Heron, J., Cruz-Suarez, R., Duran, A., Lefaire, C., Miller, D.L., Sim,
3001 H.K., Vano, E., Rehani, M., Czarwinski, R., 2010. International project on individual
3002 monitoring and radiation exposure levels in interventional cardiology. *Radiat Prot*
3003 *Dosimetry* 2011; in press.
- 3004 Rehani MM, Ortiz-Lopez P. Radiation effects in fluoroscopically guided cardiac
3005 interventions – keeping them under control.(Editorial). *Int J Cardiol* 2006; 109(2):
3006 147-151.
- 3007 Sawdy, J.M., Gocha, M.D., Olshove, V., Chisolm, J.L., Hill, S.L., Phillips, A.,
3008 Galantowicz, M., Cheatham, J.P., Holzer, R.J., 2009. Radiation protection during
3009 hybrid procedures: innovation creates new challenges. *J. Invasive Cardiol.* 21, 437-
3010 40.
- 3011 Schueler BA, Vrieze TJ, Bjarnason H, Stanson AW. An investigation of operator
3012 exposure in interventional radiology. *RadioGraphics* 2006; 26(5), 1533-1541.
- 3013 Schueler BA, Sturchio G, Landsworth R, Hindal M, Magnuson D. (2009) Does new
3014 lightweight leaded eyewear provide adequate radiation protection for fluoroscopists?
3015 (abstract) *Med Phys* 2009; 36(6), 2747-2748.
- 3016 Stratakis J, Damilakis J, Hatzidakis A, Theocharopoulos N, Gourtsoyiannis N.
3017 Occupational radiation exposure from fluoroscopically guided percutaneous
3018 transhepatic biliary procedures. *J Vasc Interv Radiol* 2006; 17(5), 863–871.
- 3019 Thornton, R.H., Dauer, L.T., Altamirano, J.P., Alvarado, K.J., St. Germain, J., Solomon,
3020 S.B., 2010. Comparing strategies for operator eye protection in the interventional
3021 radiology suite. *J. Vasc. Interv. Radiol.* 21, 1703-1707.
- 3022 Tsapaki V, Kottou S, Vano E, Kompapa T, Padovani R, Dowling A, Molfetas M,
3023 Neofotistou V. Occupational dose constraints in interventional cardiology
3024 procedures: the DIMOND approach. *Phys Med Biol.* 2004 Mar 21;49(6):997-1005.
- 3025 United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and
3026 effects of ionizing radiation. UNSCEAR 2000 report to the General Assembly, with
3027 scientific annexes. Annex E. Occupational radiation exposures. (Available at
3028 www.unscear.org). New York: United Nations; 2000.
- 3029 Vano E, González L, Beneytez F, et al. Lens injuries induced by occupational exposure
3030 in non-optimised interventional radiology laboratories. *Br J Radiol* 1998a;71:728-33.
- 3031 Vano E, Gonzalez L, Guibelalde E, et al. Radiation exposure to medical staff in
3032 interventional and cardiac radiology. *Br J Radiol* 1998b;71:954-60.

3033 Vano E. Radiation exposure to cardiologists: how it could be reduced. *Heart*. 2003;
3034 89(10):1123-4.

3035 Vano E, Gonzalez L, Fernandez JM, Alfonso F, Macaya C. Occupational radiation
3036 doses in interventional cardiology: a 15 year follow-up. *Br J Radiol*
3037 2006;79(941):383-388.

3038 Vano E, Gonzalez L, Fernandez JM, Prieto C, Guibelalde E. Influence of patient
3039 thickness and operation modes on occupational and patient doses in interventional
3040 cardiology. *Radiat Prot Dosim* 2006; 118(3): 325-330.

3041 Vano E, Gonzalez L, Fernandez M, Haskal ZJ. Eye lens exposure to radiation in
3042 interventional suites: caution is warranted. *Radiology* 2008; 248: 945-953.

3043 Vano E, Kleiman NJ, Duran A, Rehani MM, Echeverri D, Cabrera. M. Radiation
3044 cataract risk in interventional cardiology personnel. *Radiat Res*, 2010; 174(4):490-
3045 495

3046 von Boetticher H, Lachmund J, Hoffmann W. Cardiac catheterization: impact of face
3047 and neck shielding on new estimates of effective dose. *Health Phys* 2009; 97(6),
3048 622– 627.

3049 Wagner LK, Mulhern OR. Radiation-attenuating surgical gloves: effects of scatter and
3050 secondary electron production. *Radiology* 1996; 200:45-48.

3051 Wagner LK, Archer BR. *Minimizing Risks from Fluoroscopic X-Rays: Bioeffects,*
3052 *Instrumentation, and Examination.* 4th Edition. The Woodlands, Texas:(Partners in
3053 *Radiation Management*, 2004.
3054

3055

3056

Table 6.1.

3057

3058

Practical advice for interventionalists to improve staff radiation protection (from Vano et al, 2003 and Miller et al, 2010).

3059

3060

3061

- Increase your distance from the patient (the scatter radiation source) whenever possible. This is obviously only possible when angiographic runs are not performed by hand. Working at 80 cm from the isocenter instead of 40 cm can decrease scattered dose to approximately a quarter of the original dose.

3062

3063

3064

3065

- Try to position yourself in a low scatter area. Scattered radiation is higher at the x-ray tube side of the gantry and lower on the side of the image receptor.

3066

3067

- Use a ceiling suspended screen, a table-suspended screen and other protective shielding, such as a lead apron, thyroid collar and lead glasses, when possible.

3068

3069

- When appropriate, use a dose reduction pad or drape at the catheter entrance site to reduce your hand dose.

3070

3071

- Minimise the use of fluoroscopy and use low-dose fluoroscopy modes (for example, pulsed fluoroscopy) when possible.

3072

3073

- Minimize the number of cine series and the number of frames per cine series.

3074

- Use magnification as little as possible.

3075

- Collimate the x-ray beam as tightly as possible.

3076

- Obtain appropriate training in radiation management and radiation protection.

3077

- Wear your dosimeters and know your own dose.

3078

- In addition, a final general concept: reduce the patient's radiation and you will also be reducing your own dose.

3079

3080

3081

3082 Table 6.2
3083
3084 Relative increases in staff doses with changes in different operational features in a Philips
3085 Integris 5000 fluoroscopy unit (Vano et al, 2006).
3086

<i>Action</i>	<i>Increase in staff dose</i>
Changing from low to high fluoroscopy mode (for a 20 cm thick patient)	× 2.6
Changing II format from 23 cm to 17 cm (for a 20 cm thick patient)	× 1.0
Changing patient thickness from 16 to 28 cm	× 4.2
Changing from low fluoroscopy mode to cine (for a 20 cm thick patient)	× 8.3

3087

3088

3089

3090 Table 6.3
3091
3092 Protection of different lead aprons for X-ray beams filtered with 3 mm Al and generated
3093 at the kVp indicated (Vano et al, 2006).
3094

kVp	Protective apron Pb equivalent (mm)	Fraction of energy transmitted (%)
90	0.25	8.3
90	0.35	4.9
90	0.50	2.4
80	0.25	5.7
80	0.35	3.0
80	0.50	1.3
70	0.25	3.3
70	0.35	1.5
70	0.50	0.5

3095
3096

3097

3098

7. RADIOLOGICAL PROTECTION FOR NUCLEAR CARDIOLOGY

3099

3100

Main Points

3101

- Appropriate use criteria and guidelines that help to set standards for justification have been developed through consensus efforts of professional societies.

3102

3103

3104

- Optimization of nuclear cardiology procedures involves the judicious selection of radiopharmaceuticals and administered activities to ensure diagnostic image quality while minimizing patient dose.

3105

3106

3107

- For SPECT protocols, Tc-99m-based agents yield lower effective doses than Tl-201, and are preferred on dosimetric grounds.

3108

3109

- Administered activities should be within pre-specified ranges, as provided in international and national guidelines, and should reflect patient habitus.

3110

3111

- If stress imaging is normal, rest imaging can be omitted to minimize total dose.

3112

3113

- Practitioners need good quality dosimetry data to perform proper benefit-risk analyses for their patients.

3114

3115

3116

3117

7.1 Introduction

3118

3119

(131) More than 90% of nuclear cardiology studies are myocardial perfusion scintigraphy studies for the assessment of myocardial perfusion and/or viability. The vast majority of nuclear cardiology procedures are performed with single photon emission computed tomography (SPECT). A small but growing number of laboratories perform positron emission tomography (PET) studies.

3120

3121

3122

3123

3124

(132) An estimated 32.7 million diagnostic nuclear medicine procedures are performed annually worldwide (UNSCEAR 2008). Of these, approximately 14 million are nuclear cardiology procedures, and this number has increased rapidly (Davis, 2006). More nuclear cardiology procedures are performed in the United States than in the rest of the world combined. In the U.S., nuclear medicine procedures accounted for 26% of the medical exposure of patients in 2006, and cardiac studies accounted for 85% of the nuclear medicine exposure (NCRP report 160, 2009).

3125

3126

3127

3128

3129

3130

3131

3132

7.2 Radiopharmaceuticals

3133

3134

(133) The radiopharmaceuticals used most commonly for nuclear cardiology studies are summarized in **Table 7.1**. In Europe, most studies are performed using Tc-99m-based agents, while in the United States, a sizable minority of studies are performed using Tl-201, usually in the context of a dual isotope study with rest Tl-201 imaging followed by stress Tc-99m imaging. The use of thallium results in a higher dose to the patient (Einstein et al, 2007).

3135

3136

3137

3138

3139

3140

3141 Table 7.1. Commonly Used Radiopharmaceuticals for Nuclear Cardiology

Agent	Modality	Role			Physical Half-Life	Effective Dose (10 ⁻³ mSv/MBq)	ICRP Publication
		(14) perfusion	(15) unctio n	(16) iabilit y			
Tc-99m sestamibi	SPECT	+++	++	+	6h	9.0 rest/7.9 stress	80(1998)
Tc-99m tetrofosmin	SPECT	+++	++	+	6h	7.6 rest/7.0 stress	80(1998)
Tl-201	SPECT	+++	+	++	73h	140	106(2008)
Tc-99m red blood cells	Planar or SPECT MUGA	-	+++	-	6h	7.0	80(1998)
Rb-82	PET	+++	++	-	75s	3.4*	(17) 80(1998)*
N-13 ammonia	PET	+++	++	-	10m	2.0	80(1998)
F-18 fluorodeoxyglucose	PET	-	-	+++	110m	19	(18) 80(1998)

3142 SPECT: single photon emission computed tomography, PET: positron emission tomography; MUGA: multiple gated
 3143 acquisition

3144 * ICRP’s dose coefficients for Rb-82, dating to Publication 53 (1987) and reiterated in Publication 80 (1998), reflect
 3145 for some organs “worst case” conditions, as was stated in Publication 53, and thus dose estimates deriving therefrom
 3146 might be overly conservative. Three groups have recently suggested lower dose coefficients (Senthamizchelvan et al
 3147 2010, 1.11 µSv/MBq; Hunter 2010, 0.74 µSv/MBq; and Stabin 2010, 1.7 µSv/MBq); the Commission is currently
 3148 revisiting the issue of Rb-82 dosimetry.

3149
 3150 (134) Recommended administered activities for nuclear cardiology procedures vary
 3151 markedly among the professional societies and accrediting bodies in various countries
 3152 (Hesse et al., 2005). Guidelines have been published by both the American Society of
 3153 Nuclear Cardiology (ASNC) (DePuey, 2006; Henzlova, 2009) and the European Council
 3154 on Nuclear Cardiology (ECNC) (Hesse et al., 2005), a joint group of the European
 3155 Association of Nuclear Medicine (EANM) and the European Society of Cardiology
 3156 (ESC). Injected activity from these guidelines is summarized in **Table 7.2**.

3157
 3158
 3159
 3160
 3161
 3162
 3163
 3164
 3165
 3166
 3167
 3168
 3169
 3170
 3171
 3172

3173 Table 7.2. Recommended Injected Activity (MBq) for Standard Cardiac SPECT and PET
 3174 Protocols
 3175
 3176

		ASNC	EANM/ESC
SPECT	Thallium 1 injection	92 to 148	74 to 111
	Thallium 2 injections	92 to 148 (stress) 37 to 74 (re-injection)	74 to 111 (stress) 37 (re-injection)
	Technetium-99m 1 day	296 to 444 (1 st dose) 888 to 1332 (2 nd dose)	400 to 500 (1 st dose) 1200 to 1500 (2 nd dose)
	Technetium-99m 2 day	888 to 1332 each day	600 to 900 each day
	Dual Isotope	92 to 148 (Tl) 888 to 1332 (^{99m} Tc)	not specified
	MUGA	925 to 1295*	not specified
PET	Rubidium-82 2 injections	1480 to 2220 per dose**	1100 to 2200 per dose
	N-13 ammonia 2 injections	370 to 740 per dose	370 to 740 per dose
	F-18 FDG	185 to 555	200 to 350

3177
 3178
 3179
 3180
 3181

*740 to 925 for planar imaging
 **for 2 dimensional acquisition using camera with bismuth germanate or lutetium oxyorthosilicate crystals

7.3 Dosimetry for nuclear cardiology

3182
 3183
 3184
 3185
 3186
 3187
 3188
 3189
 3190

(135) Two types of dose coefficients can be determined: 1) tissue dose coefficients, which can be used to estimate the dose to a particular tissue or organ, and 2) effective dose coefficients, which can be used to estimate effective dose to the individual. Note however that effective dose is intended for use as a radiological protection quantity. Effective dose is not recommended for epidemiological evaluations, nor should it be used for detailed specific retrospective investigations of individual exposure and risk (ICRP, 2007a).

3191
 3192
 3193
 3194
 3195

(136) Estimates of organ dose and estimates of effective dose to patients are generally obtained by using mathematical biokinetic models that quantify the distribution and metabolism of a radiopharmaceutical in the body. These models incorporate biokinetic data from humans and/or animals and enable the determination of dose coefficients.

3196
 3197

(137) *Tissue dose coefficients* quantify absorbed doses to a specific organ in a typical patient, per unit activity administered. For example, ICRP's current liver dose coefficient

3198 in an adult for the PET tracer F-18 fluorodeoxyglucose is 1.1×10^{-2} mGy per MBq (ICRP,
3199 1998). Thus, a 200 MBq injection of F-18 fluorodeoxyglucose is associated with an
3200 estimated dose to the liver of 2.2 mGy.

3201 (138) *Effective dose coefficients* quantify effective dose per unit activity
3202 administered. ICRP's current effective dose coefficient in an adult for F-18
3203 fluorodeoxyglucose is 1.9×10^{-2} mSv per MBq (ICRP, 1998), and therefore the same 200
3204 MBq injection of F-18 fluorodeoxyglucose would be associated with an estimated
3205 effective dose of 3.8 mSv.

3206 (139) Several systems provide mathematical frameworks for estimating dose
3207 coefficients, including those of ICRP Publication 30 (ICRP, 1979) and those of the
3208 Society of Nuclear Medicine's Medical Internal Radiation Dose committee (Loevinger et
3209 al., 1988) and Radiation Dose Assessment Resource task group (Stabin et al., 2001).
3210 These approaches are essentially equivalent (Stabin, 2006). They estimate radiation dose
3211 as energy per unit mass. Energy is generally determined from biokinetic models of the
3212 radiopharmaceutical's time-activity curve, from tables of the mean energy per nuclear
3213 transition, and from Monte Carlo computer models. Organ masses are determined from a
3214 model of a representative person.

3215 (140) There are numerous collections of dose coefficients for specific
3216 radiopharmaceuticals. The most extensive compilations are those of the Commission, for
3217 which current estimates can be found in Publications 53 (ICRP, 1987), 80 (ICRP, 1998),
3218 and 106 (ICRP, 2008). Effective doses for commonly used radiopharmaceuticals for
3219 nuclear cardiology, based on the most recent ICRP effective dose coefficients for these
3220 radiopharmaceuticals, are listed in **Table 7.1**. These effective doses reflect ICRP
3221 Publication 60 tissue weighting factors; updated effective dose coefficients reflecting
3222 Publication 103 tissue weighting factors will be included in a forthcoming ICRP
3223 publication. In many countries there is a regulatory requirement that dose coefficients be
3224 provided in manufacturers' package inserts/product information (PI) sheets for
3225 radiopharmaceuticals.

3226

3227

7.4 Current dosimetry estimates


3228

3229 (141) The dose to a typical patient from a nuclear cardiology study can be estimated
3230 by multiplying dose coefficients by the administered activity. These estimates are
3231 illustrated in **Figure 7.1**, using the most recent ICRP dose coefficients for each agent and
3232 administered activities in the middle of the range specified in **Table 7.2**.

3233

3234

3235



3236

3237

3238

3239

3240

3241

3242

3243

3244

3245

3246

3247

3248

3249

3250

3251

3252

Figure 7.1. Effective doses from standard nuclear cardiology procedures, estimated using the most recent ICRP dose coefficients and Publication 103 tissue weighting factors (ICRP, 2007a). Stacked bars represent organ weighted equivalent doses contributing to effective dose. Doses for Tc-99m represent the average of Tc-99m sestamibi and tetrofosmin. Top: Using average recommended administered activities from American Society of Nuclear Cardiology guidelines (Henzlova, 2009; DePuey, 2006). Bottom: Using average recommended administered activities from European Council on Nuclear Cardiology guidelines (Hesse et al., 2005).

*Note that ICRP’s dose coefficients for Rb-82, dating to Publication 53 (1987) and reiterated in Publication 80 (1998), reflect for some organs “worst case” conditions, as was stated in Publication 53, and thus dose estimates derived therefrom might be overly conservative. Three groups have recently suggested lower dose coefficients (Senthamizhchelvan et al 2010, 1.11 $\mu\text{Sv}/\text{MBq}$; Hunter 2010, 0.74 $\mu\text{Sv}/\text{MBq}$; and Stabin 2010, 1.7 $\mu\text{Sv}/\text{MBq}$); the Commission is currently revisiting the issue of Rb-82 dosimetry.

3253
3254
3255
3256
3257
3258
3259
3260
3261
3262
3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
3287
3288
3289
3290
3291
3292
3293
3294
3295

7.5 Uncertainty in dosimetry

(142) Because many terms are estimated and multiplied together to determine dose coefficients, there are numerous potential sources of uncertainty in these dose estimates. Differences between planned and actual administered activity are considered to be minor contributors to the total uncertainty, if regular quality control is performed (ICRP, 1987). The three most sizable contributors to uncertainty are inter-individual variability in organ masses, absorbed fractions, and total activity in each organ. Uncertainties in organ activity reflect differences in biokinetics. (Stabin, 2008b) Experimental validation of calculated absorbed doses has indicated agreement within 20% to 60%, with the larger value applicable to patients who differed considerably from the body size and shape assumed in the calculations (Roedler, 1981). More recent publications contend that the combined uncertainties for any given dose estimate of a radiopharmaceutical are generally at least a factor of 2 (Stabin, 2008b).

7.6 Discrepancies between ICRP dosimetry and information from manufacturers

(143) The most readily available source of dosimetric data about a radiopharmaceutical is typically the information provided by the manufacturer. In several cases, dose coefficients vary considerably between those given in ICRP publications and those provided by manufacturers. These discrepancies may affect the choice of diagnostic tests and the choice of radiopharmaceuticals, since radiation risk is one factor that should be incorporated into benefit-risk analyses.

(144) One recent report evaluating package inserts in the United States found that effective doses for Tl-201 estimated from a single manufacturer's information were less than half of those estimated from ICRP tables, while doses estimated from package inserts from two other manufacturers were greater than or similar to ICRP effective doses. (Einstein et al., 2007) These discrepancies are due, in part, to the numerous sources of uncertainty incorporated into dose coefficients. However, they may also be due to the use of limited and older data by manufacturers (Gerber et al., 2009; Stabin, 2008a).

(145) The Commission recommends that national regulatory authorities implement programs to ensure the quality of dosimetric data in package inserts and product information. Aspects of quality include inclusion of effective dose coefficients (as opposed to total body dose coefficients), periodic post-approval updates to reflect the available dosimetric data, and transparency in the data sources and sample sizes used to obtain dose coefficients.

7.7 Radiological protection of patients in nuclear cardiology

3296 (146) The general principles of radiological protection (chapter 4), i.e. justification
3297 and optimisation, can be applied to the protection of patients in nuclear cardiology. Dose
3298 limitation is not appropriate, but diagnostic reference levels should be used to help
3299 manage the radiation dose so that the dose is commensurate with the clinical purpose
3300 (ICRP, 1977, ICRP, 2007a, ICRP, 2007b).

3301

3302 **7.7.1 Justification**

3303

3304 (147) Nuclear cardiology studies should always be justified on clinical grounds
3305 (Gerber et al., 2009). Even in highly expert institutions, sizable percentages of nuclear
3306 cardiology studies performed may not meet standardized criteria for appropriateness. To
3307 a certain degree this may reflect limitations with appropriateness criteria, which may not
3308 incorporate all the information included in decision making for a particular patient.
3309 However, in a recent retrospective analysis of 284 patients undergoing nuclear stress
3310 testing at the Mayo Clinic, 25% had inappropriate or uncertain indications (Gibbons et
3311 al., 2008). Four inappropriate indications accounted for 88% of inappropriate studies.
3312 The most common inappropriate indication was stress testing in an asymptomatic low-
3313 risk patient.

3314 (148) Pre-test classification of patients by indication, with a requirement for specific
3315 justification for patients with no identified appropriate indication, offers an approach to
3316 decrease the number of nuclear stress tests performed that are not justified. The
3317 Commission encourages the development and validation of national and regional
3318 appropriateness criteria for utilization of cardiac imaging. For clinical scenarios in which
3319 more than one imaging modality might be used, appropriateness criteria should
3320 simultaneously address these multiple modalities. (ACR, 2010). Alternative techniques
3321 (such as stress-echocardiography) are available, and should be considered whenever
3322 possible.

3323

3324 **7.7.2 Optimization**

3325

3326 (149) Several methods can be used to control patient dose in nuclear cardiology.
3327 These include choosing the most appropriate radiopharmaceutical(s), optimizing injected
3328 activity, avoiding rest imaging when stress imaging is normal and encouraging hydration
3329 and early micturition after radiopharmaceutical administration. Hydration and early
3330 micturition may halve the dose to the bladder wall (Einstein et al., 2007).

3331 (150) The choice of protocols is particularly critical. As illustrated in Table 2 and
3332 Figure 1, a variety of standard protocols are available for the performance of myocardial
3333 perfusion imaging. Their effective doses can range from 2 mSv to nearly 30 mSv. The
3334 lowest dose myocardial perfusion imaging protocols use N-13 ammonia. N-13 ammonia
3335 is a PET tracer that requires an on-site cyclotron due to its 10-minute half-life. This
3336 limits its availability.

3337 (151) SPECT protocols may require one or two injections of a radiopharmaceutical.
3338 The radiopharmaceutical may be Tl-201, a Tc-99m-based agent (sestamibi or
3339 tetrofosmin), or both. The effective dose depends on the radiopharmaceutical(s) and

3340 injected activities selected. In general, Tc-99m is preferable to Tl-201 on dosimetric
3341 grounds. Effective doses are typically considerably higher for protocols using Tl-201,
3342 and lowest for stress-only Tc-99m protocols. A protocol employing Tl-201 may be
3343 optimal for some patients, e.g. those with a history of Tc-99m images obscured by
3344 increased sub-diaphragmatic tracer uptake, if an alternative imaging modality is not used.
3345 For patients with a low- or low-intermediate pre-test probability of a perfusion defect, in
3346 whom it is expected that stress imaging will be normal, a stress-first/stress-only protocol
3347 is recommended, since rest imaging can be omitted if stress images are normal (Hesse et
3348 al., 2005; Mahmarian, 2010). This approach may be especially useful in conjunction with
3349 attenuation correction, which decreases the percentage of studies with perfusion defects
3350 due to artefact (Gibson et al., 2002).

3351 (152) The Commission recommends formal training in radiological protection, and in
3352 particular in the application of methods to minimize patient dose in accordance with
3353 ALARA principles, for all physicians involved in nuclear cardiology studies, regardless
3354 of their medical specialty. The recommended training is described in ICRP Publication
3355 113 (ICRP, 2009). Additional recommendations are available from the IAEA (IAEA,
3356 2001).

3357

3358 **7.7.3 Diagnostic Reference Levels in Nuclear Cardiology**

3359

3360 (153) Diagnostic reference levels are used in medical imaging to indicate whether, in
3361 routine conditions, the levels of patient dose from, or administered activity for, a
3362 specified imaging procedure are unusually high or low for that procedure (ICRP, 2007a).
3363 They are discussed further in Chapter 10. If so, a local review should be initiated to
3364 determine whether protection has been adequately optimised or whether corrective action
3365 is required.

3366 (154) Professional medical bodies (in conjunction with national health and
3367 radiological protection authorities) are encouraged to set diagnostic reference levels that
3368 best meet their specific needs and that are consistent for the regional, national, or local
3369 area to which they apply (ICRP, 2007b). In nuclear medicine, reference levels usually
3370 have been derived from pragmatic values of administered activity based on accepted
3371 custom and practice (ICRP, 2007b). Sources of diagnostic reference levels for nuclear
3372 cardiology include ASNC, ECNC, and national guidelines, which provide a range of
3373 administered activities for each protocol. The activity administered to a given patient can
3374 be adjusted within these ranges to reflect patient habitus. For example, while up to 1332
3375 MBq of technetium-99m is recommended per injection in a two-day protocol, this upper
3376 limit should be restricted to larger patients.

3377

3378

3379 **7.8 Advice to patients**

3380

3381 (155) In recent years, the threat of nuclear terrorism has led to the widespread use of
3382 radiation detectors for security screening at airports and other public facilities. Patients
3383 who have received radiopharmaceuticals for nuclear cardiology studies may retain
sufficient activity to trigger these detectors (Dauer, 2007b). In particular, patients who

3384 have received Tl-201 may trigger these detectors for up to 51 days following the
3385 procedure (Dauer, 2007a). Patients should be advised of this possibility and should be
3386 given information cards that indicate the potential time for triggering security radiation
3387 detectors after diagnostic cardiac procedures involving the use of Tl-201 or other
3388 radiopharmaceuticals (Dauer, 2007a)

3389

3390

7.9 Current research areas

3391

3392 (156) Recent technological developments in nuclear cardiology, such as more
3393 sophisticated noise-reducing image reconstruction algorithms and new camera designs
3394 that employ arrays of solid-state detectors, offer the possibility to improve camera
3395 efficiency. Research efforts using these technologies have largely focused on decreasing
3396 acquisition time and improving image quality. These technologies also offer the potential
3397 to markedly decrease administered activity and thereby patient dose, while maintaining
3398 comparable diagnostic performance in comparison to conventional scanners. Further
3399 investigation and clinical validation is required (Patton et al., 2007).

3400

3401

7.10 References

3402

3403 ACR, 2010. American College of Radiology ACR Appropriateness Criteria®. Clinical
3404 Condition: Chronic Chest Pain — High Probability of Coronary Artery Disease.
3405 Available at:

3406 http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria.aspx

3407 Accessed January 2, 2011.

3408 Dauer LT, Williamson MJ, St. Germain J, Strauss HW, 2007a. Tl-201 stress tests and
3409 homeland security. *J Nucl Cardiol* 14(4):582-588.

3410 Dauer LT, Williamson MJ, St. Germain J, Strauss HW, 2007b. Nuclear granny—reply.
3411 *J Nucl Cardiol* 14(6):904-905.

3412 Davis W. Mapping improvements in molecular imaging. *Medical Imaging*. 2006;May
3413 2006. Available at: [http://www.imagingeconomics.com/issues/articles/MI_2006-](http://www.imagingeconomics.com/issues/articles/MI_2006-05_01.asp)
3414 [05_01.asp](http://www.imagingeconomics.com/issues/articles/MI_2006-05_01.asp) Accessed December 31, 2010.

3415 DePuey, E.G., 2006. Imaging guidelines for nuclear cardiology procedures. 13, e21.

3416 Earls, J.P., Berman, E.L., Urban, B.A., Curry, C.A., Lane, J.L., Jennings, R.S.,
3417 McCulloch, C.C., Hsieh, J., Londt, J.H., 2008. Prospectively gated transverse
3418 coronary CT angiography versus retrospectively gated helical technique: improved
3419 image quality and reduced radiation dose. *Radiology* 246, 742-753.

3420 Earls, J.P., Schrack, E.C., 2008. Prospectively gated low-dose CCTA: 24 months
3421 experience in more than 2,000 clinical cases. *Int J Cardiovasc Imaging*.

3422 Einstein, A.J., Moser, K.W., Thompson, R.C., Cerqueira, M.D., Henzlova, M.J., 2007.
3423 Radiation dose to patients from cardiac diagnostic imaging. *Circulation* 116, 1290-
3424 1305.

3425 Gerber, T.C., Carr, J.J., Arai, A.E., Dixon, R.L., Ferrari, V.A., Gomes, A.S., Heller,
3426 G.V., McCollough, C.H., McNitt-Gray, M.F., Mettler, F.A., Mieres, J.H., Morin,
3427 R.L., Yester, M.V., 2009. Ionizing Radiation in Cardiac Imaging. *A Science*

- 3428 Advisory from the American Heart Association Committee on Cardiac Imaging of
3429 the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and
3430 Intervention of the Council on Cardiovascular Radiology and Intervention.
3431 Circulation 119, 1056-1065.
- 3432 Gibbons, R.J., Miller, T.D., Hodge, D., Urban, L., Araoz, P.A., Pellikka, P., McCully,
3433 R.B., 2008. Application of appropriateness criteria to stress single-photon emission
3434 computed tomography sestamibi studies and stress echocardiograms in an academic
3435 medical center. J Am Coll Cardiol 51, 1283-1289.
- 3436 Gibson, P.B., Demus, D., Noto, R., Hudson, W., Johnson, L.L., 2002. Low event rate for
3437 stress-only perfusion imaging in patients evaluated for chest pain. J Am Coll Cardiol
3438 39, 999-1004.
- 3439 Gutstein, A., Wolak, A., Lee, C., Dey, D., Ohba, M., Suzuki, Y., Cheng, V., Gransar, H.,
3440 Suzuki, S., Friedman, J., Thomson, L.E., Hayes, S., Pimentel, R., Paz, W., Slomka,
3441 P., Berman, D.S., 2008. Predicting success of prospective and retrospective gating
3442 with dual-source coronary computed tomography angiography: development of
3443 selection criteria and initial experience. Journal of Cardiovascular Computed
3444 Tomography 2, 81-90.
- 3445 Henzlova, M.J., Cerqueira, M.D., Hansen, C.L., Taillefer, R., Yao, S.-S., 2009. ASNC
3446 imaging guidelines for nuclear cardiology procedures. Stress protocols and tracers.
3447 Available at:
3448 <http://www.asnc.org/imageuploads/ImagingGuidelinesStressProtocols021109.pdf>
3449 Accessed January 2, 2011,
- 3450 Hesse, B., Tagil, K., Cuocolo, A., Anagnostopoulos, C., Bardies, M., Bax, J., Bengel, F.,
3451 Busemann Sokole, E., Davies, G., Dondi, M., Edenbrandt, L., Franken, P., Kjaer, A.,
3452 Knuuti, J., Lassmann, M., Ljungberg, M., Marcassa, C., Marie, P.Y., McKiddie, F.,
3453 O'Connor, M., Prvulovich, E., Underwood, R., van Eck-Smit, B., 2005. EANM/ESC
3454 procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J
3455 Nucl Med Mol Imaging 32, 855-897.
- 3456 Hunter, C., Ziadi, M., Etele, J., Hill, J., Beanlands, R., deKemp, R., 2010. New effective
3457 dose estimates for Rubidium-82 based on dynamic PET/CT imaging in humans. J
3458 Nucl Med. 2010; 51(Suppl 2):1429. Available at:
3459 http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/51/2_MeetingAbstracts/1429
3460 Accessed January 2, 2011.
- 3461 Husmann, L., Valenta, I., Gaemperli, O., Adda, O., Treyer, V., Wyss, C.A., Veit-
3462 Haibach, P., Tatsugami, F., von Schulthess, G.K., Kaufmann, P.A., 2008. Feasibility
3463 of low-dose coronary CT angiography: first experience with prospective ECG-
3464 gating. Eur Heart J 29, 191-197.
- 3465 IAEA, 2001. Training in radiation protection and the safe use of radiation sources.
3466 Safety Report Series No. 20. Vienna: International Atomic Energy Agency, 2001.
- 3467 ICRP, 1977. Recommendations of the International Commission on Radiological
3468 Protection. ICRP publication 26. Ann ICRP 1(3), 1-53.
- 3469 ICRP, 1979. ICRP publication 30: limits for intakes of radionuclides by workers. Ann
3470 ICRP 2, 1-116.



- 3471 ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. A report of a Task
3472 Group of Committee 2 of the International Commission on Radiological Protection.
3473 ICRP Publication 53. Ann.ICRP 18, 1-29.
- 3474 ICRP, 1998. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP
3475 publication 53). ICRP Publication 80. Ann.ICRP 28, 1-123.
- 3476 ICRP, 2001. Radiation dose to patients from radiopharmaceuticals. A report of a Task
3477 Group of Committees 2 and 3 of the International Commission on Radiological
3478 Protection. Addendum 5 to ICRP Publication 53.
- 3479 ICRP, 2007a. The 2007 recommendations of the International Commission on
3480 Radiological Protection. ICRP Publication 103. Ann.ICRP 37, 1-332.
- 3481 ICRP, 2007b. Radiological Protection in Medicine. ICRP Publication 105. Ann.ICRP
3482 37(6), 1-64.
- 3483 ICRP, 2008. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to
3484 ICRP Publication 53. ICRP Publication 106. Approved by the Commission in
3485 October 2007. Ann ICRP 38, 1-197.
- 3486 ICRP, 2009. Radiological protection education and training for healthcare staff and
3487 students (diagnostic imaging and interventional procedures). ICRP Publication 113.
3488 Ann ICRP 39 (5).
- 3489 Loevinger, R., Budinger, T., Watson, E., 1988. MIRD primer for absorbed dose
3490 calculations. Society of Nuclear Medicine, New York.
- 3491 Mahmarian, J.J., 2010. Stress only myocardial perfusion imaging: Is it time for a
3492 change? J Nucl Cardiol 17, 529-535.
- 3493 National Council on Radiation Protection and Measurements. Ionizing radiation
3494 exposure of the population of the United States. NCRP Report No. 160. Bethesda,
3495 MD: National Council on Radiation Protection and Measurements; 2009.
- 3496 Patton, J.A., Slomka, P.J., Germano, G., Berman, D.S., 2007. Recent technologic
3497 advances in nuclear cardiology. J Nucl Cardiol 14, 501-513.
- 3498 Roedler, H.D., 1981. Accuracy of internal dose calculations with special consideration of
3499 radiopharmaceutical biokinetics, Third International Radiopharmaceutical Dosimetry
3500 Symposium, HHS Publication FDA 81-8166. Department of Health and Human
3501 Welfare, Bureau of Radiological Health, Rockville, MD.
- 3502 Rybicki, F.J., Otero, H.J., Steigner, M.L., Vorobiof, G., Nallamshetty, L., Mitsouras, D.,
3503 Ersoy, H., Mather, R.T., Judy, P.F., Cai, T., Coyner, K., Schultz, K., Whitmore,
3504 A.G., Di Carli, M.F., 2008. Initial evaluation of coronary images from 320-detector
3505 row computed tomography. Int J Cardiovasc Imaging 24, 535-546.
- 3506 Senthamizhchelvan, S., Bravo, P.E., Esaias, C., Lodge, M.A., Merrill, J., Hobbs, R.F.,
3507 Sgouros, G., Bengel, F.M., 2010. Human biodistribution and radiation dosimetry of
3508 ⁸²Rb. J. Nucl. Med. 51, 1592-1599.
- 3509 Stabin, M., 2006. Nuclear medicine dosimetry. Phys Med Biol 51, R187-202.
- 3510 Stabin, M., Siegel, J., Hunt, J., Sparks, R., Lipsztein, J., Eckerman, K., 2001. RADAR:
3511 the radiation dose assessment resource—an online source of dose information for
3512 nuclear medicine and occupational radiation safety [abstract]. J Nucl Med 42(suppl),
3513 243P.

- 3514 Stabin, M.G., 2008a. Radiopharmaceuticals for nuclear cardiology: radiation dosimetry,
3515 uncertainties, and risk. J Nucl Med 49, 1555-1563.
- 3516 Stabin, M.G., 2008b. Uncertainties in internal dose calculations for
3517 radiopharmaceuticals. J Nucl Med 49, 853-860.
- 3518 Stabin, M.G., 2010. Proposed revision to the radiation dosimetry of ⁸²Rb. Health Phys.
3519 99, 811-813.
- 3520 UNSCEAR. Sources and effects of ionizing radiation: volume I, sources: annex D,
3521 medical radiation exposure. Report to the General Assembly of the United Nations;
3522 2000; New York, NY Available at:
3523 http://www.unscear.org/unscear/en/publications/2000_1.html Accessed December
3524 31, 2010.
- 3525
- 3526

8. RADIOLOGICAL PROTECTION FOR CARDIAC CT

Main Points

- **Appropriate use criteria and guidelines for justification have been developed through consensus efforts of professional societies.**
- **Justification needs to be performed on an individualized, patient-by-patient basis, weighing the benefits and risks of each imaging test under consideration as well as of doing no test. Assessment of radiation risk is one part of this process.**
- **Dose from cardiac CT is strongly dependent on scanner mode, tube current, and tube voltage.**
- **For patients with a heart rate less than 65-70 bpm and a regular rhythm, diagnostic image quality can generally be maintained while using dose-reduction methods such as ECG-controlled tube current modulation and axial imaging. The maximum tube current should be appropriate for the patient's habitus.**
- **Further research is needed to develop and validate methods, such as newer scan modes and low-voltage scanning, to minimize radiation dose to patients and practitioners.**

8.1 Introduction

(157) The possibility of CT of the coronary arteries was suggested by Sir Godfrey Hounsfield, inventor of the CT scanner, in his 1979 Nobel Lecture when he stated “A further promising field may be the detection of the coronary arteries. It may be possible to detect these under special conditions of scanning.” (Hounsfield, 1979). Unlike nuclear cardiology technology, which has remained largely static, cardiac CT technology has evolved rapidly in recent years. These advancements have enabled a variety of types of cardiac CT studies to be performed. Today, cardiac CT encompasses several distinct procedures, including coronary artery calcium (CAC) scoring, CT coronary angiography (CTCA), pulmonary vein CT angiography, and CT attenuation correction of nuclear cardiology image data. Recent technological advances have been associated with an increase in the number of procedures performed, although reliable statistics on worldwide numbers are not available at present.

8.2 Types of CT scanners

(158) Each new generation of CT scanners has varied from its predecessors in terms of technical parameters (e.g., temporal resolution, spatial resolution, craniocaudal coverage) and also in patient radiation dose. The first scanner capable of performing cardiac studies, the dynamic spatial reconstructor, used 14 x-ray sources that rotated around the patient, resulting in patient doses approaching 100 Gy (Block et al., 1984). The electron beam CT scanner, also called “ultrafast” CT due to its excellent temporal resolution, superseded this machine. Patient dose from electron beam CT was markedly

3571 lower, with typical effective doses of approximately 1 mSv for both CAC scoring and
3572 CTCA (Morin et al., 2003). Electron beam CT scanners had low spatial resolution, and
3573 have been supplanted by multiple-detector-row CT (MDCT) scanners. The improved
3574 spatial resolution of MDCT scanners enables a more accurate assessment of coronary
3575 stenosis and plaque visualization. Initial efforts at CTCA were performed with 4-slice
3576 scanners. The technology gained popularity with subsequent generations of faster 16-
3577 and 64-slice scanners and became even more widespread with the advent of 128- and
3578 256-slice scanners. MDCT is the focus of ICRP Publication 102 (ICRP, 2007a).

3579

3580

3581

8.3 Dosimetric Quantities

3582 (159) Currently, three types of dosimetric quantities are utilized for CT. These are: i)
3583 weighted CT dose index ($CTDI_w$) and volume CT dose index ($CTDI_{vol}$), ii) dose-length
3584 product (DLP), and iii) effective dose. $CTDI_w$ and $CTDI_{vol}$ are estimates of the average
3585 dose within the central portion of the scan volume. DLP integrates the $CTDI_{vol}$ over the
3586 length of the anatomy scanned, and reflects the increased patient dose when a longer
3587 portion of the patient is scanned (e.g., chest vs. heart). Effective dose is a calculated
3588 quantity used to reflect the risk of a radiation exposure to a portion of the body in terms
3589 of a uniform whole-body exposure. Effective dose was developed as a radiological
3590 protection quantity, and is used to compare radiation risk among different diagnostic
3591 examinations (ICRP, 2007b; McCollough, 2008)

3592 (160) Current MDCT scanners typically report $CTDI_{vol}$ and DLP for each study.
3593 Effective dose can be estimated by multiplying DLP by a body-region-specific
3594 conversion factor (k factor). For cardiac studies, the most commonly used conversion
3595 factor is of $0.017 \text{ mSv}\cdot\text{mGy}^{-1}\cdot\text{cm}^{-1}$, the European Guidelines on Quality Criteria for
3596 Computed Tomography chest factor (i.e., effective dose is estimated as $0.017\cdot\text{DLP}$)
3597 (Bongartz et al., 2000). This conversion factor does not reflect the more recent ICRP
3598 Publication 103 tissue weighting factors, is derived from data from single-slice scanners,
3599 and was developed for chest scans rather than cardiac scans (Christner et al., 2010;
3600 Einstein et al., 2010). This method provides a useful approximation of effective dose
3601 from cardiac CT based on easily available data, but it typically underestimates effective
3602 dose. Alternative, more complex approaches for determining effective dose are Monte
3603 Carlo simulations and determination of organ doses in physical anthropomorphic
3604 phantoms. These are discussed in more detail in ICRP Publication 102 (ICRP, 2007a).

3605

3606

3607

8.4 Factors affecting patient dose

3608 (161) Factors affecting patient dose in cardiac CT include both those intrinsic to the
3609 scanner, such as scanner generation, model and manufacturer, and parameters selected by
3610 the operator. Hausleiter et al, in an observational study of 50 sites performing CTCA,
3611 observed a marked difference between scanner manufacturers in effective dose
3612 (Hausleiter et al., 2009). Reported doses from CTCA vary depending on which
3613 generation of MDCT scanners was used (Einstein et al., 2007). The most recent
3614 generation of scanners incorporates technology with the potential to decrease patient

3615 doses considerably. Operator-selectable parameters that affect dose include x-ray tube
3616 current (mA) or tube current-time product (mAs), tube peak voltage (kVp), pitch (IEC,
3617 2009), scan length (craniocaudal coverage), scan mode, and in some cases the number of
3618 x-ray tubes employed.

3619

3620 **8.4.1 Tube Current**

3621

3622 (162) The choice of an appropriate mA and kVp for a given study reflects a trade-off
3623 between image noise and radiation dose. Increasing the tube current results in both a
3624 decrease in image noise and an increase in radiation dose. Dose increases in a roughly
3625 linear fashion with increased tube current (Gerber et al., 2005). Baseline tube current
3626 should be adjusted to reflect patient habitus, as larger patients will require a higher tube
3627 current to obtain images with standard levels of noise. For the same tube current,
3628 different scanners will produce images with different amounts of noise, so protocols must
3629 be tailored to each scanner. A sensible balance is required—overly aggressive reductions
3630 in radiation dose may render the scan non-diagnostic. New image reconstruction
3631 algorithms incorporating an iterative noise-reduction methodology may maintain image
3632 quality while decreasing tube current.

3633

3634 **8.4.2 Tube Voltage**

3635

3636 (163) For cardiac MDCT applications, a tube voltage of 120 kVp is common. For
3637 smaller patients, a lower voltage, e.g. 100 kVp, is used in some centres. Dose varies
3638 approximately with voltage to the 2.5 power, so a 37% dose reduction would be expected
3639 with this decrease in tube voltage. The evidence supporting low-voltage CTCA (Abada
3640 et al., 2006; Bischoff et al., 2009; Hausleiter et al., 2010) is not as robust as that
3641 supporting 120 kVp CTCA (Abdulla et al., 2007). However, many sites have obtained
3642 excellent image quality using reduced voltage (**Figure 8.1**).

3643



3644
3645 Figure 8.1. CT coronary angiogram, obtained using a tube voltage of 100 kVp and
3646 single-heartbeat volume scanning. Courtesy Andrew J. Einstein, MD, PhD, Columbia
3647 University Medical Centre, New York, NY, USA
3648

3649 8.4.3 Scan Length 3650

3651 (164) Patient dose is linearly related to the length of the portion of the body
3652 irradiated, which is basically equal to the scan length. Typically CTCA is performed
3653 with scanning from the carina to the base of the heart, with a small margin of error on
3654 each side to allow for patient motion. A scan length of 11-15 cm is typical. Excessively
3655 large margins result in increased patient dose without additional diagnostic information.
3656 Greater craniocaudal coverage is necessary when the aorta must be included and in cases
3657 where the patient has undergone coronary artery bypass grafting, in which case the upper
3658 limit of the scan is above the aortic arch. For pulmonary vein CT angiography, the scan
3659 length can be reduced. In this case the structures of interest are the left atrium,
3660 pulmonary veins, and their anatomic relationship to the oesophagus and aorta; these can
3661 be visualized without scanning caudally to the cardiac apex.
3662

3663 8.4.4 Scan Mode 3664

3665 (165) Scan modes include conventional helical (spiral) imaging with constant tube
3666 current, conventional helical imaging with ECG-gated tube current modulation
3667 (EGTCM), high-pitch helical imaging and axial imaging, including both step-and-shoot
3668 and volume imaging (**Figure 8.2**). CTCA using MDCT was first performed using helical
3669 mode and a constant tube current, with a typical pitch of 0.2 for 64-slice scanners
3670 (**Figure 8.2 (a)**). All current cardiac scanners offer EGTCM, which keeps tube current
3671 at its maximum during diastasis, when coronary movement is generally minimized, and
3672 decreases tube current during the remainder of the cardiac cycle (**Figure 8.2 (b)**). This
3673 limits the number of phases of the cardiac cycle in which image reconstructions can be
3674 performed without excessive noise, but for patients with low heart rates (<65 bpm) and
3675 regular heart rhythms, this generally does not pose a problem. Generally, patients should
3676 receive beta blockers or calcium channel blockers to lower heart rate and improve the
3677 efficacy of EGTCM. For patients who do not meet these conditions, reconstructions at
3678 end-systole are often quite useful for visualizing the proximal- and mid-right coronary
3679 artery (Sanz et al., 2005). If EGTCM is applied in these patients, it may be advisable to
3680 widen the period of time during which tube current is maintained at its maximal value.
3681 EGTCM typically decreases effective dose by about one-third. For single-source
3682 scanners, this decrease in dose is more pronounced with lower heart rates (Jakobs et al.,
3683 2002).

3684 (166) More recently, axial CTCA protocols have been incorporated into some MDCT
3685 scanners. This approach to scanning acquires image data only during a pre-specified
3686 phase of the cardiac cycle, and the x-ray beam is off during the remainder of the cardiac
3687 cycle. In step-and-shoot (sequential) scanning, x-rays are delivered in one cardiac cycle,
3688 the patient couch is advanced with the beam off during the next cardiac cycle, and the
3689 process is repeated until the entire craniocaudal volume of interest has been scanned. For
3690 64-detector-row scanners, this generally requires 3 or 4 iterations, i.e. 5 or 7 heartbeats (5
3691 heartbeats illustrated in **Figure 8.2 (c)**). For step-and-shoot imaging to generate
3692 interpretable cardiac images, it is generally thought that heart rate should be less than 70
3693 beats per minute and heart rhythm should be regular, although this has not been well
3694 studied. An advantage of step-and-shoot imaging is reduced dose due to the elimination
3695 of radiation exposure during much of the cardiac cycle and the absence of the overlap of
3696 irradiated areas characteristic of helical CTCA. Disadvantages include the inability to
3697 retrospectively perform image reconstruction at additional phases of the cardiac cycle and
3698 the attendant inability to assess cardiac function and wall motion.

3699 (167) One modification of axial imaging is to increase the length of time that the x-
3700 ray tube is on, thus increasing dose but enabling reconstructions within a range of phases
3701 of the cardiac cycle (**Figure 8.2 (d)**). Thus, rather than obtaining only images in a single
3702 portion of diastasis, a variety of strategies can be employed, such as obtaining images in a
3703 range of diastolic phases, or covering from end-systole through diastasis. Dose is
3704 proportional to exposure time. The optimal strategy for implementation of axial imaging
3705 has not yet been determined.


3706 (168) Two recently-introduced scan modes offer the potential for significant dose
3707 reductions. Both cover the entire heart with x-rays delivered for only a fraction of a
3708 single heartbeat (**Figure 8.2 (e)**). The extreme case of axial imaging is volume scanning,

3709 which uses a cone-beam x-ray source and a large detector array that covers the entire
 3710 heart without requiring table motion (Einstein et al., 2010). The extreme case of helical
 3711 imaging is high-pitch helical scanning, in which two x-ray sources mounted at 90° from
 3712 each other are used with a rapid table speed to enable the entire heart to be covered in a
 3713 fraction of a beat.(Achenbach et al., 2010) Each of these modes currently requires a low
 3714 heart rate to obtain excellent image quality at minimal radiation dose.

3715 (169) The clinical literature evaluating axial CTCA and the single-heartbeat modes is
 3716 limited (Earls et al., 2008; Gutstein et al., 2008; Husmann et al., 2008; Rybicki et al.,
 3717 2008). There are no multicentre studies evaluating diagnostic accuracy efficacy in
 3718 comparison to gold-standard diagnosis by invasive angiography. These scan modes
 3719 require more rigorous validation.

3720

3721 Figure 8.2



3722

3723 Scan modes used in cardiac CT. Black line denotes electrocardiographic signal, shaded
 3724 region represents tube current. (a) helical scan, (b) helical scan with

3725 electrocardiographically-gated tube current modulation, (c) axial step-and-shoot scan, (d)
3726 axial step-and-shoot scan, with extending exposure time (“padding”) to permit
3727 reconstruction of multiple cardiac phases, (e) axial single heartbeat scan (volume and
3728 high-pitch helical scans, illustrated here with no padding). Not all modes are available on
3729 all MDCT scanners.

3730

3731

8.5 Current Dosimetry Estimates

3732

3733 (170) Dosimetry from CTCA depends on many factors, and thus varies markedly
3734 between protocols. Einstein et al reviewed the published literature on effective dose from
3735 cardiac CT in 2007(Einstein et al., 2007). Effective doses from calcium scoring ranged
3736 from 1.0 to 6.2 mSv using helical technique and from 0.5 to 1.8 mSv using axial
3737 technique. For helical 64-slice CTCA, effective dose ranged from 8 to 21.4 mSv without
3738 and from 6.4 to 14 mSv with EGTCM. In a 15 centre study performed in the U.S.,
3739 median effective dose, estimated using a k factor of $0.014 \text{ mSv} \cdot \text{mGy}^{-1} \cdot \text{cm}^{-1}$, was 21 mSv
3740 prior to a best-practice dose reduction educational intervention (Raff et al., 2009). In a
3741 50-centre worldwide study, median effective dose was 12 mSv (Hausleiter et al., 2009).
3742 In Hausleiter et al’s study, there was a 6-fold range in median doses among sites
3743 performing CTCA. EGTCM was associated with a reduction in dose-length product and
3744 effective dose of 25% (95% confidence interval 23-28%), use of an x-ray tube voltage of
3745 100 kV was associated with a reduction of 46% (95% confidence interval 42-51%), and
3746 use of axial step-and-shoot scanning was associated with a reduction of 78% (95%
3747 confidence interval 77-79%) (Hausleiter et al., 2009). Other single-centre studies have
3748 evaluated axial step-and-shoot scanning, and typically report effective doses in the 2-4
3749 mSv range (Earls and Schrack, 2008). In comparison to conventional helical scanning,
3750 volume scanning has been associated with a dose reduction of 84%, (Einstein et al.,
3751 2010), and high-pitch helical scanning has been associated with effective dose of <1 mSv
3752 for patients with a slow (≤ 60 bpm) heart rate who weigh ≤ 100 kg (Achenbach et al.,
3753 2010), using a k factor of $0.014 \text{ mSv} \cdot \text{mGy}^{-1} \cdot \text{cm}^{-1}$.

3754 (171) The wide range of values for effective dose seen in clinical practice makes it
3755 impossible to provide “typical” values for cardiac CT. Effective dose is dependent on
3756 both the CT scanner and the protocol used. Estimates of approximate average values are
3757 presented in Table 8.1, but it must be appreciated that these values should not be
3758 considered as typical values, target values, or representative of clinical practice at any
3759 one institution.

3760

3761

3762

3763

3764

3765

3766

3767

3768

3769 Table 8.1 Estimated Approximate Average Effective Dose for Various Types of Cardiac
3770 CT Examinations

3771		
3772	Examination	Effective Dose (mSv)*
3773		
3774	CT coronary angiography (CTCA) (helical)	19
3775		
3776	CT coronary angiography (CTCA) (tube current modulation)	13
3777		
3778	CT coronary angiography (CTCA) (prospectively gated)	4
3779		
3780	Coronary artery calcium scoring (CAC)	2

3781
3782 *The data in the Table are reproduced from Einstein, 2009. For other estimates of
3783 effective dose, see, e.g., Einstein et al, 2007; Hausleiter et al, 2009; Kim et al, 2009;
3784 Smith-Bindman et al, 2009; Earls and Schrack, 2009; Raff et al, 2009.

3785

3786

3787

3788 (172) Effective doses reported in many of the studies assessing CT protocols are
3789 determined on a patient-by-patient basis. The existence of conversion factors, such as
3790 those in the European Guidelines on Quality Criteria for CT (Bongartz et al., 2000;
3791 Bongartz et al.), make it easy for an investigator to estimate an “effective dose” for a
3792 single study from the DLP reported on the scanner, but this is not the intended use of
3793 effective dose (Einstein et al., 2008; Gerber et al., 2009; ICRP 2007b). Citation of these
3794 studies is not an endorsement of this approach by the Commission. When the
3795 Commission introduced effective dose in 1990 (ICRP, 1991), it was defined for
3796 populations, not for specific individuals. This has not changed.

3797

3798

3798 **8.6 Radiological Protection of Patients in Cardiac CT**

3799

3800 (173) The general principles of radiological protection (chapter 4), i.e., justification
3801 and optimisation, can be applied to the protection of patients in cardiac CT. Dose
3802 limitation is not appropriate, but diagnostic reference levels should be used to help
3803 manage the radiation dose so that the dose is commensurate with the clinical purpose
3804 (ICRP, 2007b, ICRP, 2007c).

3805

3806 **8.6.1 Justification**

3807

3808 (174) The Commission recommends the development and application of appropriate
3809 use criteria for cardiac CT. Appropriate indications for cardiac CT are available from
3810 professional organizations and should be used (Taylor et al, 2010; Schroeder et al., 2008).

3811

3812 (175) In reports from one institution, 46% of CTCA studies but only 11% of stress
3813 SPECT studies were unclassifiable in terms of appropriateness, and of the remaining
3814 classifiable studies, 51% of CTCA studies and 72% of stress SPECT studies were
3815 appropriate.(Gibbons et al., 2008; Miller et al.) It is unclear from these data whether the
3816 difference between modalities primarily reflects a limitation with the first version of the
3817 U.S. CTCA appropriateness criteria, which left many studies unclassifiable, or whether
3818 CTCA studies are less likely to be performed for appropriate indications than SPECT
3819 studies. Further investigation is required, and programs to ensure maximal adherence to
3820 appropriate use criteria are also encouraged.

3821

3822 **8.6.2 Optimization**

3823

3824 (176) As discussed in section 8.3, the operator controls numerous scan parameters
3825 that affect patient dose. The operator should be provided with appropriate guidelines for
3826 mAs and kVp selection as a function of patient body habitus. Special consideration
3827 should be given to reducing mAs and/or kVp when evaluation of coronary plaques and
3828 stenoses is not the primary aim, e.g. for evaluation of possible anomalous coronaries, or
3829 prior to repeat cardiac surgery to assess the course of bypass grafts in relation to the
3830 sternum. Scan length should be limited to that needed to reliably image the volume of
3831 interest.

3832 (177) The operator should be provided with appropriate guidelines for selection of
3833 the scan mode. Scan modes that reduce dose should be employed as appropriate (Gerber
3834 et al., 2009). Scans performed for calcium scoring should be performed using axial
3835 imaging, and in combined studies should be reviewed prior to performance of CTCA.
3836 The presence of widespread, heavy coronary calcification may suggest that CTCA should
3837 not be performed, due to the high likelihood of unevaluable coronary segments. For all
3838 patients, with the possible exception of patients scanned on a multiple-source scanner
3839 with variable pitch, rate-control agents should be given as needed with the goal of
3840 decreasing heart rate to approximately 60 beats per minute.

3841 (178) The Commission recommends formal training in radiological protection, and in
3842 particular in the application of the principles of justification and optimization, for all
3843 physicians who refer patients for, or perform, cardiac CT studies (ICRP 113, 2011). This
3844 includes cardiologists, radiologists, nuclear medicine specialists, and internists.

3845 (179) Quality improvement programs have been shown to decrease radiation dose
3846 substantially for CTCA (Raff et al., 2009), and thus their implementation is encouraged.

3847

3848 **8.6.3 Diagnostic Reference Levels**

3849

3850 (180) Diagnostic reference levels are used in medical imaging to indicate whether, in
3851 routine conditions, the levels of patient dose from, or administered activity for, a
3852 specified imaging procedure are unusually high or low for that procedure (ICRP, 2007b).
3853 They are discussed further in Chapter 10. If so, a local review should be initiated to
3854 determine whether protection has been adequately optimised or whether corrective action
3855 is required.

3856 (181) Professional medical bodies (in conjunction with national health and
3857 radiological protection authorities) are encouraged to set diagnostic reference levels that
3858 best meet their specific needs and that are consistent for the regional, national, or local
3859 area to which they apply (ICRP, 2007c). At present, no diagnostic reference levels exist
3860 for cardiac CT.

3861

3862

8.7 References

3863

3864 Abada, H.T., Larchez, C., Daoud, B., Sigal-Cinqualbre, A., Paul, J.F., 2006. MDCT of
3865 the coronary arteries: feasibility of low-dose CT with ECG-pulsed tube current
3866 modulation to reduce radiation dose. *AJR Am J Roentgenol* 186, S387-390.

3867 Abdulla, J., Abildstrom, S.Z., Gotzsche, O., Christensen, E., Kober, L., Torp-Pedersen,
3868 C., 2007. 64-multislice detector computed tomography coronary angiography as
3869 potential alternative to conventional coronary angiography: a systematic review and
3870 meta-analysis. *Eur Heart J* 28, 3042-3050.

3871 Achenbach, S., Marwan, M., Ropers, D., Schepis, T., Pflederer, T., Anders, K., Kuettner,
3872 A., Daniel, W.G., Uder, M., Lell, M.M., 2010. Coronary computed tomography
3873 angiography with a consistent dose below 1 mSv using prospectively
3874 electrocardiogram-triggered high-pitch spiral acquisition. *Eur Heart J* 31, 340-346.

3875 Bischoff, B., Hein, F., Meyer, T., Hadamitzky, M., Martinoff, S., Schomig, A.,
3876 Hausleiter, J., 2009. Impact of a reduced tube voltage on CT angiography and
3877 radiation dose: results of the PROTECTION I study. *JACC Cardiovasc Imaging* 2,
3878 940-946.

3879 Block, M., Bove, A.A., Ritman, E.L., 1984. Coronary angiographic examination with the
3880 dynamic spatial reconstructor. *Circulation* 70, 209-216.

3881 Bongartz, G., Golding, S.J., Jurik, A.G., Leonardi, M., van Meerten, E.v.P., Geleijns, J.,
3882 Jessen, K.A., Panzer, W., Shrimpton, P.C., Tosi, G., 2000. European Guidelines on
3883 Quality Criteria for Computed Tomography. EUR 16262. The European
3884 Commission's Study Group on Development of Quality Criteria for Computed
3885 Tomography.

3886 Bongartz, G., Golding, S.J., Jurik, A.G., Leonardi, M., van Meerten, E.v.P., Rodríguez,
3887 R., Schneider, K., Calzado, A., Geleijns, J., Jessen, K.A., Panzer, W., Shrimpton,
3888 P.C., Tosi, G., 2004 CT Quality Criteria, European Commission.

3889 Christner, J.A., Kofler, J.M., McCollough, C.H., 2010. Estimating effective dose for CT
3890 using dose-length product compared with using organ doses: consequences of
3891 adopting International Commission on Radiological Protection publication 103 or
3892 dual-energy scanning. *AJR Am J Roentgenol* 194, 881-889.

3893 Earls, J.P., Schrack, E.C., 2009. Prospectively gated low-dose CCTA: 24 months
3894 experience in more than 2,000 clinical cases. *Int. J. Cardiovasc. Imaging* 25, 177-
3895 187.

3896 Einstein, A.J., Elliston, C.D., Arai, A.E., Chen, M.Y., Mather, R., Pearson, G.D.N.,
3897 DeLaPaz, R.L., Nickoloff, E., Dutta, A., Brenner, D.J., 2010. Radiation dose from
3898 single heartbeat coronary CT angiography performed using a 320 detector-row
3899 volume scanner. *Radiology* 254, 698-704.

- 3900 Einstein, A.J., 2009. Medical imaging: the radiation issue. *Nat. Rev. Cardiol.* 6, 436-438.
- 3901 Einstein, A.J., Moser, K.W., Thompson, R.C., Cerqueira, M.D., Henzlova, M.J., 2007.
- 3902 Radiation dose to patients from cardiac diagnostic imaging. *Circulation* 116, 1290-
- 3903 1305.
- 3904 Einstein, A.J., Sanz, J., Dellegrottaglie, S., Milite, M., Sirol, M., Henzlova, M.,
- 3905 Rajagopalan, S., 2008. Radiation dose and cancer risk estimates in 16-slice computed
- 3906 tomography coronary angiography. *J Nucl Cardiol* 15, 232-240.
- 3907 Gerber, T.C., Carr, J.J., Arai, A.E., Dixon, R.L., Ferrari, V.A., Gomes, A.S., Heller,
- 3908 G.V., McCollough, C.H., McNitt-Gray, M.F., Mettler, F.A., Mieres, J.H., Morin,
- 3909 R.L., Yester, M.V., 2009. Ionizing Radiation in Cardiac Imaging. A Science
- 3910 Advisory From the American Heart Association Committee on Cardiac Imaging of
- 3911 the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and
- 3912 Intervention of the Council on Cardiovascular Radiology and Intervention.
- 3913 *Circulation* 119, 1056-1065.
- 3914 Gerber, T.C., Stratmann, B.P., Kuzo, R.S., Kantor, B., Morin, R.L., 2005. Effect of
- 3915 acquisition technique on radiation dose and image quality in multidetector row
- 3916 computed tomography coronary angiography with submillimeter collimation.
- 3917 *Invest.Radiol.* 40, 556.
- 3918 Gibbons, R.J., Miller, T.D., Hodge, D., Urban, L., Araoz, P.A., Pellikka, P., McCully,
- 3919 R.B., 2008. Application of appropriateness criteria to stress single-photon emission
- 3920 computed tomography sestamibi studies and stress echocardiograms in an academic
- 3921 medical center. *J Am Coll Cardiol* 51, 1283-1289.
- 3922 Hausleiter, J., Meyer, T., Hadamitzky, M., Huber, E., Zankl, M., Martinoff, S., Kastrati,
- 3923 A., Schomig, A., 2006. Radiation dose estimates from cardiac multislice computed
- 3924 tomography in daily practice: impact of different scanning protocols on effective
- 3925 dose estimates. *Circulation* 113, 1305.
- 3926 Hausleiter, J., Meyer, T., Hermann, F., Hadamitzky, M., Krebs, M., Gerber, T.C.,
- 3927 McCollough, C., Martinoff, S., Kastrati, A., Schömig, A., Achenbach, S., 2009.
- 3928 Estimated radiation dose associated with cardiac CT angiography. *JAMA* 301, 500-
- 3929 507.
- 3930 Hausleiter, J., Martinoff, S., Hadamitzky, M., Martuscelli, E., Pschierer, I., Feuchtner,
- 3931 G.M., Catalan-Sanz, P., Czermak, B., Meyer, T.S., Hein, F., Bischoff, B., Kuse, M.,
- 3932 Schomig, A., Achenbach, S., 2010. Image quality and radiation exposure with a low
- 3933 tube voltage protocol for coronary CT angiography. Results of the PROTECTION II
- 3934 Trial. *JACC Cardiovasc Imaging* 3, 1113-1123.
- 3935 Hounsfield, G.N., 1979. Computed medical imaging. Nobel lecture, 8 December 1979.
- 3936 ICRP, 1991. 1990 Recommendations of the International Commission on Radiological
- 3937 Protection. ICRP Publication 60. *Ann. ICRP* 21, 1-201.
- 3938 ICRP, 2007a. Managing patient dose in multi-detector computed tomography (MDCT).
- 3939 ICRP Publication 102. *Ann. ICRP* 37(1), 1-79.
- 3940 ICRP, 2007b. The 2007 recommendations of the International Commission on
- 3941 Radiological Protection. ICRP Publication 103. *Ann. ICRP* 37, 1-332.
- 3942 ICRP, 2007c. Radiological Protection in Medicine. ICRP Publication 105. *Ann. ICRP*
- 3943 37(6), 1-64.

- 3944 IEC, 2009. Medical Electrical Equipment - Part 2-44: Particular Requirements for the
3945 Safety of X-ray Equipment for Computed Tomography. International Standard IEC
3946 60601-2-44. 3rd Edition. International Electrotechnical Commission, Geneva.
- 3947 Jakobs, T.F., Becker, C.R., Ohnesorge, B., Flohr, T., Suess, C., Schoepf, U.J., Reiser,
3948 M.F., 2002. Multislice helical CT of the heart with retrospective ECG gating:
3949 reduction of radiation exposure by ECG-controlled tube current modulation.
3950 Eur.Radiol. 12, 1081.
- 3951 Kim, K.P., Einstein, A.J., Berrington de Gonzalez, A., 2009. Coronary artery
3952 calcification screening: estimated radiation dose and cancer risk. Arch. Intern. Med.
3953 169, 1188-1194.
- 3954 McCollough, C.H., 2008. CT dose: how to measure, how to reduce. Health Physics 95,
3955 508-517.
- 3956 Miller, J.A., Raichlin, E., Williamson, E.E., McCully, R.B., Pellikka, P.A., Hodge, D.O.,
3957 Miller, T.D., Gibbons, R.J., Araoz, P.A., 2010. Evaluation of coronary CTA
3958 Appropriateness Criteria in an academic medical center. J Am Coll Radiol 7, 125-
3959 131.
- 3960 Morin, R.L., Gerber, T.C., McCollough, C.H., 2003. Radiation dose in computed
3961 tomography of the heart. Circulation 107, 917.
- 3962 Raff, G.L., Chinnaiyan, K.M., Share, D.A., Goraya, T.Y., Kazerooni, E.A., Moscucci,
3963 M., Gentry, R.E., Abidov, A., 2009. Radiation dose from cardiac computed
3964 tomography before and after implementation of radiation dose-reduction techniques.
3965 JAMA 301, 2340-2348.
- 3966 Sanz, J., Rius, T., Kuschnir, P., Fuster, V., Goldberg, J., Ye, X.Y., Wisdom, P., Poon,
3967 M., 2005. The importance of end-systole for optimal reconstruction protocol of
3968 coronary angiography with 16-slice multidetector computed tomography.
3969 Invest.Radiol. 40, 155.
- 3970 Schroeder, S., Achenbach, S., Bengel, F., Burgstahler, C., Cademartiri, F., de Feyter, P.,
3971 George, R., Kaufmann, P., Kopp, A.F., Knuuti, J., Ropers, D., Schuijff, J., Tops, L.F.,
3972 Bax, J.J., 2008. Cardiac computed tomography: indications, applications, limitations,
3973 and training requirements: report of a Writing Group deployed by the Working
3974 Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology
3975 and the European Council of Nuclear Cardiology. Eur Heart J 29, 531-556.
- 3976 Smith-Bindman, R., Lipson, J., Marcus, R., Kim, K.P., Mahesh, M., Gould, R.,
3977 Berrington de Gonzalez, A., Miglioretti, D.L., 2009. Radiation dose associated with
3978 common computed tomography examinations and the associated lifetime attributable
3979 risk of cancer. Arch. Intern. Med. 169, 2078-2086.
- 3980 Taylor, A.J., Cerqueira, M., Hodgson, J.M., Mark, D., Min, J., O'Gara, P., Rubin, G.D.,
3981 Kramer, C.M., Berman, D., Brown, A., Chaudhry, F.A., Cury, R.C., Desai, M.Y.,
3982 Einstein, A.J., Gomes, A.S., Harrington, R., Hoffmann, U., Khare, R., Lesser, J.,
3983 McGann, C., Rosenberg, A., Schwartz, R., Shelton, M., Smetana, G.W., Smith, S.C.,
3984 Jr., 2010. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010
3985 appropriate use criteria for cardiac computed tomography: a report of the American
3986 College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society
3987 of Cardiovascular Computed Tomography, the American College of Radiology, the



DRAFT REPORT FOR CONSULTATION

3988 American Heart Association, the American Society of Echocardiography, the
3989 American Society of Nuclear Cardiology, the North American Society for
3990 Cardiovascular Imaging, the Society for Cardiovascular Angiography and
3991 Interventions, and the Society for Cardiovascular Magnetic Resonance. J. Am. Coll.
3992 Cardiol. 56, 1864-1894.
3993
3994
3995
3996

9. RADIOLOGICAL PROTECTION TRAINING FOR INTERVENTIONAL FLUOROSCOPY

3997
3998
3999
4000
4001
4002
4003
4004
4005
4006
4007
4008
4009
4010
4011
4012
4013
4014
4015
4016
4017
4018
4019
4020
4021
4022

Main Points

- **Interventional cardiologists worldwide typically have little or no training in radiological protection (RP).**
- **Legislation in most countries requires that individuals who take responsibility for medical exposures must be properly trained in RP.**
- **Training activities in RP should be followed by an evaluation of the knowledge acquired from the training programme (a formal examination system).**
- **Physicians who have completed training should be able to demonstrate that they possess the knowledge specified by the curriculum by passing an appropriate certifying examination.**
- **In addition to the training recommended for other physicians who use X-rays, interventionalists, including interventional cardiologists, should receive a second, higher level of RP training.**
- **Nurses and other healthcare professionals who assist during fluoroscopic procedures should be familiar with radiation risks and radiological protection principles, in order to minimise their own exposure and that of others.**
- **Training programmes should include both initial training for all incoming staff and regular updating and retraining.**
- **Scientific congresses should include refresher courses on RP, attendance at which could be a requirement for continuing professional development**

4023
4024
4025
4026
4027
4028
4029
4030
4031
4032
4033
4034
4035
4036
4037
4038

9.1 Introduction

(182) Despite the extensive and routine use of x-rays in their clinical practice, interventional cardiologists (IC) worldwide typically have little or no training in radiological protection (RP). Traditionally, medical students do not receive training in RP during medical school. Medical professionals who subsequently specialise in radiological specialties, such as diagnostic radiology, nuclear medicine and radiotherapy, are taught radiological physics and RP as part of their specialty training. In many countries, there is no teaching of RP during training in other specialties, such as medicine and cardiology.

(183) In the past, training in radiological physics and RP was not necessary for non-radiologists, as x-rays and other radiation sources were employed only in radiology departments, by staff with reasonable training in RP. Although x-ray fluoroscopy has been in use for more than a century now, its early application involved visualization of body anatomy, movement of structures or passage of contrast media through the body. Radiologists normally performed these procedures. When fluoroscopically guided interventions were introduced, other specialists (cardiologists and an increasing number

4039 of clinicians in other medical specialties) began performing these procedures. Initially,
4040 they did so jointly with radiologists, in radiology departments. Over the years, x-ray
4041 equipment was installed in other clinical departments and used by non-radiologists
4042 without radiologist participation. These non-radiologists were not subject to the training
4043 requirements of radiological physics and RP that were mandatory for radiologists. It is
4044 now clear that this training is essential; hence the need for specific guidance for
4045 cardiology.

4046 (184) The Commission has addressed the specifics of training for interventionalists
4047 and nuclear medicine specialists, among others, in ICRP Publication 113 (ICRP 113,
4048 2009). Further information on training in nuclear medicine is presented in Section 7.7.2.

4049 **9.2 Requirements on Radiological protection**

4050
4051 (185) In its Publications 85 and 113, the Commission recommends a second level of
4052 RP training for interventional radiologists and cardiologists, in addition to the training
4053 recommended for other physicians who use X-rays (ICRP 85, 2000, ICRP 113, 2009).
4054 The Commission also recommends that nurses and other healthcare professionals who
4055 assist during fluoroscopic procedures should be familiar with radiation risks and
4056 precautions, in order to minimise their own exposure and that of others.

4057 (186) Training activities in RP should be followed by an evaluation of the knowledge
4058 acquired from the training programme. Education and training in RP should be
4059 complemented by formal examination systems to test competency before the person is
4060 awarded certification. If certification in RP is required for some medical specialties (e.g.
4061 interventional cardiology), certification should be obtained before the professional
4062 practices the specialty.. Training programmes should include both initial training for all
4063 incoming staff and regular updating and retraining. Scientific and professional societies
4064 should contribute to the development of the training syllabuses to ensure a consistent
4065 approach, and to promote and support the education and training. Scientific congresses
4066 should include refresher courses on RP, attendance at which could be a requirement for
4067 continuing professional development for professionals using ionising radiation. (ICRP
4068 113, 2009).

4069 (187) The International Basic Safety Standards for Protection against Ionising
4070 Radiation and for the Safety of Radiation Sources (BSS), published by the International
4071 Atomic Energy Agency (IAEA) and jointly sponsored by the Food and Agriculture
4072 Organization (FAO), the International Labour Organization (ILO), the Pan American
4073 Health Organization (PAHO) and the World Health Organization (WHO) (IAEA, 1996),
4074 require appropriate training that is sufficient to perform assigned tasks in the conduct of
4075 diagnostic or therapeutic procedures involving radiation.

4076 (188) The Medical Exposure Directive of EC 97/43/Euratom considers interventional
4077 radiology (Article 9) as a special practice involving high doses to patients (EU, 1997).
4078 According to Article 7, Member States shall ensure that the practitioner has adequate
4079 theoretical and practical training for the purpose of radiological practice as well as
4080 relevant competence in radiological protection. No special mention is made of
4081 interventional cardiology.

4082

4083 (189) Legislation in most countries requires that individuals who take responsibilities
4084 for medical exposure must be properly trained in RP. However, a training system and
4085 accreditation mechanism is still lacking in many countries.

4086

9.3 Training guidelines, curricula and materials

4087

4088 (190) The Commission, in Publication 85 (ICRP, 2000), states that interventional
4089 procedures are complex and demanding and that radiation dose tends to be operator
4090 dependent. It is particularly important that individuals performing these procedures are
4091 adequately trained both in clinical techniques and in radiological protection. It further
4092 states that special additional training should be planned when new x-ray systems or
4093 techniques are implemented in a centre. Basic and continuing training in radiological
4094 protection should be an integral part of this education. Training requirements are
4095 addressed in Publication 113 (ICRP 113, 2009).

4096 (191) In view of the number of radiation-induced injuries reported in recent years
4097 among patients undergoing interventional procedures (Rehani and Ortiz-Lopez, 2005,
4098 Vano and Gonzalez, 2005, ICRP, 2000, Koenig et al, 2001), a number of organizations
4099 have begun to provide recommendations for training requirements. Published guidelines
4100 were initially for interventional radiologists, but they are gradually becoming available
4101 from cardiology societies.

4102

9.3.1 USA

4103

4104 (192) The Food and Drug Administration (FDA) advisory of 1994 (FDA, 1994)
4105 alerted facilities to ensure proper training. FDA's specific recommendations for facilities
4106 in which invasive procedures are performed included the following:

4107

- 4108 • Assure appropriate credentials and training for physicians performing
4109 fluoroscopy.
- 4110 • All operators of the system must be trained and understand the operation of the
4111 fluoroscopic system, including the implications for radiation exposure from each
4112 mode of operation.
- 4113 • Facilities should ensure that physicians performing fluoroscopic procedures are
4114 educated so that they may, on a case-by-case basis, assess risks and benefits for
4115 individual patients, considering variables such as age, beam location and
4116 direction, tissues in the beam and previous fluoroscopic procedures or radiation
4117 therapy.
- 4118 •
- 4119 •

4119

4120 (193) In 1995, the American College of Cardiology Cardiac Catheterization
4121 Committee published a Position Statement indicating that appropriate training of staff is
4122 imperative, and that "Proper instruction in the principles of radiation physics and safety
4123 should be a part of every cardiologist's education" (Brinker et al., 1995). The American

4124 College of Cardiology Consensus Document further clearly delineated the need for a
4125 radiation safety knowledge base for cardiology staff (Limacher et al., 1998).

4126 (194) In 2004, an American College of Cardiology/American Heart Association/
4127 American College of Physicians (ACC/AHA/ACP) Task Force published a further report
4128 on clinical competence and training as a companion to the ACC's 1998 report (Hirshfeld
4129 et al, 2004; Limacher et al, 1998). The proposed curriculum in the 2004 document
4130 specifies the knowledge that a qualified physician should possess in order to be
4131 credentialed to use x-ray fluoroscopic machines, but does not specify a minimum number
4132 of hours of training. Physicians who have completed training should be able to
4133 demonstrate that they possess the knowledge specified by the curriculum by passing an
4134 appropriate certifying examination.

4135 (195) The necessary knowledge depth varies, depending upon the types of
4136 fluoroscopically guided procedures a particular physician performs. The ACC/AHA/ACP
4137 document outlines two different curricula—basic and advanced. The basic curriculum is
4138 appropriate for physicians who perform simpler fluoroscopically guided critical-care unit
4139 procedures such as right heart catheterization, temporary pacemaker placement, and intra-
4140 aortic balloon pump placement. The advanced curriculum is appropriate for physicians
4141 who perform angiographic, interventional, and electrophysiological procedures that
4142 employ greater amounts of radiation in more complex circumstances with different
4143 purposes and a greater attendant risk of patient and personnel injury.

4144 (196) The National Council on Radiation Protection and Measurements (NCRP) in
4145 the U.S. recently published a report on radiation dose management for fluoroscopically
4146 guided interventional medical procedures (NCRP, 2010). This report makes a number of
4147 specific recommendations, including:

- 4148
- 4149 • Each individual present in a fluoroscopically guided interventional (FGI)
4150 procedure room shall have appropriate radiological protection training.
 - 4151 • Every person who operates or supervises the use of FGI equipment shall have
4152 current training in the safe use of that specific equipment.
 - 4153 • Interventionalists who perform FGI procedures or other procedures with the
4154 potential for high patient doses require additional knowledge and training beyond
4155 that necessary for interventionalists whose practice is limited to low-dose FGI
4156 procedures.
 - 4157 • Clinical training and experience is not an acceptable substitute for formal training
4158 in radiation management.

4159 **9.3.2 European Commission**

4160 (197) In compliance with European Commission requirements, an outline for specific
4161 training in radiological protection for interventional radiology has been developed (EC,
4162 2000; Vañó et al. 1997). Although there is no special mention of interventional
4163 cardiology in the group of professionals, the table giving suggested number of training
4164 hours has a column for interventional cardiology specialists; 20-30 hours of training are
4165 suggested. The initial Spanish experience, based on these guidelines, has been reported
4166 (Vañó, 2003). This included development of a training CD (MARTIR, 2002).

4167 **9.3.3 International Atomic Energy Agency**

4168
4169 (198) The International Atomic Energy Agency (IAEA) has developed a curriculum
4170 with educational objectives specifically for interventional cardiologists. It is directed
4171 primarily at developing countries where the cardiology professional societies are not yet
4172 sufficiently robust to develop their own separate modules for basic and advanced
4173 curricula in the field of radiological protection. For these countries a “sandwich” module
4174 is ideal, particularly in view of the lack of individuals with sufficient expertise in
4175 radiological protection in diagnostic imaging to teach the subject. IAEA has also
4176 prepared educational material in the form of an electronic presentation on CD. This
4177 IAEA training material on Radiation Protection in Cardiology is available without cost
4178 and can be obtained by writing to patient.protection@iaea.org
4179 or downloaded from the website <http://rpop.iaea.org>.

4180 **9.3.4 WHO**

4181
4182 (199) The World Health Organization (WHO) has stated that specific training in
4183 interventional radiology is required in addition to basic training and has provided training
4184 requirements (WHO 2000). WHO further stated that the training process must be
4185 continued when new techniques are introduced, when new radiological systems are
4186 installed and when new staff are appointed. It also recommended continuous training and
4187 refresher courses at regular intervals. However, interventional cardiology was outside the
4188 scope of this document.

4189 **9.4 Credentialing**

4190
4191 (200) There is a distinction between the credentialing of a physician as technically
4192 competent to perform a procedure versus the credentialing of the same physician as
4193 competent to safely use a fluoroscope. Since the amount of radiation employed by the
4194 interventional cardiologist both per patient and annually is no less than that used by an
4195 interventional radiologist, the training standards of radiation physics and radiological
4196 protection in interventional cardiology should be the same as for other interventionalists
4197 (ICRP 113, 2009).

4198 **9.5 References**

4199
4200 Brinker, J.A. et al, 1995. Position paper of the American College of Cardiology Cardiac
4201 Catheterization Committee. JACC 26, 319-325.
4202 EU, 1997. Council Directive 97/43 Euratom, on health protection of individuals against the
4203 dangers ionizing radiation in relation to medical exposure, and repealing Directive
4204 84/466 Euratom. Official Journal of the European Communities No L 180, 9th July
4205 1997:22-7.
4206 http://europa.eu.int/comm/energy/nuclear/radioprotection/legislation_en.htm

- 4207 EC, 2000. Guidelines on education and training in radiation protection for medical
4208 exposures. Radiation Protection 116, European Commission. Directorate General
4209 Environment, Nuclear Safety and Civil Protection. Luxembourg, 2000. Available at:
4210 http://ec.europa.eu/energy/nuclear/radiation_protection/doc/publication/116.pdf
4211 Accessed January 2, 2011.
- 4212 FDA, 1994. Avoidance of serious x-ray-induced skin injuries to patients during
4213 fluoroscopically-guided procedures. Statement 9 Sept. 1994, Food and Drug
4214 Administration, Rockville, MD, USA.
- 4215 Hirshfeld, J.W., Jr., Balter, S., Brinker, J.A., Kern, M.J., Klein, L.W., Lindsay, B.D.,
4216 Tommaso, C.L., Tracy, C.M., Wagner, L.K., 2004. ACCF/AHA/HRS/SCAI clinical
4217 competence statement on physician knowledge to optimize patient safety and image
4218 quality in fluoroscopically guided invasive cardiovascular procedures: a report of the
4219 American College of Cardiology Foundation/American Heart Association/American
4220 College of Physicians Task Force on Clinical Competence and Training. J. Am. Coll.
4221 Cardiol. 44, 2259-2282.
- 4222 IAEA, 1996. International Basic Safety Standards against Ionizing Radiation and for the
4223 Safety of Radiation Sources, Safety Series No. 115, Vienna: IAEA.
- 4224 ICRP, 2000. Avoidance of radiation injuries from medical interventional procedures. ICRP
4225 Publication 85, Annals of the ICRP 30 (2).
- 4226 ICRP, 2009. Radiological protection education and training for healthcare staff and
4227 students (diagnostic imaging and interventional procedures). ICRP Publication 113.
4228 Ann ICRP 39 (5).
- 4229 Koenig TR, Wolff D, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided
4230 procedures: Part 1, Characteristics of radiation injury. AJR 2001; 177: 3-11
- 4231 Limacher, M.C. et al, 1998. Radiation safety in the practice of cardiology. JACC 31, 892-
4232 913.
- 4233 MARTIR (Multimedia and Audiovisual Radiation Protection Training in Interventional
4234 Radiology), 2002. CD-ROM. Radiation Protection 119, European Commission.
4235 Directorate General Environment, Nuclear Safety and Civil Protection. Luxembourg
4236 (free availability at
4237 http://ec.europa.eu/energy/nuclear/radiation_protection/publications_en.htm; go to
4238 publication 119).
- 4239 NCRP, 2010. Radiation dose management for fluoroscopically guided medical procedures.
4240 Report No. 168. National Council on Radiation Protection and Measurements,
4241 Bethesda, MD.
- 4242 Rehani, M.M. and Ortiz-Lopez, P., 2006. Radiation effects in fluoroscopically guided
4243 cardiac interventions - keeping them under control. Int. J. Cardiol. 109(2), 147-151.
- 4244 Vano E, and Gonzalez L. 2005. Accreditation in radiation protection for cardiologists and
4245 interventionalists. Radiat Prot Dosimetry. 117(1-3):69-73.
- 4246 Vañó, E., Gonzalez, L., Faulkner, K. et al, 1997. Specific training objectives in radiation
4247 protection for medical staff in interventional radiology installations. Draft document.
4248 DIMOND European Concerted Action.
- 4249 Vañó, E., Gonzalez, L., Canis, M. et al., 2003. Training in radiological protection for
4250 interventionalists. Initial Spanish experience. BJR 76, 217-219.



DRAFT REPORT FOR CONSULTATION

4251 WHO, 2000. Efficacy and radiation safety in interventional radiology. World Health
4252 Organisation, Geneva.
4253
4254
4255

4256

10. QUALITY ASSURANCE PROGRAMMES

4257

4258

Main Points

4259

4260

4261

4262

4263

4264

4265

4266

4267

4268

4269

4270

4271

4272

4273

4274

4275

4276

4277

4278

4279

4280

4281

4282

4283

4284

4285

10.1 Introduction

4286

4287

4288

4289

4290

4291

4292

4293

4294

4295

4296

4297

(201) Quality assurance programs in cardiology should cover all of the planned and systematic actions necessary to provide confidence that optimum quality has been achieved in the entire diagnostic process, i.e. there is consistent production of adequate diagnostic information with the lowest acceptable exposure of patients and personnel (WHO 1982).

(202) A quality assurance programme (QAP) for interventional cardiology includes all of the aspects of radiological protection (RP) of patients and staff in addition to the usual clinical aspects. Only the RP aspects are discussed here. Two basic objectives of the QAP are to evaluate patient radiation dose on a periodic basis and to monitor occupational radiation dose for workers in cardiology facilities where radiation is used. Table 10.1 summarizes the 10 key points to be included in a RP QAP. The RP component of the QAP for interventional cardiology should be an independent portion of the general QAP for x-ray installations in a particular health centre.

4298 (203) A cardiologist should be in charge of the QAP aspects of RP for cardiology, and
4299 should be assisted by a medical physicist. The RP QAP for cardiology should be reviewed
4300 at least annually, to allow the opportunity for updates and periodic follow up. Self-audit of
4301 the QAP is also advisable. Table 10.2 presents some questions to be answered as part of
4302 this internal audit of the QAP.

4303
4304
4305

10.2 Facilities

4306 (204) The design of a new interventional fluoroscopy laboratory, the selection and
4307 installation of a new x-ray or nuclear medicine system and the upgrade of existing
4308 equipment are all complex and expensive processes. Planning for these processes should
4309 include RP. Both a senior physician (interventionalist, nuclear medicine specialist or CT
4310 imaging specialist, as appropriate) and a medical physicist should be included in this
4311 planning. Physicians representing all of the medical specialties who will be using the new
4312 room should be involved in specifying the equipment for the room. Important aspects to
4313 consider are shown in Table 10.3.

4314 (205) Suggested architectural specifications for catheterization laboratories have been
4315 published by scientific societies (ACC/AHA 1991): adequate dimensions (50 m²), a
4316 sufficiently large control room with a wide leaded window, sufficient ceiling height (3 m,
4317 allowing for ceiling suspended support of the C-arm, monitors, etc.), appropriate radiation
4318 shielding (including window and doors), easy access for personnel and patients, etc. New x-
4319 ray rooms should be of sufficient size to allow personnel to be positioned at a distance from
4320 the patient when inside the X ray room during the procedures. The installation should
4321 include a control room with a wide shielded glass window, so that other clinicians and other
4322 personnel can follow the procedures without radiation exposure.

4323 (206) Appropriate shielding, access to the x-ray room and RP tools (aprons, thyroid
4324 protectors, protective gloves and glasses, protective screens, ceiling-suspended and under-
4325 table shields), should be part of the planning for catheterization laboratories.
4326 Dose reduction technology, including the capabilities to measure, record, and transfer
4327 patient dose data to the patient's medical record, should be considered an important factor
4328 in the selection of new fluoroscopy and CT equipment. Appropriate standards should be
4329 taken into account (IEC 2010).

4330
4331
4332

10.3 Acceptance and constancy testing

4333 (207) Acceptance tests shall be made by the company supplying the equipment in the
4334 presence of technical personnel from the centre buying the system, or by centre technical
4335 personnel. Commissioning of the new equipment before its clinical use should be the
4336 responsibility of the personnel of the centre.

4337 (208) Periodic quality controls (QC), including dosimeter calibration, should be
4338 planned taking into account international standards, local recommendations and the
4339 recommendations of the x-ray system manufacturer. These should also include practical
4340 results for the appropriate management of patient doses by the cardiologists (e.g. dose rate

4341 in the different fluoroscopy modes, dose per frame during cine acquisition, CT scan
4342 protocols).

4343 (209) Periodic evaluation of image quality and procedure protocols should also be
4344 included in the QAP. Image quality should be measured with test objects during the
4345 acceptance and constancy tests. With the new digital imaging detectors it is possible to
4346 select a wide range of dose values to obtain the required level of quality in the images. It is
4347 easy to specify excessive dose rates, as these do not impair image quality and are not easily
4348 detected from inspection of the image. Cardiologists, in cooperation with the medical
4349 physicist and the industry engineer should set the fluoroscopic or CT system doses to
4350 achieve the appropriate balance between image quality and dose.

4351 (210) It is possible to perform this periodic evaluation of image quality using clinical
4352 criteria. The European consortium DIMOND (DIMOND 2008) has proposed a set of
4353 criteria to evaluate fluoroscopic cardiac imaging (Bernardi 2001a and 2001b).

4354 (211) Cardiologists should learn the dose required to obtain a certain level of
4355 diagnostic information. For interventional fluoroscopy, this is related to fluoroscopy time,
4356 number of series, number of frames/series, fluoroscopy and cine modes and dose rates,
4357 etc.). It is also important to verify that wedge filters, collimation and C-arm angulations are
4358 used properly. CT scan protocols, modes, and technique factors, and their effect on patient
4359 dose, are discussed in Chapter 8. Concerns related to nuclear medicine doses are discussed
4360 in Chapter 7.

4361
4362
4363

10.4 Staff

4364 (212) An important aspect of the QAP is a description of the roles and responsibilities
4365 of personnel. There should be enough staff to avoid an excessive number of procedures per
4366 specialist, and sufficient nursing and technologist support. Support by network specialists
4367 (for new digital systems), maintenance and service personnel and medical physics
4368 specialists is advised.

4369 (213) Analysis of staff radiation dose should be included in the QAP. Calibrated
4370 dosimeters for staff must be available. In addition to the dosimeter in the x-ray system for
4371 the evaluation of patient dose, personnel working in the catheterization laboratories should
4372 wear appropriate dosimeters, and a strict policy for their use should be implemented.
4373 Additional electronic dosimeters may also be useful, especially for RP training of students
4374 and inexperienced personnel. The QAP should ensure the regular use of personal
4375 dosimeters and include a review of all abnormal dose values.

4376
4377
4378

10.5 Training

4379 (214) Training in RP is another important item to be included in the QAP. Initial
4380 accreditation in RP should follow local requirements. Special attention to training in RP
4381 should be given to fellows and residents. Seminars to analyse patient and staff dose results
4382 can be an excellent educational tool as well as a useful QA activity. Training is discussed in
4383 more detail in chapter 9 and in ICRP Publication 113 (ICRP, 2009).

4384

4429

4430 10.7.1 Diagnostic Reference Levels

4431

4432 (219) Dose guidelines were first introduced in the U.S and the U.K. in the late 1980s
4433 and early 1990s (Wall, 1998). They were introduced into ICRP recommendations as
4434 “investigation levels” in Publication 60 (ICRP, 1990) and as “diagnostic reference levels”
4435 (DRLs) in Publication 73 (ICRP, 1996). DRLs are now an established method of defining
4436 feedback levels for high volume examinations such as chest radiographs or mammograms.
4437 The Commission continues to recommend their use (ICRP 85, ICRP 103, ICRP 105).

4438

4439 (220) DRLs are used to help avoid radiation dose to the patient that does not contribute
4440 to the medical imaging task. They provide practitioners with a straightforward tool for
4441 comparing the radiation doses that they deliver to their patients with the radiation doses
4442 delivered by their colleagues. They are a guide to good practice, but are neither dose limits
4443 nor thresholds that define competent performance of the operator or the equipment. They
4444 are intended to provide guidance on what is achievable with current good practice rather
4445 than optimum performance, and help identify unusually high radiation doses or exposure
4446 levels. A mean dose for a procedure that is less than the reference level does not guarantee
4447 that the procedure is being performed optimally.

4448

4449 (221) To use DRLs as a quality improvement tool, an institution or individual
4450 practitioner collects radiation dose data for cases of a procedure performed in their own
4451 practice. The recommended number of cases varies from 10 to >50, with the latter number
4452 suggested for interventional fluoroscopy procedures because of the high individual
4453 variability in patient dose of cases of image-guided interventional procedures (Wall, 1998,
4454 Vano 2008). The mean radiation dose for the procedure is then compared to the DRL. If
4455 local practice results in a mean radiation dose that is greater than the DRL, the fluoroscopic
4456 equipment should be investigated. If the fluoroscopic equipment is functioning properly
4457 and within specification, operator technique and procedure protocols should be examined
4458 (Vano, 2001). Investigations are also appropriate where local values are substantially below
4459 the DRL, as excessively low doses may be associated with poor image quality.

4460

**4461 10.7.2 Application of Diagnostic Reference Levels in interventional fluoroscopy
4462 procedures**

4463

4464 (222) At present, there is little evidence to indicate that dose levels are decreasing in
4465 interventional cardiology. If anything, dose levels are increasing due to the increased
4466 complexity of fluoroscopically guided procedures. As the Commission has noted,
4467 reference levels, in principle, could be useful for dose optimization in interventional
4468 fluoroscopy procedures (ICRP 105). However, patient dose distributions for interventional
4469 fluoroscopy procedures extend over a wide range and are very variable due to the differing
4470 complexity of the procedures, different patient sizes and different operational modes. The
4471 Commission has suggested that a potential approach to this problem is to take into account

4472 the relative “complexity” of the procedure (ICRP 105). Other methods have also been
4473 proposed (NCRP 2010).

4474 (223) Recent studies have provided DRLs for cardiovascular procedures (Peterzol et al
4475 2005, Neofotistou et al 2003, Balter et al 2008, D'Helft et al 2009). Some diagnostic
4476 invasive procedures (e.g., routine coronary angiography) are done in a relatively
4477 standardized way and in sufficient volumes that a valid DRL might be constructed.

4478 (224) The European DIMOND consortium proposed provisional RLs for radiation
4479 doses delivered to patients during two types of invasive cardiology procedures, coronary
4480 angiography (CA) and percutaneous transluminal coronary angioplasty (PTCA). The
4481 proposed DRLs for CA and PTCA were KAP values of 45 Gy·cm² and 75 Gy·cm²,
4482 fluoroscopy times of 7.5 min and 17 min and 1250 and 1300 frames, respectively. The
4483 consortium concluded that more studies were required to establish “tolerances” from the
4484 proposed levels, taking into account the complexity of the procedure and the patient's size.

4485 (225) Bernardi and co-workers performed studies in Udine, Italy (Bernardi, 2000) and
4486 later in several European hospitals (Neofotistou, 2003), with quantitative assessments of
4487 complexity in relation to a patient's exposure to radiation. The relationships between
4488 several clinical factors, anatomic factors and technical factors versus fluoroscopy time were
4489 evaluated for PTCA. A scoring system was developed, and two complexity indexes were
4490 conceived, based on which the procedures were divided into three groups: simple, medium,
4491 and complex. The relative complexity of procedures carried out in different centres should
4492 be taken into account when comparing typical patient doses with reference levels.

4493 (226) The IAEA carried out an international project to determine the feasibility of
4494 establishing guidance levels for cardiac catheterization and percutaneous coronary
4495 interventions (IAEA, 2009). The IAEA report has been summarized in a separate
4496 publication (Balter et al, 2008). For PTCA procedures, the report recommended the use of a
4497 reference level, using KAP, of 100 Gy·cm² for simple procedures, 125 Gy·cm² for
4498 moderate complexity procedures and 200 Gy·cm² for complex procedures. Unfortunately,
4499 methods for quantifying complexity have not yet been developed for other interventional
4500 cardiology procedures, such as electrophysiology ablation or pacemaker insertion.

4501

4502 **10.7.3 Evaluation of high dose interventional fluoroscopy procedures**

4503

4504 (227) Reference levels are used to evaluate the average dose per procedure. Because of
4505 the lognormal dose distribution that is characteristic of fluoroscopically guided
4506 interventions, an additional process is needed to evaluate the high dose “tail”. The high
4507 dose tail is of particular interest, because this tail represents the cases where patient doses
4508 may be high enough to cause deterministic effects.

4509 (228) Cases that required a radiation dose greater than the SRDL (section 10.6) should
4510 be identified and reported to the laboratory director and laboratory quality manager on a
4511 periodic basis. A monthly report is helpful, to ensure that patients with high radiation doses
4512 receive appropriate education and follow-up.

4513 (229) For each such procedure, the report should include patient identifier(s), the dose
4514 delivered during the procedure, the type of procedure, the room in which the procedure was
4515 performed, the operator's name, a count of the patient's previous invasive procedures

4516 (essential for estimating total skin dose), and any special notes. The goal of this report is to
4517 help assure that all patients who received a high radiation dose have been appropriately
4518 educated, and that appropriate follow-up is scheduled and performed (Miller et al, 2010).

4519 (230) Cases resulting in possible radiation injuries should be discussed at the next
4520 laboratory QA meeting. This discussion should include any available diagnoses, planned
4521 patient follow-up, and outcomes. Unless it is clear that the injury was not radiation-
4522 induced, the procedure should be reviewed for the appropriate use of radiation in the
4523 clinical context (Miller et al, 2010).

4524

4525 **10.7.4 Evaluation of skin dose for interventional fluoroscopy procedures**

4526

4527 (231) It is advisable to measure the skin dose distribution in a sample of patients, to
4528 verify that basic aspects of patient protection are being followed (e.g. appropriate
4529 collimation, use of wedge filter, avoidance of a high concentration of radiation fields in the
4530 same skin area). (Vano 1997; Guibelalde 2003). Skin dose may be measured with special
4531 film, with dosimeters placed directly on the patient's skin, and by other means (Miller et al,
4532 2004). A qualified physicist should be consulted for these measurements.

4533

4534

4535

4536

4537

4538 **Table 10.1. Some key aspects to be included in the section of radiological protection of**
4539 **the quality assurance programme for cardiac facilities using ionising radiation.**

4540

4541

4542

1. Facility design.

4543

2. X ray equipment (selection criteria).

4544

3. Radiological protection tools.

4545

4. Availability of dosimeters.

4546

5. Availability of personnel and their responsibilities.

4547

6. Training in radiological protection (initial and continuing).

4548

7. Patient dose audit and reporting.

4549

8. Clinical follow up for high patient doses

4550

9. Image quality and procedure evaluation.

4551

10. Staff doses.

4552

4553

4554

4555

4556

4557

4558

Table 10.2. Examples of quality indicators

4559

Can your centre report patient dose values from the last year?

4560

Do you have a procedure for the clinical follow-up of high doses to patients?

4561

Do you know the results of your x-ray system QCs?

4562

Are you following your staff dose values?

4563

Do you have a continuous training programme in RP?

4564

4565

4566 **Table 10.3 Facility procurement considerations (ICRP, 2000)**

4567		
4568	Analysis of clinical need	Workload
4569		
4570	Equipment specification	General requirements
4571		Major equipment components
4572		Functional requirements
4573		Specific equipment requirements
4574		
4575	Computer capabilities	Image display matrix
4576		Processing times
4577		Memory/image storage
4578		PACS linkages*
4579		HIS linkages†
4580		
4581	Systems performance	Image quality
4582		Patient dose
4583		Dose control measures
4584		
4585	User manuals	Technical training
4586		Operational training
4587		
4588	Compliance with national	Electrical safety
4589	and international standards	Mechanical safety
4590		Radiation safety
4591		Room design/shielding
4592		
4593	Service and warranty	Maintenance programme
4594		Quality control programmes
4595		Access to service software protocols/
4596		rationale for service schedules
4597		
4598	Operation costs	Cost of consumables - projected over 5 years
4599		

4600 *PACS=picture archiving and communication system

4601 †HIS=hospital information system

4602

REFERENCES

- 4603
4604
4605 American College of Cardiology/American Heart Association ad hoc Task Force on
4606 Cardiac Catheterization. ACC/AHA Guidelines for Cardiac Catheterization and
4607 Cardiac Catheterization Laboratories. JACC 1991; 18 (5): 1149-82.
- 4608 Balter, S., Miller, D.L., Vano, E., Ortiz Lopez, P., Bernardi, G., Cotelo, E., Faulkner, K.,
4609 Nowotny, R., Padovani, R., Ramirez, A., 2008. A pilot study exploring the possibility
4610 of establishing guidance levels in x-ray directed interventional procedures. Med Phys
4611 35, 673-680.
- 4612 Bernardi G, Padovani R, Morocutti G, Vano E, Malisan MR, Rinuncini M, Spedicato L,
4613 Fioretti PM. Clinical and technical determinants of the complexity of percutaneous
4614 transluminal coronary angioplasty procedures: analysis in relation to radiation
4615 exposure parameters. Catheter Cardiovasc Interv 2000 Sep;51(1):1-9; discussion 10.
- 4616 Bernardi G, Padovani R, Morocutti G, Spedicato L, Giannuleas JD, Neofotistou E,
4617 Manginas A, Goicolea JC, McNeill J, Vano E, Marzocchi A, Tsapaki V, Fioretti PM,
4618 Malone J. Quality criteria for cardiac images in diagnostic and interventional
4619 cardiology. Br J Radiol. 2001 Sep;74(885):852-5.
- 4620 Bernardi G, Padovani R, Morocutti G, Spedicato L, Giannuleas JD, Neofotistou E,
4621 Maginas A, Goicolea JC, McNeill J, Vano E. A method based on DIMOND quality
4622 criteria to evaluate imaging in diagnostic and interventional cardiology. Radiat Prot
4623 Dosimetry. 2001;94(1-2):167-72.
- 4624 D'Helft CJ, Brennan PC, McGee AM, et al. Potential Irish dose reference levels for cardiac
4625 interventional examinations. Br J Radiol 2009; 82:296-302
- 4626 DIMOND. Available at <http://www.dimond3.org/> Last updated October, 2008. Accessed
4627 May 9, 2011.
- 4628 EC, 2000. Guidelines on education and training in radiation protection for medical
4629 exposures. Radiation Protection 116, European Commission. Directorate General
4630 Environment, Nuclear Safety and Civil Protection. Luxembourg, 2000. Available at:
4631 http://ec.europa.eu/energy/nuclear/radiation_protection/doc/publication/116.pdf
4632 Accessed January 2, 2011.
- 4633 Guibelalde E, Vano E, Gonzalez L, Prieto C, Fernandez JM, Ten JI. Practical aspects for
4634 the evaluation of skin doses in interventional cardiology using a new slow film. Br J
4635 Radiol. 2003 May;76(905):332-6.
- 4636 Hirshfeld JW Jr, Balter S, Brinker JA, Kern MJ et al. American College of Cardiology
4637 Foundation; American Heart Association; HRS; SCAI; American College of
4638 Physicians Task Force on Clinical Competence and Training. ACCF/AHA/HRS/SCAI
4639 clinical competence statement on physician knowledge to optimize patient safety and
4640 image quality in fluoroscopically guided invasive cardiovascular procedures: a report
4641 of the American College of Cardiology Foundation/American Heart
4642 Association/American College of Physicians Task Force on Clinical Competence and
4643 Training. Circulation. 2005 Feb 1;111(4):511-32.
- 4644

- 4645 IAEA, 2009. Establishing guidance levels in x ray guided medical interventional
4646 procedures: A pilot study. Safety Reports Series No. 59. International Atomic Energy
4647 Agency, Vienna.
- 4648 IEC, 2010. Medical electrical equipment. Part 2-43: Particular requirements for the safety
4649 of X-ray equipment for interventional procedures. IEC 60601-2-43. 2nd edition.
4650 International Electrotechnical Commission. Geneva, Switzerland.
- 4651 ICRP, 1990. The 1990 Recommendations of the International Commission on
4652 Radiological Protection. ICRP Publication 60. Ann ICRP 1991; 21(1-3):1-201
- 4653 ICRP, 1996. Radiological protection and safety in medicine. ICRP Publication 73. Ann
4654 ICRP 26(2):1-47
- 4655 ICRP, 2000. Avoidance of radiation injuries from medical interventional procedures.
4656 ICRP Publication 85. Ann ICRP 30(2):1-67
- 4657 ICRP, 2007a. The 2007 Recommendations of the International Commission on
4658 Radiological Protection. ICRP publication 103. Ann. ICRP 37, 1-332.
- 4659 ICRP, 2007b. Radiological protection in medicine. ICRP Publication 105. Ann ICRP
4660 37:1-63.
- 4661 ICRP, 2009. Radiological protection education and training for healthcare staff and
4662 students (diagnostic imaging and interventional procedures). ICRP Publication 113.
4663 Ann ICRP 39 (5).
- 4664 Miller, D.L., Balter, S., Wagner, L.K., Cardella, J.F., Clark, T.W.I., Neithamer, C.D., Jr.,
4665 Schwartzberg, M.S., Swan, T.L., Towbin, R.B., Rholl, K.S., Sacks, D., 2004. Quality
4666 improvement guidelines for recording patient radiation dose in the medical record. J
4667 Vasc Interv Radiol 15, 423-429.
- 4668 Miller DL, Balter S, Schueler BA, Wagner LK, Strauss KJ, Vano E. Clinical radiation
4669 management for fluoroscopically guided interventional procedures. Radiology 2010;
4670 257(2):321-332.
- 4671 NCI. Interventional fluoroscopy: reducing radiation risks for patients and staff. NIH
4672 Publication No. 05-5286. Bethesda, MD: National Cancer Institute, 2005. Available
4673 at: [http://www.cancer.gov/images/Documents/45bae965-697a-4de8-9dae-
4674 b77222e0e79d/InterventionalFluor.pdf](http://www.cancer.gov/images/Documents/45bae965-697a-4de8-9dae-b77222e0e79d/InterventionalFluor.pdf) Accessed January 1, 2011.
- 4675 Neofotistou V, Vano E, Padovani R, et al. Preliminary reference levels in interventional
4676 cardiology. Eur Radiol 2003; 13:2259-2263.
- 4677 NCRP, 2010. Radiation dose management for fluoroscopically guided medical procedures.
4678 NCRP Report No. 168. National Council on Radiation Protection and Measurements,
4679 Bethesda, MD.
- 4680 Padovani R, Bernardi G, Malisan MR, Vano E, Morocutti G, Fioretti PM. Patient dose
4681 related to the complexity of interventional cardiology procedures. Radiat Prot
4682 Dosimetry. 2001;94(1-2):189-92.
- 4683 Peterzol A, Quai E, Padovani R, Bernardi G, Kotre J, Dowling A. Reference levels in
4684 PTCA as a function of procedure complexity. Radiat Prot Dosimetry 2005; 117(1-3);
4685 54-58.
- 4686 Vano E, Guibelalde E, Fernandez JM, Gonzalez L, Ten JJ. Patient dosimetry in
4687 interventional radiology using slow films. Br J Radiol. 1997 Feb;70:195-200.
4688

- 4689 Vano E, Gonzalez E. Approaches to establishing reference levels in interventional
4690 radiology. *Radiat Prot Dosim* 2001; 94:109-112.
- 4691 Vano E, Gonzalez L, Canis M, Hernandez-Lezana A. Training in radiological protection
4692 for interventionalists. Initial Spanish experience. *Br J Radiol*. 2003 Apr;76(904):217-9.
- 4693 Vano E, Järvinen H, Kosunen A, et al. Patient dose in interventional radiology: a European
4694 survey. *Radiat Prot Dosimetry* 2008; 129:39-45.
- 4695 Wall BF, Shrimpton PC. The historical development of reference doses in diagnostic
4696 radiology. *Radiat Prot Dosimetry* 1998; 80:15-19.
- 4697 WHO, 1982. *Quality Assurance in Diagnostic Radiology*. Geneva.
- 4698 WHO, 2000. *Efficacy and Radiation Safety in Interventional Radiology*. Geneva.
- 4699
- 4700 4818-2733-7736, v. 3